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Abstract 
 
It is becoming increasingly more common to use culture expanded human mesenchymal 
stem cells (hMSCs) in regenerative medicine due to their low incidence in vivo.  
However, their successful application is hampered by a lack of selective markers to 
positively identify the expanded multipotent cells.  This study aimed to characterise 
STRO-1 antigen as a potential biomarker of multipotency on cultured bone marrow 
derived hMSCs.  In an attempt to identify the nature of this antigen, two techniques 
were implemented: peptide phage display technology and a microarray based approach.  
 
Changes in the expression of STRO-1 were investigated during culture expansion of 
hMSCs.  STRO-1 expression positively correlated with cellular morphology and 
multilineage potential, whereby senescent cells down-regulated STRO-1 antigen and 
exhibited decreased adipogenic and osteogenic potential.  Furthermore, STRO-1 was 
found to be heterogeneously expressed on hMSC populations and enrichment followed 
by lineage specific induction of the STRO-1BRIGHT fraction resulted in enhanced 
adipogenic and osteogenic differentiation potential.   The expression of STRO-1 antigen 
was further characterised as a marker of differentiation, whereby differentiating cells 
were found to down-regulate STRO-1.  A cellular hierarchy in hMSC population was 
therefore proposed based on STRO-1 status, with the highest STRO-1 expressive cells 
representing the multipotent subset.  In an attempt to identify the epitope that STRO-1 
IgM antibody recognised, peptide phage display technology was used as solid and liquid 
phase panning systems but the approach yielded no promising peptide candidate.  
Subsequently, comparative gene expression microarray analysis of osteosarcoma cell 
lines (143B, CAL72, G-292, HOS, MG-63, Saos-2 and U-2-OS) was implemented and 
a list of eight potential candidate genes encoding STRO-1 antigen was selected.   
 
This work ultimately led to the identification of putative cancer stem cells (CSCs) in 
seven osteosarcoma cell lines initially based on STRO-1 expression.  With MG-63 
strongly expressing STRO-1, the maintenance of MSC-like properties by STRO-1 
expressing cell lines was investigated.  A heterogeneous pattern of osteogenic 
differentiation was observed between and within the cell lines.  Closer inspection 
revealed a cellular hierarchy comprising of holoclones and paraclones, with the 
holoclones representing the putative CSCs in osteosarcoma.  Overall, this thesis 
addressed the fields of regenerative medicine as well as oncology by proposing STRO-1 
antigen as a marker of multipotency on hMSCs and osteosarcoma holoclonal cells as the 
putative cancer stem cell targets for anti-cancer drug development. 
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1.1 Introduction to stem cells 
 
Stem cells have been described as cells having extensive self-renewal capacity and the 
ability to generate a number of differentiated progeny of multiple types (Lajtha, 1979, 
Hall and Watt, 1989, Joseph and Morrison, 2005).  Additional characteristics associated 
with stem cells include quiescence in vivo, the ability to undergo asymmetric cell 
division and the ability to regenerate tissue following injury (Morrison et al., 1997).  
However, these characteristics vary with stem cell populations and within a single stem 
cell population with time (Potten and Loeffler, 1990). 
 
The isolation of stem cells from embryos as well as adult tissues demonstrates that these 
cells are present throughout the development of an organism and therefore, stem cells 
have been categorised based on their developmental potential.  Totipotency refers to 
cells which are able to form all extra-embryonic and embryonic tissues and is a 
characteristic of the fertilised egg (Sell, 2004).  Pluripotency defines cells which are 
able to give rise to the three embryonic germ layers which are the: endoderm (cells 
forming the gastrointestinal tract and internal organs such as the liver), mesoderm 
(blood, blood vessels and connective tissue such as bone) and ectoderm (skin and 
nervous system).  Pluripotent cells can be derived from the inner cell mass of the 
blastocyst four to five days post-fertilisation and are termed embryonic stem cells 
(Thomson et al., 1998).  Work on these cells was pioneered by Martin and Evans who 
successfully isolated and expanded embryonic stem cells from mice in vitro (Martin and 
Evans, 1975, Martin, 1981).  Stem cell populations which give rise to several cell 
lineages, generally within one germ layer are termed multipotent or oligopotent; adult 
stem cells are classically described in this way, although controversial cases of trans-
differentiation of adult stem cells have been documented (Raff, 2003).  Multipotent 
cells are able to give rise to unipotent progenitors of multiple cell types, which 
ultimately form the mature functional tissues of the organism (Sell, 2004). 
 
Stem cell populations are commonly identified by virtue of their surface marker 
expression and specific functional characteristics (Alison et al., 2006a).  The key 
properties of stem cells are demonstrated in vivo by the regeneration of a specific tissue 
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type from a single cell after transplantation into an animal model, from which further 
stem cells can be derived displaying the same properties, although most work 
demonstrating stem cell properties are based on in vitro work (Weissman and Shizuru, 
2008).  In vitro, stem cells are assessed by the ability of clonal populations to form 
differentiated cells of multiple types (Joseph and Morrison, 2005, Watt et al., 2006).   
 
The prospect of expanding and manipulating stem cells in vitro present them as 
promising candidates in the field of regenerative medicine.  Stem cells can be cultured 
extensively and differentiated to the required cell type to be implemented in cell-based 
therapies.  More importantly, the ability to study stem cells in a laboratory setting 
provides a means of understanding the mechanisms regulating ontogeny, thereby 
increasing our knowledge of cellular development and differentiation.  
 
1.1.1 Adult stem cells (ASCs) 
 
The development of a multi-cellular organism is driven by a series of events pre-
programmed in the genome from the time of fertilisation.  These events encompass cell 
proliferation, lineage commitment, lineage progression, lineage expression, cellular 
inhibition and regulated cell death (Young and Black, 2004).  The sequential 
progression of cells through these events culminates in the formation of differentiated 
cells, tissues and organs that constitute an individual.  Although most cells undergo 
these crucial stages during growth, a subset of cells exit the developmental continuum at 
specific time points and become quiescent cells.  The quiescent cells have been 
identified as adult stem cells (ASCs) and have been derived from almost every organ of 
the body, including the brain (Morrison et al., 1999, Uchida et al., 2000).  ASCs reside 
in specific locations within the tissue or organ and are responsible for continual cellular 
turn-over and tissue repair following trauma or disease.   
 
ASCs is the general term used for cells which are isolated from a post-natal individual 
and which have the potential to self-renew and give rise to differentiated cells with 
specific functions.  ASCs are multipotent and, as such, are able to give rise to 
differentiated cells of the germ layer or organ in which they reside.  However, there 
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have been reports of ASC trans-differentiation, whereby ASCs isolated from one organ 
could be re-programmed to form tissues of another organ (Forbes et al., 2002, Poulsom 
et al., 2002).  This issue of ASC plasticity has been challenged over the past decade and 
there is limited evidence suggesting the presence of lineage-uncommitted pluripotent 
stem cells (PPSCs) (Romero-Ramos et al., 2002, Young and Black, 2004).  PPSCs are 
thought to be pluripotent (endo-, meso- and ectodermal precursors), therefore having a 
wider differentiation spectrum than ASCs which are committed to a specific germ layer.  
Young and colleagues (Young et al., 2001) suggested the presence of contaminating 
PPSCs in the organ-specific ASCs population isolated in the studies claiming trans-
differentiation.  Following exposure to inductive factors different to those present in the 
organ from which they were derived, PPSCs are able to respond and differentiate into 
specialised cells of a totally different organ; for instance bone marrow derived stem 
cells forming neurons (Brazelton et al., 2000) or hepatocytes (Petersen et al., 1999). 
While it is not clear whether presumed trans-differentiation is actually the work of 
PPSCs, cell fusion has also been proposed as an explanation for the observed plasticity 
in ASCs (Forbes et al., 2002, Poulsom et al., 2002).  There are reports confirming the 
presence of fused bone marrow cells among the differentiated cells in the newly formed 
organ, albeit at low frequency.  Bone marrow cells from GFP transgenic mice were 
shown to fuse to embryonic stem cells, thereby adopting the phenotypic and pluripotent 
characteristics of the latter (Terada et al., 2002, Ying et al., 2002). 
 
1.1.2 Bone marrow derived adult stem cells 
 
The bone marrow is an organ composed of two main systems: the haematopoietic tissue 
proper and the associated supporting stroma, which are maintained by two distinct sets 
of stem cells, namely the haematopoietic stem cells (HSCs) and the mesenchymal stem 
cells (MSCs) respectively (Bonnet, 2003).  Both sets of stem cells co-exist and function 
as two distinct populations in the same organ. 
 
HSCs form specialised cells of the haematopoietic lineage and therefore are responsible 
for the production and maintenance of all the mature blood cell types.  From the early 
post-natal period and onwards, haematopoiesis (formation of new blood cells) occurs in 
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the bone marrow with the progenitor cells entering the circulation where they are able to 
home to specific locations and undergo maturation.  In the bone marrow, MSCs are 
responsible for the formation of bone (osteocytes), cartilage (chondrocytes), fat 
(adipocytes) and haematopoiesis-supporting stroma.  It is generally accepted that MSCs 
line the endosteal and trabecular surfaces of the bone structure, along side other cells of 
mesenchymal origin (Aubin and Liu, 1996). 
 
After development of the bone and the bone marrow, a dynamic relationship is 
established between the compartments of the two stem cell populations.  The marrow 
cavities in all bones of newborn mammals are made up of the haematopoietic tissue and 
the haematopoiesis supportive stroma (haematopoietic micro-environment), a composite 
referred to as red bone marrow.  During growth, the haematopoietic micro-environment, 
mainly in bones of the extremities, is gradually replaced by lipid-containing 
mesenchymal cells forming a fatty tissue referred to as yellow or fatty bone marrow.  
Therefore with age, the haematopoietic micro-environment in tubular bones is 
converted to fatty tissue and thus loses its ability to support haematopoiesis.  However, 
cancellous bones are able to support haematopoiesis permanently despite the 
accumulation of some fat-containing cells.  Cancellous bone, by virtue of its spongy 
structure, has a larger internal bone surface area than tubular bone and therefore 
harbours more MSCs which are able to form the haematopoiesis-supporting stroma, 
thus sustaining haematopoiesis (Gurevitch et al., 2009). 
 
Haematopoiesis is dependent on MSCs as these cells are the precursors of the 
supportive stroma required for the maintenance of the haematopoietic tissue.  The 
formation of haematopoiesis-supportive stroma acts as an intermediate step between the 
MSC precursor and adipocyte formation.  Gurevitch and co-workers (2007) describe an 
in vivo transition of stromal cells (arising from MSCs) to adipose tissue, thus gradually 
forming yellow marrow.  Therefore with age, the continual formation of 
haematopoiesis-supportive stroma tends to deplete the MSC pool, while increasing the 
ratio of yellow to red bone marrow (Gurevitch et al., 2007). 
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1.2 Mesenchymal Stem Cells (MSCs) 
 
MSCs are multipotent stem cells which were first described in the bone marrow of 
guinea pigs by Friedenstein and colleagues (Friedenstein et al., 1970).  The cells were 
referred to as ‘osteogenic stem cells’ and described as clonal and fibroblastic stromal 
cells able to form adherent colonies in culture and possessing robust osteogenic 
potential (Friedenstein et al., 1987). The terminology used to describe these cells have 
been debated over the years, namely colony forming unit fibroblasts (CFU-F) 
(Friedenstein et al., 1970), mesenchymal stromal cells (MSC) (Lazarus et al., 1995), 
bone marrow stromal cells (BMSC) (Gronthos et al., 2003) and mesenchymal adult 
stem cells (MASCS) (Belema-Bedada et al., 2008). 
 
In 1991, the term ‘mesenchymal stem cells’ (MSCs) was coined by Caplan based on 
their self-renewal ability and capacity to commit to a distinctive phenotypic pathway to 
regenerate mesenchymal tissues (Caplan, 1991).  Therefore consistent with this 
terminology, mesenchymal stem cells will be adopted to refer to the adherent population 
of bone marrow derived cells in this thesis.  The multilineage differentiation potential 
into bone, cartilage, fat and marrow-supportive stroma was further characterised by 
Pittenger and co-workers (2009).  This group undertook a large scale MSC investigation 
(bone marrow MSC isolated from 350 patients) to show that a subset of clonally 
expanded adherent cells retained multilineage potential.  This further supported the true 
nature of MSC as possessing stem cell properties.  Interestingly, some clones were only 
able to commit to one or two lineages suggesting that the adherent cell population may 
comprise of a set of lineage committed progenitors or the loss of multilineage properties 
upon in vitro expansion (Pittenger et al., 1999).  Since the discovery of MSCs in the 
bone marrow, cells with MSC-like characteristics have been identified in a number of 
adult and foetal tissues (Figure 1.1).  The bone marrow derived non-haemaopoietic stem 
cells have been ascribed different names and further categorised (Section 1.2.4).  
Moreover, trans-differentiation of MSCs to non-mesodermal lineages such as 
ectodermal skin (Sasaki et al., 2008) and neurons (Woodbury et al., 2000, Kopen et al., 
1999) and endodermal myocytes (Ferrari et al., 1998) and hepatocytes (Sato et al., 
2005) has been reported.  However the validity of these plasticity studies is still being 
                                                                                         Chapter 1.  General Introduction 
 
 22 
questioned, mainly due to the variety of MSC isolation techniques employed and 
inappropriate differentiation assays used whereby differentiated cells are not 
characterised by functional assays (Phinney and Prockop, 2007).  Despite these reports 
of MSCs’ ability to differentiate to cells of the three germ layers, the consensus within 
the field is that the cells are ‘multipotent’ rather than ‘pluripotent’. 
 
 
Figure 1.1: Sources of mesenchymal stem cells (MSCs) and their multi-lineage 
potential.  Clonal population of MSCs has been shown to give rise to cells of the 
mesodermal lineage, whereas their potential to differentiate to the ectodermal and 
endodermal lineages is still under debate (denoted by ?). 
 
1.2.1 Surface marker characterisation of hMSCs 
 
Despite the significant progress in understanding MSC biology, to date there is ongoing 
controversy over the cell surface antigen that uniquely identifies MSCs in vitro and in 
vivo (Jones and McGonagle, 2008).  In an attempt to assign a uniform mode of 
identification of MSCs, the International Society for Cellular Therapy (ISCT) has 
established three minimal criteria based on the current state of knowledge (Horwitz et 
al., 2005, Dominici et al., 2006).  MSCs isolated from the bone marrow and other 
tissues of mesenchymal origin must demonstrate in vitro (i) plastic adherence in 
standard culture conditions, (ii) specific surface antigenic profile, and (iii) multipotent 
differentiation potential along the osteogenic, chondrogenic and adipogenic lineages as 
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confirmed by histological staining and other methods.  Plastic adherence and 
multipotency to the required lineages are the undisputed criteria that all workers in the 
field abide by.  The limitation lies in the varied antigenic profile employed by different 
groups to positively identify the hMSC populations even though it is from a common 
source, for instance the bone marrow (Table 1.1).   
 
The consensus of the ISCT, which is not based on the source of the isolated MSCs and 
subject to future modification, dictates that flow cytometry measurements must show at 
least 95 % of the MSC population to express CD73 (ecto-5’-nucleotidase), CD90 (Thy-
1) and CD105 (endoglin), and no more than 2 % of the cell population may express 
CD34 (haematopoietic progenitor and endothelial cell marker), CD45 (pan-leukocyte 
marker), CD11b or CD14 (monocyte and macrophage markers), CD19 or CD79α (B 
cell markers), and HLA-DR (marker of stimulated hMSCs).  Further to the list of 
markers produced by the ISCT, other surface antigens defining hMSC populations have 
been described, although the issue remains whether the markers characterised are able 
to identify freshly isolated as well as cultured hMSCs.  Jones and co-workers (Jones et 
al., 2004) characterised CD271 (also referred to as low-affinity nerve growth factor 
receptor, LNGFR) as a positive marker to identify MSCs in vivo.  Their purification 
protocol consisted of the exclusion of fibroblasts using D7-FIB, and the subsequent 
sorting of the cells to yield hMSCs, of which more than 95 % expressed CD271.  
However, the cells positive for CD271 also expressed HLA-DR (Jones et al., 2006b), 
which according to the ISCT criteria may indicate that the isolated population of cells 
was activated (Dominici et al., 2006).  More recently, CD146 (MCAM//MUC18) has 
been identified as a putative marker for the detection of MSCs.  CD146 is expressed on 
sub-endothelial cells (also referred to as pericytes) which share the properties of hMSCs 
in terms of their ability to support the haematopoetic micro-environment and 
differentiate towards the adipogenic, osteogenic and chondrogenic lineages (Doherty et 
al., 1998, Farrington-Rock et al., 2004).  In this aspect, hMSCs and pericytes are 
thought to share the same identity (Section 1.2.3) (Crisan et al., 2008).  This hypothesis 
is further supported by the observation that both cell populations share a common set of 
markers, among which is STRO-1 (Shi and Gronthos, 2003). 
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Marker/marker combination 
 
Application Reference 
 
CD49a 
 
Isolation 
 
(Deschaseaux and 
Charbord, 2000) 
 
CD105 (SH2) Isolation and 
Characterisation 
 
(Majumdar et al., 2000) 
CD45/GlyA Isolation 
 
(Reyes et al., 2001) 
 
CD271 (LNGFR), D45/GlyA Isolation and 
Characterisation 
 
(Quirici et al., 2002) 
D7-FIB/CD45/CD271/GlyA Isolation and 
Characterisation 
 
(Jones et al., 2002) 
STRO-1/CD106 (VCAM-1) Isolation and 
Characterisation 
 
(Gronthos et al., 2003) 
STRO-1/CD146 Isolation and 
Characterisation 
 
(Shi and Gronthos, 2003) 
STRO-1/ CD63 (HOP-26), 
CD49, CD166 
 
Isolation (Stewart et al., 2003) 
CD49, CD45 Isolation and 
Characterisation 
 
(Deschaseaux et al., 2003) 
CD105, D7-FIB Isolation and 
Characterisation 
 
(Campioni et al., 2003) 
CD45/GlyA, lineage negative 
cocktail (CD3, CD14, CD19, 
CD38, CD66) 
 
Isolation (Tondreau et al., 2004) 
CD73 (SH3), CD105, CD90, 
CD49, CD45 
Isolation (Boiret et al., 2005) 
 
Table 1.1: A review of recently used antibodies to identify bone marrow derived 
MSCs (Adapted from Jones et al. 2006b). 
 
 
                                                                                         Chapter 1.  General Introduction 
 
 25 
1.2.2 STRO-1 as a marker of hMSCs 
 
STRO-1 is an IgM monoclonal antibody discovered by Simmons and Torok-Storb 
(1991) binding to a minor subset, between (0.001 % and 0.01 %) of bone marrow 
mononuclear cells.  In an attempt to raise antibodies against progenitor and precursor 
cells from the CD34 positive bone marrow cells, STRO-1 was identified as an antibody 
selecting for the adherent portion of cells from the bone marrow. Mice were immunised 
intra-splenically with a population of human CD34 positive bone marrow cells and 
boosted four times at 3-week intervals.  Hybridomas were produced by fusion of the 
splenocytes with myeloma cells and cultured for supernatant collections which were 
then screened for antibodies negatively reacting to a panel of B- and T-cells.  STRO-1 
was then identified as an antibody that reacted with less than 10 % of the bone marrow 
mononuclear cells which also included nucleated erythroid progenitors (Glycophorin A 
positive cells).  Using FACS, the STRO-1+/glycophorin A- cell population was found to 
form an adherent layer in culture possessing an enhanced ability to support 
haematopoiesis and exhibiting differentiation potential. 
 
Analysis of STRO-1 expression on fresh bone marrow cells showed that the number of 
positive cells increased over the first two weeks in culture, corresponding to the period 
of adherent layer establishment, followed by a progressive decline.  This modulation in 
STRO-1 expression was argued to be either an in vitro epiphenomenon unrelated to the 
normal regulation of STRO-1 expression taking place in vivo, or the developmentally 
programmed antigen down-regulation caused by in vitro maturation of stromal 
precursors into more differentiated stromal cell types.  Since the nature of the STRO-1 
antigen is as yet unknown (apart from being trypsin-resistant), its role in the regulation 
of MSC’s behaviour remains unclear.  One interesting feature which Simmons and 
Torok-Storb (Simmons and Torok-Storb, 1991) observed was the higher expression of 
STRO-1 on pre-adipocytes compared to mature adipocytes, indicating that the STRO-1 
antigen may be a differentiation antigen present on the cell’s surface before maturation.  
However this aspect of STRO-1 function and its modulation under different conditions 
have not been fully investigated, hence became one of the primary purpose of this 
thesis. 
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Among the panel of markers used to isolate hMSCs, STRO-1 was the only one to 
exhibit a heterogeneous expression characterised by the fluorescence intensity of FACS 
measurement defined by low expression (STRO-1DULL), intermediate expression 
(STRO-1INT) and high expression (STRO-1BRIGHT) (Gronthos et al., 2003).  Following 
sorting, the STRO-1DULL sub-population failed to form the MSC-characteristic adherent 
fibroblastic colonies indicating that the multipotent MSCs reside in the STRO-1BRIGHT 
and STRO-1INT sub-populations.  By using CD106 (also known as, vascular cell 
adhesion molecule-1, VCAM-1) as an accessory marker, the freshly isolated STRO-
1+/CD106+ population exhibited phenotypic characteristics previously attributed to stem 
cells in other renewing tissues; lack of Ki-67 antigen indicating quiescence in vivo, 
telomerase activity in the parent population and their progeny and the undifferentiated 
state as demonstrated by the absence of gene products attributed to mature stromal 
elements such as adipocytes, osteocytes and chondrocytes.  More importantly, highly 
proliferative clones derived from single STRO-1BRIGHT/CD106+ exhibited the tri-lineage 
potential of hMSCs further demonstrating that the multipotent progenitors reside in the 
STRO-1BRIGHT fraction of the population (Gronthos et al., 2003).  As such, the adherent 
population of bone marrow mononuclear cells represent a mixed population of multi-, 
bi- and uni-potential progenitors at different stages of differentiation (Owen and 
Friedenstein, 1988, Pittenger et al., 1999) and the heterogeneous expression of STRO-1 
may be an indicator of the stage of differentiation a cell is at; the multipotent cells being 
the most expressive of STRO-1, although this has yet to be proven. 
 
1.2.3 The perivascular niche of hMSCs 
 
The stem cell niche has been described as a dynamic micro-environment including 
extracellular matrix that mediates local and systemic cues to ultimately influence stem 
cell fate (Chen, 2010).  The concept of stem cell niche was first described in the context 
of haematopoiesis by Schofield (Schofield, 1978).   The niche encompasses stem cells 
as well as the support cells with the secretory mediators which interact to dictate stem 
cell behaviour.  As such, conditions created within the micro-environment by the 
support cells maintain the cells in a quiescent state or trigger proliferation (symmetric 
and asymmetric division) and differentiation in response to inductive factors. 
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The anatomical location and phenotypic characteristics of hMSCs in vivo have not been 
well defined so far because of the lack of definitive marker to identify the cells in situ.  
Several studies have shown that cells with hMSC characteristics are present in a variety 
of adult tissues (Figure 1.1).  This observation led to the concept of hMSCs residing in a 
perivascular niche in close association with blood vessels (Shi and Gronthos, 2003, 
Crisan et al., 2008).  A number of recent reports suggest that hMSCs are directly 
comparable to pericytes by virtue of their phenotypic and differentiation similarities and 
there is mounting evidence indicating that the two cell types may be one and the same 
(Crisan et al., 2008).  Pericytes (also known as Rouget or mural cells; mesangial cells in 
the kidney; Ito cells in the liver) are located adjacent to endothelial cells of capillaries 
and microvessels, and are associated with the smooth muscle cells of macrovessels 
(Andreeva et al., 1998, Tintut et al., 2003).  Similar to pericytes, hMSCs have also been 
isolated from small and large blood vessels and both cell types share a number of 
common markers such as STRO-1, α-smooth muscle actin, CD44, CD73, CD90, CD105 
and CD146 (Shi and Gronthos, 2003, Sacchetti et al., 2007, Crisan et al., 2008).  Their 
similarity is further demonstrated by the ability of pericytes to undergo multi-lineage 
differentiation potential, a crucial characteristic of hMSCs (Doherty et al., 1998, Tintut 
et al., 2003, Farrington-Rock et al., 2004).  Having hMSCs in a perivascular niche 
throughout the body may be beneficial as this could enhance their migratory capability 
and may allow them to home into local and distant tissues in response to systemic 
influences following trauma or disease.  
 
 
 
 
 
 
 
 
 
 
                                                                                         Chapter 1.  General Introduction 
 
 28 
1.2.4 Heterogeneity of non-haematopoietic bone marrow derived stem cells 
 
It is a well established concept that the bone marrow is the reservoir of a heterogeneous 
mix of stem cells capable of regenerating various tissues and organs, categorised as the 
haematopoietic and non-haematopoietic lineage.  Following Fridenstein’s (Friedenstein 
et al., 1987) initial discovery of the plastic adherent MSC population in the bone-
marrow, the non-haematopoietic stem cells have been further characterised and sub-
populations identified.  The presence of these various populations of stem cells in the 
bone marrow is believed to be the result of ‘developmental migration’ of stem cells 
during ontogenesis, whereby the cells are responsive to chemo-attractants such as 
stromal derived growth factor (SDF-1), and home into the bone marrow which provides 
a permissive environment (Nagasawa, 2000).  Based on the different experimental 
strategies used to isolate the non-haematopoietic stem cells (Table 1.1), it is very likely 
that the same cell population may have been assigned different names given the 
common expression of certain markers (Table 1.2).  More-so, the observed phenomenon 
of trans-differentiation (Figure 1.1) may be due to the isolation of a heterogeneous 
population of MSCs with a subset of cells having a more primitive status. 
 
Endothelial progenitor cells (EPCs) 
Bone marrow from post-natal humans and animals have been shown to contain EPCs 
which contribute to vascularisation at injury sites (Asahara et al., 1997, Asahara et al., 
1999).  The EPCs residing in the marrow may be released in response to specific growth 
factors and are able to home to distant locations where they contribute to the 
reconstruction of the vascular network (Kawamoto et al., 2001, Shintani et al., 2001).  
More recently, the recruitment of EPCs in pathologic neovascularisation in diabetic 
retinopathy has been documented (Liu et al., 2010).  Furthermore, EPCs are reported to 
participate in angiogenesis supporting tumour growth and development in a number of 
cancers including lung and breast (Nowak et al., 2010, Le Bourhis et al., 2010). 
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Multipotent adult progenitor cells (MAPCs) 
MAPCs isolated from bone marrow mononuclear cells have been associated with MSCs 
in terms of their fibroblastic morphology, although these cells were reported to be 
pluripotent and having greater proliferation ability than MSCs, possibly due to the fact 
that they are grown in different culture conditions to MSCs.  These cells were first 
identified by Verfaillie’s team in 2002 which was then subject to controversy (Jiang et 
al., 2002).  The reported ability of MAPCs to give rise to the non-mesodermal lineages 
has now been confirmed by a Chinese group which employed a modified protocol to 
that used by Verfaillie’s group to isolate MAPCs from rat bone marrow (Ji et al., 2008).  
More recently, Verfaillie’s group have published a stepwise method to isolate MAPCs 
from rodent bone marrow, a protocol which promises to be reproducible by more 
independent laboratories (Subramanian et al., 2010).  
 
Marrow-isolated adult multilineage inducible (MIAMI) cells 
This cell population was isolated from the bone marrow of people aged three to 
seventy-two years old.  The cells were cultured at low density in low oxygen tension 
conditions and on fibronectin to mimic an in vivo environment (D'Ippolito et al., 2004).  
MIAMI cells exhibited a high proliferative potential with no sign of senescence and 
retained multilineage differentiation potential assessed by the expression of several 
markers of the three germ layers.  However, the contribution of MIAMI cells to 
blastocyst development thus confirming their pluripotency has not been tested to date 
and the in vitro isolation of this same population awaits confirmation by other 
laboratories. 
 
Very small embryonic-like stem cells (VSELs) 
VSELs were first identified in murine bone marrow and then in other organs such as 
foetal liver, spleen and thymus (Kucia et al., 2006).  The same group later identified 
VSELs in human cord blood and presented evidence of its presence in bone marrow of 
young patients (Kucia et al., 2007).  VSELs have been reported to have similar features 
as embryonic stem cells, namely expression of Oct-4 and Nanog among others and their 
relatively small size containing a large nucleus and minimal peripheral cytoplasm.  
Ratajczak and colleagues (Ratajczak et al., 2007) postulate that VSELs are pluripotent 
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stem cells derived from the inner cell mass (epiblast) during embryogenesis and become 
deposited in the bone marrow.  These cells are able to last through adulthood and are 
recruited to injury sites to assist in tissue repair.  
 
Mature Mesenchymal Stem Cells (mMSCs) and Recycling Stem cells (RS-1 and RS-2) 
Prockop’s group reported the identification and characterisation of a group of cells 
(termed Recycling Stem (RS) cells) which are distinct from MSCs by virtue of their 
very small round shapes and their ability to rapidly self-renew (Prockop et al., 2001).  
These cells were isolated from adult bone marrow and cultured at very low densities (as 
low as 0.5 cell/cm2) (Colter et al., 2000).  The RS cells were further divided based on 
their prevalence at different growth stages of the cultures and their granularity as 
assessed by flow cytometry scatter plots.  The cultures were defined as a heterogeneous 
mix of cells categorised as follows: mature MSCs (mMSCs) which were large and 
moderately granular, resting RS-1 cells which were small and agranular and finally 
cycling RS-2 cells which were small and granular.  Their antigenic profiles and 
differentiation potential was also assayed.  Of particular interest, STRO-1 expression 
was low on the mMSCs while the RS cells were negative for STRO-1, although RS 
cells displayed a better tri-lineage differentiation potential (adipogenic, osteogenic and 
chondrogenic lineages) than mMSCs (Colter et al., 2001).   
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Type of bone marrow derived 
non-haematopoietic stem cells 
 
Antigenic Phenotype 
 
Mesenchymal stem cells 
(MSCs) 
 
International Society for Cellular Therapy Criteria: 
CD105+, CD73+, CD90+, CD45-, CD34-, CD14-, 
CD11b-, CD79a-, CD19-, HLA-DR-  
 
Endothelial progenitor cells 
(EPCs) 
CD133+, CD34+, c-kit (CD117)+, VE-cadherin+, 
VEGFR2+, CD146+, vWF+, CD31+ 
 
Multipotent adult progenitor 
cells (MAPCs) 
SSEA-1+, CD13+, Flk-1low, Thy-1low, CD34-, CD44-, 
CD45-, CD117 (c-kit)-, MHC I-, MHC II- 
 
Marrow-isolated adult-
multilineage inducible 
(MIAMI) cells 
CD29+, CD63+, CD81+, CD122+, CD164+, c-met+, 
BMPR1B+, NTRK3+, CD34-, CD36-, CD45-, CD117 
(c-kit)-, HLA-DR- 
 
Very small embryonic-like stem 
cells (VSELs) 
CXCR4+, AC133+, CD34+, SSEA-1+ (mouse) or 
SSEA-4+ (human), AP+, c-met+, LIF-R+, CD45-, Lin-, 
CD90-, CD29-, CD105-, MC I-, HLA-DR- 
 
Mature Mesenchymal Stem 
Cells (mMSCs) 
 
 
Recycling Stem Cells 1 (RS-1 
cells) 
 
 
Recycling Stem Cells 2 (RS-2 
cells) 
CD34-, CD113 (Mac-1)-, CD43-, CD45-, CD31low, 
CD38low, CD117 (c-kit)low, STRO-1low, CD90 (Thy-
1)+, Flk-1- 
 
CD34-, CD113 (Mac-1)-, CD43-, CD45-, CD31low, 
CD38low, CD117 (c-kit)-, STRO-1-, CD90 (Thy-1)low, 
Flk-1+ 
 
CD34-, CD113 (Mac-1)-, CD43-, CD45-, CD31low, 
CD38low, CD117 (c-kit)-, STRO-1-, CD90 (Thy-1)-, 
Flk-1low 
 
 
Table 1.2: Non-haematopoietic stem cells identified in the bone marrow and their 
relative antigenic profiles.  Minus sign (-) infers no expression while (low) infers 
low levels of expression.  (Adapted from Ratajczak et al., 2007). 
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1.3 Therapeutic applications of hMSCs 
 
hMSCs stand out as a very promising therapeutic candidate for a variety of emerging 
unmet medical needs.  Apart from being ethically favoured, hMSCs offer a range of 
advantages which include: in vitro expansion, multipotency and possible plasticity, 
paracrine effects, immunomodulatory properties and migratory behaviour (Miura et al., 
2006).  Since the pioneering work of Dr Alexander Friedenstein (Friedenstein et al., 
1987, Friedenstein et al., 1970), the last decade has witnessed an overwhelming number 
of reports documenting the prospects of hMSC application in pre-clinical and clinical 
settings (reviewed in (Caplan and Bruder, 2001, Salem and Thiemermann, 2009). 
 
1.3.1 Orthopaedic applications 
 
MSCs have been exploited primarily for their multipotential ability and the prospect of 
differentiating them to bone and cartilage in vitro and in vivo poses them as a valuable 
tool in skeletal tissue regeneration.  Remodelling of bone is continuous throughout life 
in order to maintain skeletal integrity and mechanical strength.  Bone homeostasis is 
dependent on the fine balance between bone producing cells (osteoblasts, derived from 
MSC) and bone resorbing cells (osteoclasts, derived from HSC) (Section 1.4) (Bielby et 
al., 2007).  MSCs play a key role in this process as they directly influence the rate at 
which osteoblasts are formed and mature into osteocytes.  However, under certain 
conditions, such as fractures and diseases including osteoporosis, osteoarthritis and 
cancer, this balance is lost leading to poor bone healing and reduced bone strength 
(Masi and Brandi, 2001).  Furthermore, the associated connective tissues including 
cartilage, tendon and ligament exhibit a limited regeneration capacity in response to 
damage caused by trauma or disease.  To address these issues, a variety of MSC 
preparations have been assayed as novel cell-based therapies for the repair of damaged 
skeletal tissues, including cranial bones and articular cartilage (Chang et al., 2004, 
Chang et al., 2008).  These MSC preparations are based on optimal numbers of MSC 
which are either directly injected into the targeted site or cultured as explants in 2D and 
3D cultures.  
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A wide range of scaffolds have been used as a vehicle for MSC grafts, ranging from 
biodegradable natural materials such as silk (Kim et al., 2008), extracellular matrix 
materials such as collagen (Howard et al., 2008) and synthetic polymers like poly 
glycolic acid (PGA) and poly lactic acid (PLA) (Jiang et al., 2006).  While the optimal 
biocompatibility properties are still being studied, the advent of TheriForm 3D-printing 
process has made it possible to design ‘made-to-measure’ scaffolds.  This process has 
already been implemented in clinical trials of cartilaginous defects whereby scaffolds 
are prepared based on the shape and size required (Sherwood et al., 2002).  
Furthermore, alternatives to the above-mentioned traditional scaffolds coupled with 
optimal culture conditions are currently being developed (Frith et al., 2009).  In the 
laboratory setting, MSCs have been successfully grown as sheets and then attached onto 
bone grafts which facilitate their differentiation into osteochondral derivatives (Ouyang 
et al., 2006).  However, the efficacy of this new generation of tissue engineering awaits 
validation in large animal pre-clinical and human clinical studies. 
 
1.3.2 Immunomodulation 
 
Solid organ and tissue transplantations often result in alloreactivity whereby the host 
rejects the grafted foreign material, a condition known as graft-versus-host disease 
(GVHD).  Treatment of GVHD following transplantation requires life-long 
administration of aggressive immunosuppressive drugs including corticosteroids, anti-
metabolites and T cell depletion cocktails.  These therapies are often accompanied by 
opportunistic infections in the immunodeficient individual thereby increasing the risk of 
graft rejection and relapse.  Further complications arise in steroid-refractory GVHD 
whereby the traditional steroid therapy is rendered ineffective due to resistance.  MSCs 
display two major immunological properties which could potentially be exploited for 
diseases requiring allografts; MSCs do not express co-stimulatory antigens such as B7 
(immunoprivileged) and inhibit T cell proliferation (immunosuppressive) (reviewed in 
(Brooke et al., 2007). 
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Canine studies have demonstrated the successful engraftment of major 
histocompatibility complex (MHC)-mismatched MSCs in large bone defects.  The 
implanted MSCs were able to regenerate new bone tissues at the site of injury with no 
evidence of immunologic rejection (Kraus and Kirker-Head, 2006).  It is possible that 
the implanted MSCs only act as an initiator of the tissue regeneration cascade, whereby 
the new or re-modelled tissue is formed from the subsequent mobilisation of autologous 
migratory MSCs to the repair site.  Although, the underlying mechanism related to this 
procedure is still under investigation, the promising results observed in this pre-clinical 
study suggest that allogeneic MSCs could be made available as an ‘off-the-shelf’ 
therapy for such tissue engineering applications.   
 
The immunosuppressive mechanism of MSCs has not been fully identified but is known 
to involve several factors such as cytokines which lead to T cell suppression (Aggarwal 
and Pittenger, 2005, Le Blanc and Ringden, 2007).  A number of case reports 
demonstrate the use of MSC to successfully prevent transplantation rejection and 
resolve drug refractory GVHD (Le Blanc et al., 2004, Lazarus et al., 2005).  On a larger 
scale, the European Bone Marrow Transplant Group reported a 68 % overall positive 
response following MSC treatment of 40 patients with grades III-IV GVHD (Brooke et 
al., 2007).  A Phase II trial conducted by Osiris Therapeutics (Osiris Therapeutics Inc. 
website: www.osiristx.com) reported a higher complete response rate in GVHD patients 
treated with corticosteroids and MSC compared to those treated with corticosteroids 
alone.  Despite the lack of understanding in the immunosuppressive mechanism of 
action of MSCs, the promising results from case studies have prompted increased 
interest in the use of MSCs as GVHD therapy in the clinic. 
 
1.3.3 Cardiovascular applications 
Research in the use of MSCs in the instance of cardiovascular disease has increased 
over the past decade.  Whether it be in the case of cardiac dysfunction or myocardial 
ischaemia, cellular therapy using MSCs represents a promising tool for tissue repair as 
they may have the potential to generate functional cardiomyocytes and contribute to the 
generation of new blood vessels to support and nourish the regenerating tissues (Psaltis 
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et al., 2008).  Clinical transplantation of MSCs for cardiovascular applications is also 
facilitated by the local immuno-suppressive properties and mobilisation of the cells to 
the site of repair (Wang and Li, 2007, Zannettino et al., 2008).  The proposed 
mechanisms of the reparative action of MSCs are illustrated in Figure 1.2.  Of particular 
interest, an in vitro investigation of STRO-1 enriched MSCs from bone marrow 
mononuclear cells displayed enhanced cardio-therapeutic properties compared to plastic 
adherent MSCs.  The STRO-1 enriched cells displayed paracrine influence on 
cardiomyocytes with respect to cardiac cell proliferation and migration.  Moreover 
conditioned media from the STRO-1 positive cells was shown to enhance endothelial 
cell migration and tube formation (Psaltis et al., 2010).  Taken together, the successful 
identification of MSCs with enhanced reparative properties and the prospective 
successful in vivo application to repair cardiac tissues may improve the outcome of 
clinical trials and speed the use of MSCs in clinical settings. 
 
   
Figure 1.2: Proposed mechanisms of action of MSCs mediating cardiovascular 
repair.  Paracrine mechanisms contributing to the reparative effects of MSC 
transplantation may be mediated by the release of soluble cytokines or growth factors as 
well as direct contact between transplanted cells and resident cardiac cells.  In vivo 
transdifferentiation of MSCs into functional cardiomyocytes or vascular cells is limited 
by current transplantation strategies (Adapted from Psaltis et al., 2008). 
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1.4  Bone development 
 
Bone is a highly specialised form of connective living tissue and functions as an internal 
support system in all higher vertebrates.  With a mineralised extracellular matrix, bone 
confers strength and rigidity to the skeleton, while maintaining some degree of 
elasticity.  There are two forms of bone distinguished by their structural and functional 
differences: cortical (compact) bone providing mechanical and protective functions and 
cancellous (spongy) bone providing metabolic functions.  Bone is composed of four 
different cell types, namely osteoblasts, osteoclasts, bone lining cells present on the 
bone surface and osteocytes integrated into the mineralised interior (Aubin and Liu, 
1996).  Osteoblasts, osteocytes and bone lining cells originate from MSCs involved in 
bone formation while osteoclasts arise from mononuclear precursors (monocyte-
macrophage fusion) of haematopoietic origin involved in bone resorption.  Osteoblasts 
are responsible for the formation of the bone matrix by secreting type I collagen and 
mature to osteocytes which in turn take up the role of maintaining the matrix.  Besides 
synthesising matrix, osteocytes are capable of resorption but to a lesser extent than 
osteoclasts (Sims and Gooi, 2008).  Osteocytes have well-developed filopodial 
processes which allow communication with adjacent cells, internal and external surfaces 
of the bone and with blood vessels running through the matrix (Matsuo and Irie, 2008).  
Bone lining cells are flat and elongated cells which appear dormant on the bone surfaces 
and possessing no functional characteristics.  These cells do not participate in bone 
formation or resorption but it is speculated that they may be precursors for osteoblasts 
under specific stimuli (Dobnig and Turner, 1995). 
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1.4.1 Bone formation (ossification) and the osteoblast lineage 
 
There are two types of bone formation processes occurring during foetal development: 
endochondral and intra-membranous.  Endochondral ossification occurs by the 
condensation of MSCs to form a primary cartilage model which acts as a template that 
is later replaced by bone.  Long bones of the arms, legs and ribs are formed in this way.  
Intra-membranous ossification is responsible for the development of flat bones of the 
skull and remodelling the outer surfaces of long bones (periosteal).  It occurs by the 
condensation of MSCs and direct differentiation to osteoblasts, without the formation of 
cartilage (Olsen et al., 2000).  In this thesis, emphasis will be laid on intra-membranous 
ossification which occurs during remodelling of long bones of adults. 
 
Irrespective of the route of bone formation, the end result of osteo-induction signals is 
the formation of mature functional osteoblasts capable of structuring tissues 
recognizable as bone.  The osteoblast lineage consists of four maturational stages and 
these have been identified in situ as: pre-osteoblast, osteoblast, osteocyte and bone 
lining cell (Figure 1.3).  Pre-osteoblasts arise from MSCs and are considered the 
immediate precursors of osteoblasts.  They are positioned adjacent to the osteoblast 
layers which line the bone forming surfaces.  Despite their morphological resemblance 
to osteoblasts (including positive alkaline phosphatase activity), pre-osteoblasts lack the 
differentiated characteristics associated with mature osteoblasts.  Unlike osteoblasts, 
pre-osteoblasts are believed to have the ability to proliferate to a limited extent.  
Osteoblasts are post-proliferative cells with a cuboidal morphology situated along the 
sites of active bone matrix production (Franceschi, 1999).  The mature osteoblasts are 
characterised by the ability of the cells to synthesise membrane-associated alkaline 
phosphatase, hormone and specific growth factor receptors (parathyroid hormone 
receptor PTH-R), bone matrix macro-molecules such as α1 collagen type I (Col1A1) 
and a variety of non-collagenous proteins including osteocalcin (OCN), osteopontin 
(OP), bone sialoprotein (BSP) and proteoglycans (Franz-Odendaal et al., 2006).   
 
The osteoblast repertoire is a spectrum of cells at different stages of maturation and 
therefore, different osteoblasts may express only a subset of these molecules at a given 
time.  Osteoblasts are metabolically active and have well-developed organelles; large 
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eccentric nucleus with one to three nucleoli, prominent rough endoplasmic reticulum 
(RER) and Golgi bodies.  A small proportion of osteoblasts, estimated at 10-20 %, 
incorporate themselves within the newly formed extracellular matrix (osteoid).  These 
cells are considered to be at the most mature differentiation stage of the osteoblast 
lineage and are termed osteocytes.  The sequential transition of osteoblasts to osteocytes 
is characterised by a reduction in intracellular organelles corresponding to a decrease in 
protein synthesis and secretion (Dudley and Spiro, 1961).  Many of the previously 
expressed bone markers become down-regulated or switched off.  The mature 
osteocytes may adopt different shapes depending on the bone type: woven bone 
consisting of random organisation of collagen fibres and mechanically weak have 
isodiametric osteocytes while lamellar bone consisting of regular parallel alignment of 
collagen sheets (lamellae) and mechanically strong has flattened osteocytes.  Within the 
bone matrix, mature osteocytes are stellate-shaped with long cell processes (Currey, 
2003). 
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Figure 1.3: The different stages in osteoblast differentiation. Multipotent 
mesenchymal stem cells (MSC) commit to the osteoblast lineage by giving rise to the 
osteo-progenitor cells which possess limited self-renewal but extensive proliferation 
potential.  As the progenitor cell differentiates, they lose their proliferative potential and 
in response to specific stimuli become specialised cells which maintain the bone 
structure (Adapted from Aubin and Liu, 1996). 
 
1.4.2 Regulation of the osteoblast lineage 
 
Bone formation during both development and remodelling requires stringent control of 
osteoblast proliferation and differentiation.  The regulation of these processes involves 
the temporal expression of cell growth and bone-specific genes in response to 
physiological mediators, such as growth factors and hormones.  Once MSCs are 
committed to the osteoblast lineage, they undergo a series of morphological and 
functional changes which are triggered by specific changes in gene expression.  The 
sequential progression of the uncommitted stem cell to the mature osteocyte is tightly 
regulated and any failure in the control mechanism may result in diseased conditions 
(Aubin and Liu, 1996).  
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The key molecular players in osteogenesis can be divided into intracellular messengers 
including the transcription gene Cbfa-1 (core binding factor 1) and the Wnt-β-catenin 
canonical pathway and extracellular messengers such as bone morphogenic proteins 
(BMPs).  Other equally important factors influencing osteogenesis has been reviewed in 
(Deschaseaux et al., 2009).   
 
Cbfa-1 as the master gene of bone formation 
Cbfa-1 is a runt-related gene also referred to as Runt-related 2 (Runx2).  It is the master 
transcription factor involved in commitment to the osteogenic lineage and functions by 
binding DNA via its runt domain (Figure 1.4).  Cbfa-1 is a nuclear factor binding to 
OSE2 (osteoblast-specific cis-acting element 2) found at the promoter sites of bone-
specific genes such as osteocalcin (OCN), bone sialoprotein (BSP), osteopontin (OP) 
and the α1 type I collagen gene (Col1A1) (Ducy, 2000).  The involvement of Cbfa-1 in 
the regulation of these vital osteoblastic genes was revealed by functional experiments 
in the first instance in vitro and later confirmed by in vivo work.  Forced expression of 
Cbfa-1 in primary fibroblasts resulted in the expression of OCN and BSP (Ducy et al., 
1997) while silencing the gene inhibited the expression of these proteins (Banerjee et 
al., 1997, Ducy et al., 1997).  Hinoi et al. (2006) demonstrated that Cbfa-1 deficient 
(Cbfa-1-/-) mice were unable to survive and exhibited no bone formation further 
indicating that Cbfa-1 is a major factor in osteoblastic differentiation.   
 
The binding of Cbfa-1 to DNA has been shown to be affected by various factors (Figure 
1.4).  During early development before commitment to the osteoblastic lineage, the 
nuclear protein Twist-1 and Cbfa-1 are transiently expressed, whereby Twist-1 delays 
osteogenesis by inhibiting Cbfa-1 activity.  Upon initiation to the osteogenic lineage, 
Twist-1 is degraded causing activation of Cbfa-1 which induces the cell to differentiate 
(Bialek et al., 2004).  During osteoblast differentiation, other nuclear proteins are able 
to inhibit Cbfa-1 by physically interacting with its DNA binding domain.  One such 
protein is the transcription factor signal transducer and activator of transcription 1 
(Stat1), which is modulated by extracellular signals such as interferons (Kim et al., 
2003).  Schnurri 3 (Shn3) is a zinc finger adapter protein which also acts as an inhibitor 
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of Cbfa-1 (Jones et al., 2006a).  Both Stat1 and Shn3 negatively regulate Cbfa-1 activity 
by preventing its translocation to the nucleus.   
 
Positive regulators of Cbfa-1 have also been identified; homeobox-containing protein 
muscle segment homeobox homolog (MSX2), an upstream promoter of Cbfa-1 
(Satokata et al., 2000) and special AT-rich sequence-binding protein 2 (Satb2), a 
nuclear matrix protein (FitzPatrick et al., 2003).  Satb2 positively influence osteoblast 
differentiation either by directly binding to the promoter element of BSP or in the case 
of OCN, by physical interaction with Cbfa-1 (Dobreva et al., 2006).  Satb2 is also able 
to exert its influence on bone formation via inhibition of the homeo box A2 (Hoxa2), a 
negative regulator of bone formation, by binding to the enhancer element present in the 
Hoxa2 promoter region (Kanzler et al., 1998).  Mouse models have shown the 
involvement of another transcription factor termed Osterix (Osx), found to be crucial to 
bone development.  Osx is an osteoblast-specific zinc finger-containing transcription 
factor.  Osx specifically affects intra-membranous bone formation whereby Osx-
deficient mice were deprived of mineralised matrix (Nakashima et al., 2002).  Osx is 
thought to exert its effect downstream of Cbfa-1 in the transcriptional cascade of 
osteoblast differentiation and that its expression is directly controlled by the binding of 
Cbfa-1 to the promoter region of Osx (Nishio et al., 2006).  Recent studies have 
identified other Osx-interacting molecules which may enhance bone formation.  The 
transcription factor Nfatc1 (nuclear factor activated T cell 1) coupled with Osx form a 
DNA binding complex which activates the promoter fragment of Col1A1, a vital 
component in bone formation (Koga et al., 2005).  The transcriptional control of 
osteoblast differentiation is a complex mechanism which requires tight regulation to 
maintain the balance between cell proliferation and cell differentiation at each stage of 
the developmental programme.   
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Figure 1.4:  Schematic representation of the regulation of cellular differentiation 
along the osteoblast lineage.  Lines with arrowheads indicate activation and lines with 
bars indicate inhibition.  In blue is transcriptional control and in red is post-
transcriptional control.  
 
Wnt-β-catenin canonical pathway in bone formation 
Wnt molecules are a family of secreted proteins which are crucial to osteogenesis 
(particularly Wnt 1, 3a, 4, 5, 10b and 13), among many other cellular functions (Liu et 
al., 2008). Activation of the Wnt-β-catenin pathway positively influences proliferation 
and differentiation of MSCs to the osteogenic lineage while inhibiting the formation of 
adipocytes and chondrocytes (Takada et al., 2007).  Wnts act by binding to their 
membrane receptors, Frizzled 1 (Fzd1), 2, 4 and 5, and their co-receptor low-density 
lipoprotein receptor-related protein 5 (Lpr5) and 6.  Following receptor binding, the 
canonical signalling pathway is activated and β-catenin is translocated to the nucleus 
(Etheridge et al., 2004).  This involves dishevelled (Dsh) and axin cytoplasmic proteins 
moving to the membrane to inhibit β-catenin degradation, consequently causing 
accumulation of β-catenin in the cytoplasm and nucleus.  In the nucleus, β-catenin 
interacts with a transcription repressor lymphoid enhancer-binding factor/T-cell-specific 
transcription factor (LEF/TCF).  This allows activation of gene transcription via the 
recruitment of the histone acetylase CBP/p300 (CREB binding protein).  In the absence 
of Wnt, β-catenin is phosphorylated by GSK3β leading to its degradation by 
ubiquitination.  Wnts are able to act endogenously and their effects appear to be 
concentration dependent.  High levels of endogenous Wnt appear to favour proliferation 
to differentiation (Deschaseaux et al., 2009).  On addition of specific inhibitors such as 
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Dickkopfs 1 (DKK1), Wnt signals are decreased and osteogenesis is induced.  DKK1 
binds to Lpr5 co-receptor to modulate Wnt signalling and its effect has been 
demonstrated in DKK1-deficient mice which showed increased bone mass (Morvan et 
al., 2006).   
 
Bone Morphogenetic Proteins (BMPs) 
BMPs are members of the transforming growth factor β (TGFβ) family of paracrine 
factors (Grimaud et al., 2002).  There are two major forms of BMP receptors; type I 
receptors also known as Activin receptor-like kinase (Alk) 1-7 and type II receptors 
which are constitutively active and phosphorylate type I receptors upon ligand binding.  
Alk2, 3 and 6 are targets for BMPs while Alk4 and 5 are targets for activin (TGFβ-like 
protein) and TGFβ1, respectively.  On activation by the type II BMP receptors, Alks 
transduce signals to Smad proteins within the cytoplasm.  The different Smad molecules 
are then able to form complexes which are translocated to the nucleus to activate 
specific target genes (Chen et al., 2004).  The BMPs (notably BMP2 and BMP4) play a 
crucial role in terminal differentiation of osteoblasts and do so by activating the 
transcription factor Osx downstream of Cbfa-1 via the Smad pathway (Nakashima et al., 
2002). However in a recent study by Seib and colleagues (Seib et al., 2009), 
endogenously expressed BMPs (particularly 2, 4 and 6) were found to be active through 
a mitogen-activated protein kinase pathway (MAPK) rather than the Smad pathway.   
 
The MAPK pathway acts at different stages of the differentiation process and is 
involved in activating molecules by phosphorylation.  MAPK responds to the 
extracellular molecular environment and exerts its effect on either proliferation of MSC 
or commitment to differentiation depending on the stimuli, which includes growth 
factors and pro-inflammatory molecules (Xiao et al., 2000).  The pivotal roles of 
MAPK include phosphorylation of master transcription factor Cbfa-1 in pre-osteoblasts, 
activation of GSK3β in the Wnt pathway leading to β-catenin accumulation and pro-
osteogenic signal transduction triggered by endogenous BMPs (Thornton et al., 2008). 
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1.5  Osteosarcoma (OS) 
 
The mechanism of bone formation is a complex process involving intricate pathways 
which necessitate numerous regulatory checkpoints.  Despite advances in the field of 
bone biology, the molecular mechanisms and transcriptional regulators mediating the 
decisions of cell differentiation and osteoblast-specific gene expression are not well 
understood.  Impaired regulatory elements at any stage of the osteoblast lineage results 
in bone pathologies, among which is osteosarcoma (OS). 
 
OS is a tumour of the bone and mainly affects adolescents when skeletal growth is at its 
peak.  OS is the most common non-haematopoietic cancer and has a poor prognosis in 
patients with relapse or recurrence (Bruland and Pihl, 1997, Meyers and Gorlick, 1997, 
Toledo et al., 2010).  Several proto-oncogenes such as c-myc, c-ras, c-sis, c-bos and c-
abl have been implicated in OS induced conditions, but none of them could be 
attributed to a particular osteoblast phenotype (Schon et al., 1986, Bogenmann et al., 
1987, Nardeux et al., 1987).  As in other cancer pathologies, inactivating mutations in 
the tumour suppressor genes pRb and p53 have been found to contribute to uncontrolled 
cellular proliferation in OS (Diller et al., 1990, Miller et al., 1996).  While there is no 
one specific gene mutation identified in osteosarcoma specimens, one key player, the 
nuclear oncogene and transcription factor c-Fos, has been identified as an important 
regulator of the fate of specific bone cell populations, both in normal development and 
in bone disease (Grigoriadis et al., 1995).  The expression of c-fos is known to be 
elevated in OS derived from both mice and human (Wu et al., 1990, Honoki et al., 
1992).  The c-fos onco-protein is a major component of AP-1 transcription factor 
complex, which also includes several other Fos-related and Jun-related proteins 
(Ransone and Verma, 1990).  Fos-Jun complexes activate gene transcription by directly 
binding to the regulatory region of the target gene (Angel and Karin, 1991) and suppress 
gene transcription by physical protein-protein interaction (Beato et al., 1995).  In 
response to extracellular signals, c-fos is able to mediate short and long-term changes in 
gene expression to modulate cellular proliferation and differentiation suggesting its 
involvement in the osteoblastic lineage. 
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1.5.1 Stem Cells and Cancer 
 
Under normal circumstances, stem cells generate tissue-specific differentiated cells in 
response to damage or to tissue renewal.  However, genetic mutations in the precursor 
cells may result in uncontrolled tissue regeneration and tumour formation.  The two 
major properties of stem cells are that of extensive self-renewal ability and 
differentiation potential.  Based on these criteria, cancers are believed to be a disease of 
stem cells (McDonald et al., 2009).  Firstly, according to the mutation and selection 
theory of cancer, stem cells represent a rare population of cells which are able to survive 
long enough to accumulate the requisite number of genetic changes leading to aberrant 
self-renewal and tumour formation (Tomlinson and Bodmer, 1999).  Secondly, the 
presence of multiple cell types within a tumour mass points towards a multipotent cell 
origin (Pierce, 1977). 
 
Many reports suggest similarities between normal stem cells and tumourigenic cells.  To 
better illustrate this comparison, it is fair to view a tumour as an aberrant organ (Reya et 
al., 2001).  According to the principles of normal stem cell biology and organogenesis, 
the aberrant organ is believed to originate from a tumorigenic cancer cell which has 
acquired the ability for unlimited proliferation via accumulated mutations (Morrison et 
al., 1997).  As such, both normal stem cells and tumorigenic cancer cells have an 
extensive proliferative potential and the ability to form new tissues (normal and 
abnormal) (Weissman, 2000).  Normal tissues as well as tumours are composed of a 
heterogeneous population of cells with varied phenotypic characteristics and 
proliferative potentials (Fidler and Hart, 1982, Heppner, 1984). 
 
Although some of the heterogeneity observed in tumours is due to continuing 
mutagenesis, it is likely that the heterogeneity also arises from aberrant differentiation 
of cancer cells. The presence of cancer cells with heterogeneous phenotypes within a 
tumour has been reported in different cancers and appears to depict the normal aspects 
of differentiation in the tissues from which the tumours arise (Fialkow, 1976).  This is 
further supported by the variable expression of normal differentiation tissue-specific 
markers on cancerous cells within a tumour indicating anomalous differentiation of the 
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tumour cells (Sell and Pierce, 1994).  Analogous to normal stem cells, tumorigenic cells 
are able to give rise to phenotypically heterogeneous cells which exhibit different levels 
of differentiation.  The anomaly resides in the fact that the aberrant organ (tumour) 
formed from the cancer cells has no functional characteristics and is detrimental to the 
individual. 
 
1.5.2 Evidence of Cancer Stem Cells (CSCs) 
 
In 1977, Hamburger and Salmon proposed the cancer stem cell theory which was based 
on the observation that only a sub-population of cancer cells was able to form colonies 
in a soft agar in vitro assay (Hamburger and Salmon, 1977).  The first set of in culture 
and in vivo experiments were carried out on haematopoietic cancers such as leukaemia 
and multiple myeloma (Park et al., 1971, Bruce and Van Der Gaag, 1963).  These 
observations were later extended to solid cancers whereby it was shown that the 
tumours were phenotypically heterogeneous and only a small proportion of cells (1 in 
1000 to 1 in 5000 for lung, ovarian and neuroblastoma cells) was able to proliferate in 
vitro and in vivo (Fidler and Kripke, 1977, Nowell, 1986).  Although the rarity of these 
tumourigenic cells is still being debated, the cancer stem cell theory is gaining 
popularity and putative markers for the identification of this cell subset are being 
investigated (Yoo and Hatfield, 2008).  Existing cancer therapies which are aimed at 
tumour shrinkage are based on the stochastic model (Figure 1.4 A) but the failure of 
these approaches suggests that the cancer stem cell model (Figure 1.4 B) may be more 
appropriate.   
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Figure 1.5: Two models of heterogeneity in solid cancer cells.  (A) Stochastic model; 
cancer cells of different phenotype have extensive proliferation potential and any one 
cell is able to generate new tumours when transplanted.  (B) Cancer Stem Cell model; 
cancer cells are heterogeneous and only the cancer stem cells (CSCs; in red) have 
extensive proliferation potential and are able to generate tumours when transplanted.  
(Adapted from (Reya et al., 2001). 
 
1.5.3 Markers of CSCs 
 
CSCs feature as a promising target in cancer therapy as these cells are thought to be 
responsible for cancer relapses, due to their resistance to chemotherapy and ability to 
extensively proliferate (Mimeault et al., 2007).  Considerable effort is being invested in 
the quest for markers of CSCs and there is mounting evidence to suggest that these 
malignant cells would have retained certain molecules expressed by their normal 
counterparts (McDonald et al., 2009).  Most of the markers studied appear to be 
restricted to the tissue the tumours are derived from and may not represent a general 
marker for all CSCs.  Among them are molecules involved in maintaining stemness, 
niche adhesion and cytoprotection (Alison and Islam, 2009). 
 
CD44 is a multi-structural and multi-functional transmembrane glycoprotein often over-
expressed on tumour cells. Originally described as a lymphocyte homing receptor 
(Gallatin et al., 1983), the different splice variants of CD44 were later shown to be 
implicated in cancer metastasis (Gunthert et al., 1991).  Cancer progression is greatly 
dependent on the tumour cell’s ability to attach to and detach from the various cellular 
components during migration.  CD44 has been shown to play a crucial role as an 
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adhesion molecule mediating cell to cell and cell to extra-cellular matrix interaction, 
promoting dissemination of malignant cells (Jothy, 2003, Marhaba and Zoller, 2004).  
As such the enhanced expression of CD44 in combination with other markers has been 
used to identify CSCs in a number of solid cancers (Section 1.5.3).  More recently, 
CD44 is being investigated as a therapeutic target for metastasising tumours by 
induction of apoptosis in the cancer cells (Orian-Rousseau, 2010). 
 
Putative CSCs are able to withstand cytotoxic insults by efficient enzyme-based 
detoxifying mechanisms or rapid efflux of potentially harmful xenobiotics.  Indeed, 
these cells have been shown to have elevated expression of aldehyde dehydrogenase 
(ALDH) gene superfamily encoding detoxifying enzymes and ATP-binding cassette 
(ABC) superfamily of membrane transporters (Vasiliou and Nebert, 2005).  Treatment 
of human colorectal tumours with cyclophosphamide resulted in an enrichment of 
CD44+ALDH+ cells, subsequently found to be more tumourigenic than cells enriched on 
the basis of CD44 alone (Dylla et al., 2008), indicating that the double positive cells 
may represent the CSC population.  The ABC proteins are able to hydrolyse ATP and 
efflux substrates against concentration gradients.  These transporters are found on a 
subpopulation of cells, referred to as the ‘side population’ (SP) by virtue of their ability 
to efflux the Hoechst dye (Goodell et al., 1996).  The SP phenotype has often been 
associated with the stem cell population in cancers, for instance ABCG2 transporter, 
also known as the breast cancer resistance protein (Hirschmann-Jax et al., 2005).  
However, this observation does not stand for all tissues as SP cells have been found to 
correspond to a non stem cell population in the human and mouse epidermis (Triel et 
al., 2004).  In a study by Alison and co-workers (Alison et al., 2006b), it was found that 
the SP cells from colorectal cancers were not enriched in CSCs and that both SP-
enriched and SP-negative cells were equally able to induce tumours in immunodeficient 
mice.   
 
In the recent years, the molecule CD133 (Prominin-1) has gained widespread popularity 
in the CSC field.  CD133 is a pentaspan membrane protein originally identified on 
plasma membrane protrusions such as epithelial microvilli and epididymal ductal 
epithelial sterocilia.  AC133 antigen, a glycosylation-dependent epitope of CD133, was 
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later found to be expressed on CD34+ progenitor populations from adult blood and bone 
marrow, featuring CD133 as a marker of haematopoietic progenitors (Yin et al., 1997).  
Since then, CD133 has been explored as a cell surface marker of adult stem cells.  A 
number of studies have reported the use of CD133 positive cells as stem cells capable of 
self-renewal and multi-lineage differentiation (Mizrak et al., 2008).  For instance, 
CD133+ cells isolated from the adult human kidney were shown to regenerate renal 
tissues by differentiating to both the epithelial and endothelial lineages (Bussolati et al., 
2005) and more recently CD133+ cells isolated from the human embryonic forebrain 
were used to enrich for neural progenitors (Barraud et al., 2007).  While CD133 has 
been used as a marker of stem cells in many adult tissues, it has also been studied as a 
marker of CSCs in various human tumours (Table 1.3).  CD133+ cells are generally 
assessed as being CSCs by their ability to form colonies and proliferate in vitro and 
their potential to recapitulate the original tumour phenotype when transplanted either 
subcutaneously or into the renal capsule of immunodeficient mice (O'Brien et al., 2007, 
Yin et al., 2007).   
 
Recent work by Tirino and co-workers (Tirino et al., 2008) reported to have identified 
the CSC population in osteosarcoma using CD133 as a positive marker.  Using three 
osteosarcoma cell lines (MG-63, Saos-2 and U-2-OS), they found that about 3 to 5 % of 
the whole population were CD133+ by flow cytometry while immuno-fluorescence data 
revealed that all the three cell lines exhibited positive intracellular staining.  Of the cell 
subset displaying surface CD133 expression, only a small proportion (0.97 %) exhibited 
characteristics attributed to CSCs,  namely the SP profile and presence of the ABCG2 
transporter (member of the ABC superfamily of membrane transporters).  However, the 
tumorigenicity of the CD133+ population remains to be confirmed in vivo given that to 
date there is no robust mouse model able to successfully engraft osteosarcoma cells.  
Due to inconsistency in screening methodology, there are contradictory data suggesting 
that CD133 may not be a marker of CSCs but a marker of normal progenitor cells 
restricted to certain specific cell type, for instance in human brain tissues and 
haematopoietic cells (Uchida et al., 2000, Corbeil et al., 2000, Patru et al., 2010).  
Furthermore, it is important to distinguish between CD133 and the glycosylated epitope 
                                                                                         Chapter 1.  General Introduction 
 
 50 
AC133 as being a reliable CSC marker given that these two terms have been used 
interchangeably in the literature.   
 
Tumour origin Antigenic phenotype Reference 
Osteosarcoma CD133, ABCG2, SP (Tirino et al., 2008) 
Prostate tumours CD133, CD44, α1β2 (Collins et al., 2005) 
Pancreatic adenocarcinoma CD133, ABCG2 (Olempska et al., 2007) 
Colon carcinoma CD133 (Ricci-Vitiani et al., 2007) 
Hepatocellular carcinoma CD133 (Suetsugu et al., 2006) 
Neural tumours CD133, nestin (Singh et al., 2003) 
Renal tumours CD133 (Bruno et al., 2006) 
 
Table 1.3: CD133, often in combination with other markers, used to identify 
cancer stem cells (CSCs) in a variety of human solid cancers. 
 
1.5.4 Epithelial-Mesenchymal Transition (EMT) 
 
The epithelial-mesenchymal transition (EMT) is a major developmental process 
occurring during cancer metastasis and invasion.  It involves a phenotypic shift whereby 
epithelial cells from the primary tumour breaks down cell-cell and cell-extracellular 
matrix connections and then migrate as mesenchymal cells to distant locations in the 
body.  Upon EMT, the mesenchymal cells acquire a stem cell phenotype allowing them 
to spawn secondary tumours in the body.  Once the migrating cells become lodged in 
their destination, they undergo reverse EMT, mesenchymal-epithelial transition (MET) 
and form a tumour recapitulating the phenotype of the tumour of origin (Figure 1.6) 
(Radisky and LaBarge, 2008). 
 
EMT is a natural process which takes place during ontogeny.  It is vital during 
gastrulation (early embryonic developmental phase to produce the three germ layers) 
and post-natal organ morphogenesis (tissue reconstruction and regeneration) (Shook and 
Keller, 2003).  Recently, with the growing acceptance of the involvement of CSCs in 
oncology, EMT or EMT-like processes have been implicated in the metastatic and 
invasive mechanisms of tumour growth and the migrating cells are thought to be the 
putative CSCs (Thiery and Sleeman, 2006, Hugo et al., 2007).  A number of 
experiments in epithelial tumours have attempted to prove this theory and CD44 has 
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been a marker commonly used to achieve this.  Al-Hajj and co-workers (Al-Hajj et al., 
2003) demonstrated that in metastatic human breast cancer, a small subset of the 
carcinoma cells exhibiting the stem cell antigenic phenotype CD44high/CD24low were 
able to initiate new tumours in mice unlike the majority of the tumour cells of 
CD44low/CD24high phenotype.  The metastatic process parallels the processes of tissue 
regeneration, whereby stem cells exit their niche (for instance MSC exiting the bone 
marrow) and enter the circulation to home into injury sites where they proliferate and 
differentiate to contribute to tissue repair.  In vivo the ability of the cancer cells to 
colonise a distant location would require them to survive dissemination via the 
lymphatic or vascular system and to possess self-renewal capacity characteristic of stem 
cells.   
 
A compelling study by Mani and co-workers (2008) has established a link between 
putative CSCs and the migrating cells in an induced EMT model of immortalised 
human mammary epithelial cells.  By inducing EMT in the mammary epithelial cells 
(via ectopic expression of transcription factors Snail and Twist or exposure to TGFβ1), 
the cells adopted a mesenchymal phenotype characterised by down-regulation of E-
cadherin, and up-regulation of fibronectin and vimentin.  Further to this the induced 
mesenchymal cells expressed the stem cell antigenic profile CD44high/CD24low, 
previously ascribed to neoplastic mammary stem cells (Al-Hajj et al., 2003, Sleeman et 
al., 2006, Liao et al., 2007).  In a tumour forming assay, the CD44high/CD24low 
mesenchymal induced population were found to readily form mammospheres (between 
30-40 % more) compared to their CD44low/CD24high epithelial counterparts (Mani et al., 
2008).  These results clearly illustrate the vital role played by the EMT process in the 
metastasis of carcinomas and that the CSCs may be the migrating mesenchymal-like 
cells.   
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Figure 1.6: Proposed model of EMT induction in epithelial cells mediating cancer 
metastasis.  (A) Induced EMT, via ectopic expression of Snail/Twist or exposure to 
TGFβ1, gives rise to migratory cells possessing the cancer stem cell phenotype 
CD44high/CD24low. (B) EMT facilitates intravasation of tumour cells into blood or 
lymph vessels, allowing them to migrate to different anatomical locations, where MET 
results in the formation of secondary tumours (Adapted from Mani et al., 2008). 
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1.5.5 Cellular hierarchy in cancers 
 
It has long been established that the basic key properties defining stem cells are high 
self-renewal capacity and the ability to generate cells that can differentiate to maintain 
tissue structure and function (Lajtha, 1979).  In continuously renewing tissues, such as 
blood and epithelia, an additional proliferative phase has been described whereby the 
cells produced by stem cell divisions (symmetric and asymmetric as illustrated in Figure 
1.7) enter the differentiation pathway by undergoing a series of divisions to amplify the 
maturing population prior to terminal differentiation (Potten, 1981, Morrison et al., 
1997).  While emerging evidence shows that tumour development follows the CSC 
model (Figure 1.5 B), a similar stem cell pattern to that seen in normal tissues has been 
proposed in cancers (Mackenzie, 2005).    Mackenzie’s group characterised the cellular 
hierarchy which exists within epithelial tissues by identifying three categories of cells 
as: (i) stem cells with infrequent cell divisions but retaining extensive self-renewal 
potential, (ii) amplifying cells with limited capacity to proliferate and (iii) post-mitotic 
differentiating or terminally differentiated cells (Tudor et al., 2004).  Thereafter, a 
cellular hierarchy analogous to that observed in normal epithelial tissues was identified 
in carcinoma cell lines and the three cell types were indentified as holoclones, 
meroclones and paraclones (Locke et al., 2005).   
 
Studying the cellular hierarchy exhibited by stem cells in vivo is very difficult and in 
vitro systems that retain similar stem cell patterns have been found appropriate for such 
investigations (Sherley, 2002).  However, malignant cell lines naturally exhibit marked 
morphological heterogeneity due to the cellular diversity caused by genetic instability 
and possibly in vitro conditions (Burdall et al., 2003), thus leading to criticisms of such 
in vitro studies (Pardal et al., 2003).  Nevertheless, the morphological heterogeneity 
described in carcinoma cells lines (Locke et al., 2005) parallels the cellular hierarchy 
previously described in normal keratinocytes in vitro (Barrandon and Green, 1987) 
therefore supporting the in vitro system as a reliable method to study stem cell patterns 
in malignant cell lines.  As such, the characterised colonies identified in carcinoma cell 
lines reflect those characterised in normal keratinocyte populations whereby holoclones 
appear as compact round colonies, paraclones forming irregular loosely attached 
colonies and meroclones exhibiting intermediate features (Mackenzie, 2005). 
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Figure 1.7: Stem cell pattern of division in epithelial tissues (a) Symmetric pattern of 
division produces two identical daughter cells and leads to the depletion of the stem cell 
reservoir (SC).  (b) Assymetric pattern of division produces two dissimilar cells, one 
which remains identical to the parental cell and replenishes the stem cell reservoir (SC) 
and the other which enters the differentiation pathway and loses stem cell properties.  
The pathway is represented by three tiers separated by dashed lines T1 and T2.  The 
tiers are categorised as stem cells (SC), transient amplifying cells (A1 to A4) and 
terminally differentiated cells (TD). The amplification pathway follows a series of cell 
divisions resulting in expansion of the differentiating cell population (A1 to A4) which 
ultimately become terminally differentiated (TD).  The ratio of cells present in each tier 
is influenced by numerous factors, including the rate of stem cell division and the time 
taken for cells to differentiate (Adapted from Mackenzie 2006). 
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An in-depth combined investigation of fifteen cell lines derived from oral carcinomas, 
the prostate cell line DU145, breast cancer cell line MCF7 and a range of established 
and freshly derived head and neck squamous cell carcinoma cell lines by Mackzenzie’s 
group described the presence of cells of holoclonal, meroclonal and paraclonal 
morphologies, although the meroclonal cells were arbitrarily classified because of the 
continuous gradient of change from one colony form to the other (Locke et al., 2005, 
Harper et al., 2007).  The malignant holoclonal cells were found to be small, rapidly 
adhesive and highly clonogenic exhibiting high levels of β1-integrin, β-catenin, E-
cadherin and cytokeratin 15, markers normally over-expressed in epithelial stem cells 
(Cotsarelis et al., 1999, Tudor et al., 2004).  In addition to the epithelial markers, the 
holoclones displayed stronger CD44 expression than paraclones, a selective molecule in 
identifying CSCs in breast cancers (Al-Hajj et al., 2003) and exhibited high levels of 
CD133 staining at the centre of the holoclonal colonies in line with previous reports of 
CD133 as a marker of CSC in solid tumours (Table 1.3).  Moreover, contrary to the 
paraclonal cells, cells isolated and expanded from the holoclonal colonies were able to 
generate colonies of heterogeneous morphology as observed in the parental cell line.  
The lack of expansion potential of paraclones indicated that these cells may represent 
the late amplifying or differentiated cells in the stem cell pattern of division described 
above, while the holoclones by virtue of their stem cell expansion and marker properties 
may represent the malignant stem cell population in the carcinoma cell lines 
(Mackenzie, 2005, Mackenzie, 2006). 
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1.6 Thesis hypothesis and aims 
 
The primary hypothesis of this thesis is that STRO-1 is an antigen expressed by 
multipotent hMSCs and therefore a potential biomarker in the isolation of homogeneous 
populations of in vitro expanded multipotent hMSCs.  The STRO-1 antigen is as yet 
unidentified.  Characterising and elucidating the identity of STRO-1 antigen will further 
our knowledge on factors maintaining hMSC primitive properties and enable isolation 
of pure hMSC populations for clinical applications.  Furthermore, knowing the 
antigenic determinant of STRO-1 will open up avenues to generate novel antibodies 
against the multipotent hMSCs and subsequently developing new tools promoting 
successful MSC isolation.  Secondly, STRO-1 is hypothesised as a putative marker for 
CSCs in osteosarcoma.  There is mounting evidence in the literature to suggest that 
osteosarcomas are mesenchymal tumours which arise from CSCs originating from 
mutated MSCs.  Following this principle, CSCs in osteosarcoma may have retained 
certain stem cell markers such as STRO-1.  By employing STRO-1 as a CSC marker in 
osteosarcoma, and possibly applying it to other mesenchymal tumours, these rare 
tumourigenic cells can be identified leading to development of targeted chemotherapy. 
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In order to investigate the hypotheses, the main aims of the thesis are to achieve the 
following: 
 
• Characterise STRO-1 expression on in vitro expanded hMSCs.  Freshly 
derived bone marrow hMSC populations have been shown to heterogeneously 
express STRO-1.  Culture expanded hMSCs will be monitored for their STRO-1 
expression and differentiation potential and a relationship between the level of 
STRO-1 expression and multilineage ability will be established. 
 
• Elucidate the identity of the STRO-1 antigen. Two methods will be used in an 
attempt to identify the STRO-1 antigen.  In the first instance, phage display 
technology will be undertaken as an epitope mapping approach.  Secondly, a 
comparison of gene expression microarray profiles of osteosarcoma cell lines 
will be employed to identify potential candidate genes encoding the STRO-1 
antigen.  
 
• Identify putative CSCs in osteosarcoma cell lines.  A panel of osteosarcoma 
cell lines will be characterised in terms of their antigenic and cellular phenotypes 
as well as stem cell properties.  The relationship between STRO-1 expression 
and retention of MSC characteristics will also be studied.  A cellular hierarchy 
in osteosarcoma will be proposed and investigated.     
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2.1 Materials 
 
All reagents, histochemical stains and general chemicals were obtained from Sigma-
Aldrich (Dorset, UK) unless otherwise stated.  All tissue culture media and reagents 
were obtained from Invitrogen (GIBCO®; Paisley, UK), unless otherwise stated.  
Antibodies used in cell profiling are listed in Table 2.2 and those used for other 
applications are specified within relevant sections.  Primers used in gene expression 
analysis (Table 2.3) were commercially synthesised by Invitrogen (Paisley, UK).  The 
source of all other materials is specified in the relevant sections. 
 
Human Mesenchymal Stem Cells (hMSCs: M24♂, N24♂, 31♂, 38♀) were isolated 
previously in this laboratory (Westwood 2006 and Vujovic 2006).  The seven 
osteosarcoma cell lines (143B, CAL72, G-292, HOS, MG-63, Saos-2 and U-2-OS) were 
generous gifts from Professor Adrienne Flanagan and Dr Nadege Presneau (The Cancer 
Institute, University College London). 
 
2.2 Cells 
 
hMSC isolation (Westwood 2006 and Vujovic 2006) 
Human bone marrow derived mesenchymal stem cells (hMSCs) were obtained from 
four healthy donors and labelled as M24♂ (24 year old male), N24♂ (24 year old male), 
31♂ (31 year old male) and 38♀ (38 year old female).  Bone marrow aspirates (about 
10 mL) were taken from the iliac crest of transplantation donors after informed consent 
and with prior approval from University College London Hospital ethics of human 
research committee, in association with the Molecular Haematology Department, UCL.  
Briefly, mononuclear cells were isolated by Ficoll-Plaque gradient and seeded at 2x105 
bone marrow mononuclear cells/cm2 in 6-well plates.  Non-adherent cells were removed 
two days after plating, adherent cells fed with fresh media and colonies formed were 
designated as passage 0 (p0). 
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Osteosarcoma cell lines 
The panel of osteosarcoma cell lines used in this study are 143B, CAL72, G-292, HOS, 
MG-63, Saos-2 and U-2-OS.  The cell lines were derived from bone tumours in 
teenagers and are banked by ATCC® (American Type Culture Collection) except for 
CAL 72 which was derived by Rochet et al. (1999) (Table 2.1).  143B and HOS were 
derived from the parent TE85 by Ki-ras transformation  (McAllister et al., 1971) and N-
methyl-N’-nitro-N-nitrosoguanidine (MNNG) treatment  (Rhim et al., 1977) 
respectively. 
 
Cell line Source ATCC® number 
143B*1 13 year old, female CRL_8303 
CAL72 10 year old, male          # 
G-292 9 year old, female CRL_1423 
HOS*2 13 year old, female CRL_1543 
MG-63 14 year old, male CRL_1427 
Saos-2 11 year old, female HTB_85 
U-2-OS 15 year old female HTB_96 
 
Table 2.1: Osteosarcoma cell lines screened.  * indicates cell lines derived from TE85 
by Ki-ras transformation (*1) and by N-methyl-N’-nitro-N-nitrosoguanidine MNNG 
treatment (*2).  # indicates ATCC® bank number not available; cell line derived by 
(Rochet et al., 1999). 
 
2.2.1 Cell culture 
 
hMSCs were cultured in Alpha-Minimal Essential Medium (α-MEM) supplemented 
with 10 % FCS (HyClone, Fisher Scientific) and 1 ng/mL basic Fibroblastic Growth 
Factor (bFGF) (Peprotech, UK).  Osteosarcoma cell lines were cultured in DMEM 
supplemented with 10 % Fetal Calf Serum (FCS) (GIBCO®) and antibiotic-antimycotic 
(GIBCO®:100X stock, 10 000 units/mL penicillin G sodium, 10 000 µg/mL 
streptomycin sulphate and 25 µg/mL amphotericin) where required.  To initiate culture, 
cells from liquid nitrogen storage were quickly thawed in a 37 ºC water bath, washed 
with warm complete media to remove traces of freezing medium and seeded in tissue 
culture dishes.  After seeding, cells were cultured in a humid 37 ºC incubator (BINDER 
APT.line™ C150), maintained at 5 % CO2, and fed every three days with appropriate 
media. 
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2.2.2 Passaging cells 
 
During hMSCs expansion, cells were maintained at sub-confluency.  When 75-85% 
confluency was reached, they were passaged and re-seeded or frozen down.  Briefly, the 
adherent monolayer was washed with DPBS (Calcium and Magnesium free), detached 
with 0.25 % trypsin enzyme treatment (10x stock) for 2-3 min at 37 °C and the trypsin 
inactivated with 10 % FCS-containing media.  The cells were then centrifuged at 1000 
rpm for 5 min (IEC CL30 Centrifuge, Thermo Scientific) and the cell pellet suspended 
in the appropriate volume of media and seeded at 4x103 cells/cm2 or suspended in FCS 
containing 10 % v/v dimethyl sulfoxide (BD Biosciences) for storage in liquid nitrogen. 
 
Osteosarcoma cells lines were grown to 80-90% confluency before passaging either 1:4 
(one dish subcultured into four dishes) (CAL72, Saos-2) or 1:5 (one dish subcultured 
into five dishes) (143B, G-292, HOS, MG-63, U-2-OS).  Osteosarcoma cells were 
detached using trypsin enzymatic treatment and passaged or frozen down as described 
above.  
 
2.2.3 STRO-1 hybridoma culture 
 
STRO-1 hybridoma frozen cell line was purchased from DSHB (Developmental Studies 
Hybridoma Bank, Iowa, USA).  The cells were grown in suspension in RPMI-1640 
media supplemented with 10 % FCS (HyClone).  Three days after seeding in 20 mL 
media, the cells were split 1:2, media volume adjusted to 20 mL and a further 20 mL 
fresh media added at 2 day intervals for 4 days.  After 14 days, the cells reached 
stationary phase and the supernatant was collected via centrifugation (IEC CL30 
Centrifuge, Thermo Scientific, 1000 rpm, 5 min), filtered (0.2 µm pore size), dispensed 
in aliquots and stored at 4 ºC. 
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2.2.4 STRO-1 antibody concentration from hybridoma culture 
 
The concentration of STRO-1 antibody produced from the hybridoma culture was 
quantified by ELISA against a standard curve drawn from known concentrations of 
STRO-1 antibody purchased from R&D Systems (Oxford, UK).  Commercially 
obtained STRO-1 was reconstituted in DPBS to a concentration of 500 µg/mL and 
stored at -20 ºC as 10 µL aliquots.  Wells of a 96-well plate were coated (overnight at 4 
ºC in a humid chamber) with 100 µL of different concentrations of commercial STRO-1 
antibody, 100 µL neat supernatant and RPMI complete media, in triplicate.  The 
following day, the wells were washed once with DBS (200 µL/well), blocked with 1 % 
BSA/PBS (200 µL/well) for 2 h, washed twice with DPBS and incubated 1:2000 with 
goat anti-mouse IgM (µ chain specific) HRP conjugated antibody (Southern Biotech, 
Birmingham, USA) for 2 h at room temperature.  The colour was developed using 100 
µL reconstituted ABTS per well for 20 min in the dark and absorbance read at 405 nm 
(Sunrise, TECAN™). 
 
2.2.5 Soft agarose assay 
 
Osteosarcoma cell lines were assayed for anchorage-independent growth in 6-well plate 
formats in triplicates.  A 2 % stock of agarose solution was prepared by melting 6 % 
low melting point agarose solution, uniformly mixed with complete DMEM medium 
(containing antibiotic/antimycotic) and kept at 55 ºC.  For the base layer, the 2 % 
agarose stock solution was diluted to 0.6 % in complete media and 2 mL of the solution 
was layered in each well.  The base layer agarose was left to set for 30 min at 4 ºC and 
prior to seeding the top layer, the plate was warmed for 5 min at 37 ºC.  The cells were 
trypsinised, counted using a haemocytometer and suspended in 2 % agarose to make a 
final concentration of 0.35 % agarose of which 2 mL was seeded per well to give a 
density of 1x104 cells per well.  The agarose was set for 30 min at 4 ºC and then placed 
in the incubator at 37 ºC.  The next day, the cells were fed with 2 mL complete DMEM 
and every 3 days from then on, for up to 12 days.  Colony formation was monitored at 
specific time points under phase contrast microscope (Inverso 3650, Medline Scientific 
Limited). 
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2.3 Differentiation 
2.3.1 Differentiation assays 
The monolayer cultures were grown to confluency in appropriate media and induced to 
the adipogenic and osteogenic lineages by the addition of specific differentiation 
cocktails as described in the relevant sections. 
2.3.1.1 Adipogenic differentiation 
Cells were grown to confluency and induced at one day post-confluency.  On the day of 
adipogenic induction (day 0), the medium was changed to adipogenic differentiation 
medium comprising of basal media with 10 % FCS (α-MEM for MSC and DMEM for 
osteosarcoma cells) supplemented with 1 µM Dexamethasone, 500 µM Isobutyl-
methylxanthine, 100 µM Indomethacin and 10 µg/ml Insulin (Roche).  The cells were 
fed every 3 days with freshly prepared adipogenic differentiation medium and 
differentiated for 8 days. 
2.3.1.2 Osteogenic differentiation  
Cells were grown to confluency and induced at one day post-confluency.  On the day of 
osteogenic differentiation (day 0), the media was changed to osteogenic differentiation 
medium comprising of basal media with 10 % FCS (α-MEM for MSC and DMEM for 
osteosarcoma cells) supplemented with 0.1 µM Dexamethasone, 10 mM β-
glycerophosphate and 50 µM L-Ascorbic acid 2 phosphate.  The cells were fed every 3 
days with freshly prepared osteogenic differentiation medium and differentiated for up 
to 21 days. 
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2.3.2 Staining protocols for assessment of differentiation 
2.3.2.1 Adipogenesis: Oil Red O 
After 8 days of adipogenic differentiation, the lipid droplets inside the adipocytes were 
stained with Oil Red O.  Cells were carefully washed with DPBS and fixed with fixative 
solution (4 % formaldehyde, 75 mM sodium phosphate buffer pH 7, 1.5 % methanol) 
for 30 min at room temperature.  Cells were then washed 3 times with DPBS and 
stained with Oil Red O solution for 2-3 h in the dark.  Oil Red O dye was prepared by 
making up a 1 mg/mL stock solution in 60 % triethyl phosphate.  After allowing the 
crystals to dissolve for 1 h, a working solution of the dye of 60:40 in distilled water was 
prepared and filtered through Whatman filter paper.  After staining the cells, the dye 
solution was removed and washed twice with DPBS to remove unbound dye.  Stained 
cells were covered with DPBS and either stored at 4 °C or quantified for adipogenesis. 
2.3.2.2 Osteogenesis: Alkaline phosphatase  (ALP) activity 
After the specified period of differentiation, osteogenesis was assayed by alkaline 
phosphatase activity.  Using Vector® Blue substrate kit III (Vector Laboratories, 
Peterborough UK) and following the manufacturer’s protocol, cells undergoing 
osteogenesis were stained blue, positively indicating ALP activity.  Stained cells were 
visualised using phase contrast microscope (Inverso 3650). 
2.3.2.3 Osteogenesis: Alizarin Red S (AR) staining 
Calcium deposition was assessed by using 1 % w/v AR solution (VWR).  Using the 
protocol adapted from (Gregory et al., 2004), the monolayers were fixed in fixative 
solution (4 % formaldehyde, 75 mM sodium phosphate buffer pH 7, 1.5 % methanol) 
for 15 min at room temperature, washed twice with distilled water and stained with AR 
solution (pH 4.2) for 30 min.  Unincorporated dye was then aspirated and cells washed 
3 times with distilled water.   After the staining procedure, cells were covered with 
distilled water and observed using phase contrast microscope (Inverso 3650).   
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2.3.3 Quantification of differentiation 
2.3.3.1 Adipogenesis: Adipocyte count 
Adipogenic differentiation for quantification was carried out in 24-well formats unless 
otherwise stated.  Cells containing Oil Red O stained lipid droplets indicative of 
adipocyte formation were counted under x10 magnification of phase contrast (Inverso 
3650) per three random fields of view per well.  The number of adipocytes formed was 
expressed as an average of the 3 wells. 
2.3.3.2 Adipogenesis: Oil Red O dye extraction 
Adipogenic differentiation was also quantified using a protocol adapted from (Gregory 
et al., 2005).  Briefly, Oil Red O stained cells were washed with DBPS and 500 µL of 
extraction buffer (50 % v/v ethanol, 2 % SDS) was added to each well and incubated for 
30 min at 37 ºC.  The extracted dye was transferred in triplicates of 100 µL to a 96-well 
plate and the absorbance measured at 405 nm (Sunrise, TECAN™).  The amount of 
extracted dye was normalised to cell number using the Cyquant® NF Cell Proliferation 
assay kit (Invitrogen, Molecular Probes®). 
2.3.3.3 Osteogenesis: Alkaline phosphatase (ALP) activity  
ALP activity was assayed in 24-well formats in triplicate.  At the end of differentiation, 
cell monolayer was washed with DPBS and 200 µL of 0.1 % Triton X-100 was added to 
each well which was then stored at -80 ºC.  Subsequently, the plates were thawed on ice 
and cell monolayer scraped into 1.5 mL tubes and sonicated for 10 min on ice (Branson 
200, 40 KHz).  An aliquot of 50 µL sample was added to 500 µL of p-nitrophenyl 
phosphate (p-NPP) reaction buffer (526 mg diethanolamine, 23.2 mg p-NPP dissolved 
in 4 mL 0.1 M HCl, 50 µL 1 M MgCl2, made up to 100 mL with distilled water).  
Phosphate standards (0 to 4 mM) were prepared in duplicate and added to 500 µL p-
NPP buffer.  After incubating the tubes for 20 min at 37 ºC, the reactions were stopped 
by the addition of 500 µL of 0.2 M Sodium hydroxide solution.  The yellow colour 
developed from the phosphatase reaction was measured at 405 nm as 100 µL triplicates 
in a 96-well plate.  The amount of ALP enzyme was deduced from the standard curve 
drawn from phosphate standards at each quantification procedure and normalised to cell 
number using the Cyquant® assay (Appendix Figure I). 
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2.3.3.4 Osteogenesis: Alizarin Red S (AR) dye extraction 
Following AR staining, cell monolayer in 24-well format was washed with distilled 
water and air-dried.  Using the protocol adapted from (Gregory et al., 2004), the dye 
was recovered by acetic acid extraction.  Briefly, 400 µL of 10 % v/v acetic acid 
(Fisher) was added to each well and incubated for 30 min while shaking at room 
temperature.  Using a wide-mouthed pipette, the loosely attached cells were scraped and 
transferred to a 1.5 mL tube and vortexed for 30 sec.  The slurry obtained was covered 
with approximately 500 µL mineral oil, and heated for 10 min at 85 ºC.  The tubes were 
then iced for 5 min and centrifuged (accuSpin™ Micro) at 13 000 rpm for 15 min.  A 
volume of 300 µL of the supernatant was transferred to a fresh tube containing 100 µL 
of 10 % v/v ammonium hydroxide and the pH measured to ensure a range of between 
4.1-4.5.  Aliquots of 100 µL were read in triplicate in a 96-well plate at an absorbance 
of 405 nm.  The amount of dye extracted was normalised to cell number using the 
Cyquant® assay. 
 
2.3.3.5 Cell number normalisation: Cyquant® NF Cell Proliferation assay 
Quantification of differentiation was normalised to cell number via DNA content 
measurements, following manufacturer’s protocol.  The dye binding solution was 
diluted in cell lysis buffer (Invitrogen) and 600 µL of the solution was aliquoted in each 
well of DPBS washed differentiated cells in a 24-well plate.  After 30 min incubation at 
37 ºC, the cells were detached and 100 µL aliquots transferred in triplicates to a black 
walled 96-well plate.  The fluorescence intensity was measured using FLUOstar 
OPTIMA™ (BMG Labtech) set at 480 nm excitation/520 emission.  All quantification 
measurements were normalised to approximately 3x104 cells. 
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2.4 Immunofluorescence 
 
Cells were seeded, expanded and/or differentiated on coverslips in 6-well plates after 
which they were fixed in 4 % formaldehyde for 15 min.  The cells were then washed 
twice with DPBS and stored in DPBS at 4 ºC.  For internal cellular staining, cells were 
permeabilised for 10 min with 0.2 % Triton X-100/DPBS while cells for surface 
staining were left in DPBS.  They were then blocked for 30 min in PBS containing 5 % 
milk, 5 % FCS and 2 % fish gelatine at room temperature.  The coverslips were washed 
in PBS, incubated in a humid chamber for 1 h in 10 µg/mL STRO-1 solution (5 % FCS/ 
2 % fish gelatine/ PBS), washed 3 times in PBS and incubated in goat anti-mouse IgM 
(µ chain specific) FITC conjugated secondary (Southern Biotech) 1:50 solution (5 % 
FCS/ 2 % fish gelatine/ PBS), along with DAPI and phalloidin when required, for 45 
min in the dark.  After the secondary incubation, the coverslips were washed 3 times in 
PBS with a final wash in distilled water and mounted on pre-warmed Mowiol.  The 
slides were left to dry overnight in the dark and subsequently viewed by fluorescent 
microscopy (Axioplan, Zeiss) and confocal scanning laser microscopy (Leica SP2 TCS 
Confocal microscope; image analysis performed by Leica Software Version 2.6.1). 
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2.5 Flow cytometry 
2.5.1 Antibody staining for marker expression profiling 
 
Cells at specified confluency and passage were harvested (Section 2.3.2) and washed in 
MACS buffer (DPBS containing 1 % FCS and 2 mM EDTA, pH 7.2) via centrifugation 
at 1000 rpm for 5 min (IEC CL30 Centrifuge) to remove traces of media.  Aliquots of 
5x105 cells per sample were incubated with the appropriate primary antibody 
(monoclonal raised in mouse) for the specific time (Table 2.2 for antibody information, 
dilutions and incubation time) in MACS buffer (final volume 100 µL) on ice and in the 
dark.  Cells incubated with the anti-CD133 antibody were simultaneously incubated 
with human Fc receptor blocking reagent (Miltenyi Biotech, Surrey, UK) to avoid 
cross-reaction of the antibody with this receptor.  After removal of excess antibody via 
three MACS buffer washes (2000 rpm, 3 min, accuSpin ™ Micro), the secondary 
antibody (goat anti-mouse IgM µ chain specific, fluochrome conjugated) incubation was 
carried out as before if required, followed by a further two MACS buffer washes.  
Control samples were labelled with FITC-secondary antibody only for FITC conjugated 
antibodies, RPE-secondary antibody only for RPE-conjugated antibodies and control 
cells were unlabelled for APC-conjugated antibodies.  Surface marker expression was 
then determined by counting at least 20 000 events per sample and normalised to 10 000 
events per sample (unless otherwise stated) on a CyAn™ ADP flow cytometer 
(DakoCytomation).  Isotype control profiles are illustrated in Appendix Figure II. 
 
Using the Summit v4.3 software, protocols were set up using unlabelled samples to 
accommodate cell size and shape and gates (indicated as R to represent Region on 
histograms) were set up to exclude debris and cell doublets.  Control cells (either 
unlabelled or labelled with the appropriate control antibody) were analysed on the 
wavelength corresponding to the fluorescent signal being detected.  Positive events in 
specific antibody-labelled cells were then scored as those above the background level 
and represented as an overlay or scatter plot. 
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Table 2.2: Antibodies used to define cell surface marker profile of hMSCs and 
osteosarcoma cell lines by flow cytometry.  The dilution, incubation time and source 
of each antibody are indicated.  * indicates co-incubation with Fc Receptor block whilst 
staining.  All primary antibodies were monoclonal and raised in mouse; all secondary 
antibodies were polyclonal goat anti-mouse immunoglobulins.  Southern Biotech 
(Birmingham, USA); Miltenyi Biotec (Gladbach, Germany); BioLegend (San Diego, 
USA); BD Biosciences (Oxford, UK); R&D Systems (Oxford, UK). 
 
2.5.2 MACS enrichment 
 
The STRO-1 highly positive fraction of passage 6 hMSCs (N24♂) was enriched on a 
miniMACS® columns (Miltenyi Biotech) according to manufacturer’s protocol.  
Briefly, 4x106 cells were labelled with 100 µg/mL primary STRO-1 antibody (2.6.1) 
and conjugated to rat anti-mouse IgM Microbeads (20 µL per 1x107 cells, Miltenyi 
Biotech).  The cells were washed twice with MACS buffer and enriched by allowing the 
cells to flow freely through the magnetic column.  The column was then washed 3 times 
with MACS buffer to collect the negative fraction.  The STRO-1 positive hMSCs bound 
to the column were recovered by flushing out the cells with a plunger via 3 buffer 
applications.  The cells recovered were counted and seeded at 4x103 cells/cm2 for 
expansion and differentiation (Section 2.2.1).  An aliquot of each fraction was labelled 
with the fluochrome conjugated secondary antibody (Table 2.2) and analysed on the 
flow cytometer (Cyan) to ensure enrichment of STRO-1 positive hMSCs. 
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2.5.3 Live/Dead Discrimination 
 
In order to exclude dead cells in the flow analysis, propidium iodide (PI) and Live/Dead 
fixable dead cell stain kit (Invitrogen, Molecular Probes®) were used.  PI was used to 
discriminate dead cells while setting up the analysis protocol.  Unlabelled cells were 
incubated for 15 min on ice in 1 µg/mL PI and analysed on the flow cytometer 
(CyAn™).  Late apoptotic cells incorporate PI into their DNA and can be detected in 
the PE red channel.  These PI positive cells were therefore gated out during the flow 
analysis. 
 
The Live/Dead kit contains a dye which when reacts with free amines inside the cell 
fluoresces in the near-IR channel (APC-Cy7).  The dye was reconstituted following the 
manufacturer’s protocol and the cells were washed with DPBS and stained (1:1000, 30 
min on ice) after fluorescent labelling with appropriate secondary antibodies where 
required (Table 2.2).  After the Live/Dead staining, the cells were washed once with 
DPBS and suspended in MACS buffer to be analysed by flow cytometry.  The 
Live/Dead discrimination stain was used in conjunction with antibodies conjugated to 
FITC, PE and RPE and gates were set up to exclude apoptotic cells having 
compromised cell membrane. 
2.5.4 Cell proliferation assay 
 
The seven osteosarcoma cell lines were assayed for their proliferative potential using 
the CellTrace™ CFSE cell proliferation kit (Invitrogen, Molecular Probes®).  Cells 
were harvested (Section 2.3.2), suspended in DPBS and counted using a 
haemocytometer.  The CFSE dye was reconstituted following manufacturer’s protocol 
and was optimised to be used at a final concentration of 2.5 µM per 2-3x106 cells.  
Briefly, 1 mL cell suspension was incubated with CFSE dye for 15 min at 37 ºC, 
centrifuged (IEC CL30 Centrifuge, 1000 rpm, 5 min), then incubated in 1 mL warm 
complete media for 30 min at 37 ºC.  Unincorporated dye was washed in excess media, 
suspended in fresh media at the required dilution and seeded at 1x105 cells per well in a 
6-well plate.  Cells were harvested (Section 2.3.2) after 24 h, suspended in MACS 
buffer and analysed by flow cytometry (CyAn™) set on the fluorescein filter. 
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2.6 Phage display 
 
The two phage libraries used in this study were the Ph.D-12TM library (New England 
Biolabs, Ipswich, USA) and the Dean’s library (prepared for R.W Johnson 
Pharmaceutical Research Institute, gifted by Dr Angray S. Kang).  The Ph.D-12TM  
peptide library expresses 12-mer peptides on the pIII surface coat protein of M13 phage 
while the Dean’s library expresses 16-mer peptides on the pVIII surface coat protein of 
the M13 phage. 
 
2.6.1 Solid-phase panning 
 
Solid-phase panning was carried out according to the NEB protocol.  Wells from a 96-
well plate were coated with 100 µL (100 µg/mL) STRO-1 antibody solution (R&D 
Systems, Oxford, UK) in PBS or with 0.5 % BSA (negative control) overnight at 4 °C.  
The wells were then blocked for 2 h at room temperature and washed 6 times with TBS 
containing 0.1 % Tween (TBST).  A 100 µL phage suspension of approximately 1x1011 
pfu/mL in TBST was added to each well in duplicate.  After 1 h incubation at room 
temperature, the wells were washed 10 times with TBST and bound phage was eluted 
with 100 µL elution buffer (0.2 M Glycine-HCl, 1 mg/mL BSA, pH 2.2) for 10 min at 
room temperature.  The 200 µL eluate was then neutralised with 30 µL 1 M Tris-HCl 
(pH 9).  The eluted phage was titred and propagated for the next round of panning 
(Figure 2.1). 
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Figure 2.1: Schematic illustration of solid phase panning.  (A) Plastic microtitre 
wells were coated overnight with 100 µg/mL STRO-1 IgM or 0.5 % BSA control.  (B) 
Phage library of input titre 1x1011 pfu/mL was selected against coated wells, (C) eluted, 
quantified and propagated for subsequent panning rounds.  (D) The specific phage 
enrichment process was repeated five times. 
 
2.6.2 Liquid-phase panning 
 
Liquid-phase panning was carried out according to the NEB protocol.  Protein A 
agarose beads (Calbiochem, Nottingham, UK) were used.  A 50 µL aliquot of the beads 
(50 % suspension in PBS) was first coated with 1 mL (100 µg/mL) goat anti-mouse IgM 
antibody (µ-chain specific, Sigma) for 30 min at 4 °C then blocked with 0.5 % 
BSA/PBS for 30 min at 4 °C.  In a separate tube, 1.5x1011 pfu/mL phage suspension 
was incubated with 10 nM STRO-1 or 0.5 % BSA/PBS (negative control) at room 
temperature for 20 min.  The phage-STRO-1 complex suspension was transferred to the 
coated bead suspension and incubated for 10 min at room temperature.  The phage-
STRO-1 complex was pulled down by the coated beads at 3000 rpm for 1 min 
(accuSpin™ Micro, Fisher Scientific).  A volume of 200 µl of freshly prepared elution 
buffer was added to the resin to elute the bound phage.  The eluate was then neutralised 
with 30 µL 1 M Tris-HCl.  The eluted phage was titred and propagated for the next 
round of panning (Figure 2.2). 
 
                                                                                      Chapter 2.  Materials and Methods 
           
 
 73 
 
Figure 2.2: Schematic illustration of liquid phase panning.  (A) A Phage library titre 
of 1.5x1011 pfu/mL was incubated with 10 nM STRO-1 or 0.5% BSA control.  (B) In a 
separate reaction, protein A agarose beads were coated with 100 µg/mL goat anti-mouse 
IgM .  (C) Phage/STRO-1 complex was then pulled down by coated agarose beads and 
STRO-1 specific peptide phage was eluted, quantified and propagated for subsequent 
panning rounds.  The process was repeated five teams. 
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2.6.3 Phage propagation 
 
An aliquot of 10 µL of the eluted phage was retained to determine the phage output titre 
while the remaining eluate was used for propagation in E.coli XL1 Blue cells 
(Stratagene, California, USA).  Propagation consisted of infecting 200 µL of XL1 Blue 
(O.D600 0.4/0.5) with the eluted phage in 20 mL LB medium (Fisher, Loughborough,  
UK) for 4.5 h at 37 °C with vigorous shaking (250 rpm, Innova®43, New Brunswick 
Scientific).  The bacteria and phage suspension was then separated via centrifugation at 
4000 rpm for 10 min at 4 °C (accuSpin™).  The bacterial pellet was discarded and 4 mL 
of PEG/NaCl was added to the supernatant to precipitate the phage overnight at 4 °C.  
The following day, the precipitated phage was recovered by centrifugation at 10 000 
rpm for 15 min at 4 °C (Universal 320R, Hettich Zentrifugen) and suspended in 200 µL 
TBST/0.02 % sodium azide to be stored at -20 ºC.  The titre of the amplified phage was 
determined by plaque assay. 
 
2.6.4 Plaque assay 
 
The phage titre after each round of panning was determined by serial dilution of the 
phage suspension in LB medium.  A volume of 10 µL of the appropriate phage dilution 
or LB medium (negative control) was plated with 200 µL XL1 Blue (O.D600 0.4/0.5) in 
3.5 mL overlay agar (1.5 % w/v) on 20 mL of set nutrient agar (3 % w/v).  The plates 
were incubated overnight at 37 °C.  Each dilution was plated in duplicate and the titre 
determined from the readings of three dilutions.  The titre was assayed as the number of 
plaque forming units per millilitre of phage suspension (pfu/mL). 
 
2.6.5 Plaque lifts 
 
Plaques formed from the plated phage were transferred to a nitrocellulose membrane for 
probing with the STRO-1 antibody.  The membrane was blocked using 1 % BSA/PBS 
for 1 h at room temperature.  It was then washed three times with PBST (0.05 % 
Tween) and incubated with 1 µg/mL STRO-1 in 10 mL PBST for 2 h.  STRO-1 binding 
was detected with polyclonal rabbit anti-mouse HRP conjugated immunoglobulins 
(DakoCytomation, Glostrup, Denmark) or goat anti-mouse IgM HRP conjugated 
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immunoglobulins (Southern Biotech, Cambridge, UK) in 10 ml PBST (1:1000) for 2 h 
and peroxidase activity was detected by colour development using 2 mg/mL DAB (3,3’-
Diaminobenzidine, Bio-Rad Laboratories, Hertfordshire, UK) for 15 min in the dark.   
 
2.6.6 Dot Blots 
 
A 1 µL volume of antibody solution (mouse STRO-1 IgM or mouse TUJ1 IgG) of 
appropriate concentrations in PBS were spotted on nitrocellulose membrane and 
allowed to air dry for 15 min.  The membrane was then blocked with 1 % BSA/PBS or 
1 % semi-skimmed milk for 1 h before probing with polyclonal rabbit anti-mouse HRP 
conjugated immunoglobulins (1:1000) or goat anti-mouse IgM HRP (Southern Biotech, 
Cambridge, UK) for 2 h.  The colour was developed using 2 mg/mL DAB for 15 min in 
the dark. 
 
2.6.7 STRO-1 antibody binding to microtitre plate 
 
Wells from a 96-well plate were coated with 100 µL of 100 µg/mL STRO-1 antibody or 
1 % BSA/PBS (negative control) overnight in a humid environment at 4 °C.  The 
following day, the wells were washed 3 times with PBST (0.1 % Tween) and blocked 
with 1 % BSA for 2 h at room temperature.  The wells were then washed 5 times in 
excess PBST before adding 100 µL of 20 µg/mL goat anti-mouse IgM into each well 
for 1 h at room temperature.  After washing 3 times with PBST and a final wash with 
PBS, 100 µL of anti-goat HRP (1:2000) (DAKO, Cambridge, UK) was added to each 
well for 1 h.  ABTS (2,2’-Azino-bis(3-Ethylbenzthiazoline-6-sulfonic acid; Roche, 
Sussex, UK) was used as substrate (100 µL per well for 30 min in the dark) and 
absorbance readings were taken at 405 nm (Sunrise TECAN™). 
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2.7 Comparison of gene expression microarray analysis (performed by 
Stephen Henderson, The Cancer Institute, University College London). 
 
A comparison of gene expression microarray data of the seven osteosarcoma cell lines 
and MSC cultures was undertaken (Affymetrix HGU133a).  The data had been pre-
processed, normalised and summarised using the R statistical environment and the 
‘rma’ algorithm (part of the affy package).  Probesets which most highly correlated 
(Pearson’s R2) to the STRO-1 flow cytometry expression values were then retrieved.  
By inspecting the correlation rankings a cut off of the top 20 probesets were selected. 
 
A heatmap of twenty candidate genes encoding STRO-1 antigen was generated using 
gplots package for the R statistical environments.  Sub-cellular location information, 
where available, was extracted from the Gene Ontology (GO) database (Appendix Table 
I). 
 
The procedure is outlined as a flow diagram in Appendix III (Figure III). 
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2.8 Gene expression analysis 
2.8.1 RNA extraction 
 
Total RNA was isolated from differentiating cells at time points indicated.  Primarily, 
the cells cultured in a 10 cm dish were harvested (2.2.1), suspended in 1 mL of TRIzol® 
reagent (Invitrogen) and stored as 2 aliquots of 500 µL at -80 ºC.  To extract the RNA, 
one aliquot was thawed on ice, and incubated for 3 min at room temperature.  A volume 
of 100 µL of BCP (1-bromo-3-chloro propane) was added and the tube was shaken 
vigorously for 2 min and left for 3 min at room temperature.  Cellular debris was 
removed by centrifugation at 4000 rpm for 15 min at 4 ºC (Universal 320R).  Carefully, 
300 µL of the aqueous phase was transferred to a fresh tube to which 75 µL of 
isopropanol (molecular grade) was added.  The tube was gently inverted 3 times and 
RNA allowed to precipitate overnight at -20 ºC.  The following day, the RNA was 
pelleted by centrifugation at 15 000 rpm for 30 min at 4 ºC.  The pellet was then washed 
with 500 µL of  70 % ethanol, centrifuged at 10 000 rpm for 10 min at 4 ºC, ethanol 
removed and pellet allowed to air dry for 2 min.  The RNA pellet was then suspended in 
30 µL DEPC treated water, quantified by Nanodrop 1000 Spectrophotometer (Thermo 
Scientific) and stored at -80 ºC. 
 
2.8.2 cDNA synthesis 
 
cDNA was synthesised from 0.3 µg total RNA using Protoscript® First Strand cDNA 
Synthesis Kit (New England Biolabs), following the manufacturer’s protocol.  RNA 
was diluted to a volume of 5 µL in DEPC treated water, and 2 µl of dNTP mix and 1 µL 
of oligo (dT23VN) primer were added (stock concentrations 2.5 mM and 50 µM, 
respectively).  The mixture was incubated for 5 min at 70 ºC, spun and iced for 3 min, 
then 1 µL reverse transcriptase buffer (10x stock), 0.5 µL RNase inhibitor (5 units) and 
0.5 µL M-MuLV reverse transcriptase enzyme (12.5 units) were added.  First strand 
cDNA synthesis was carried out for 1 h at 42 ºC, and the reaction was inactivated for 5 
min at 95 ºC.  Subsequently, the reaction was diluted to 30 µL in DEPC treated water 
and stored at -20 ºC. 
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2.8.3 Polymerase Chain Reaction (PCR) 
 
PCR screens were executed using Bio-Rad MJ Mini™ thermal cycler.  A typical 25 µL 
reaction was set up with final concentration of reagents as follows: 1x Qiagen PCR 
buffer containing 1.5 mM MgCl2 (Qiagen, Crawley, UK), 200 µM dNTP mix 
(Eppendorf, UK), 1 µM each primer, 1 unit DyNazyme EXT DNA polymerase 
(Finnzymes) and 20 ng cDNA template.  The PCR conditions used for gene screening 
were: 95 ºC for 5 min, 30 cycles of (94 ºC for 15 sec, x ºC for 1 min, 72 ºC for 1 min), 
then 72 ºC for 10 min, where x refers to the annealing temperature used for specific 
primer pair.  Information on the annealing temperatures and primer pairs used for each 
gene is listed in Table 2.3. 
 
 
Table 2.3: Details of primers used in RT-PCR for gene expression analysis in 
hMSCs and osteosarcoma cells.   
2.8.4 Agarose gel electrophoresis 
 
PCR products were separated on 1.5-2 % w/v agarose gels with 0.5 µg/mL ethidium 
bromide for DNA visualisation.  PCR samples were mixed with DNA loading buffer 
(6x stock concentration: Bromophenol Blue/Glycerol), electrophoresed  for typically 1 h 
and visualised on Uvitec™ transilluminator imaging system.  
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3.1 Introduction and aims 
 
Human Mesenchymal Stem Cells (hMSCs) have the capacity to differentiate in vitro 
and in vivo along a number of lineages including the adipogenic, chondrogenic and 
osteogenic pathways (Pittenger et al., 1999).  This population of cells is maintained 
throughout adulthood and can be isolated from numerous locations in the body (Figure 
1.1).  The most well characterised hMSC population is derived from the bone marrow 
and a variety of methods have been employed by different laboratories in an attempt to 
obtain homogeneous populations of hMSCs (Jones et al., 2002).  The classic method of 
hMSC isolation is via plastic adherence but other methods including antibody-aided 
selection are also being developed (Table 1.1).  Cell surface marker profiles and lineage 
differentiation assays are frequently used to define the cell populations as hMSCs.  A 
panel of antibodies has been developed which positively identify hMSCs and the most 
specific one to date is STRO-1, reacting to an as yet unidentified antigen (Simmons and 
Torok-Storb, 1991).  However, little is known about the expression of STRO-1 antigen 
on hMSCs and its modulation during different culture conditions. 
 
STRO-1 identifies 10 % of bone marrow mononuclear cells of which 95 % are 
nucleated erythroid progenitors.  Following exclusion of erythroid progenitors by 
glycophorin A depletion, all the cells recovered were found to be plastic adherent with a 
fibroblastic morphology (reminiscent of the CFU-F description) and able to differentiate 
to myelosupportive stroma (Simmons and Torok-Storb, 1991).  Further investigation 
demonstrated that clonally derived CFU-F were STRO-1 positive and gave rise to the 
tri-lineage characteristic of hMSCs (Pittenger et al., 1999).   Analysis of fresh bone 
marrow mononuclear cells demonstrated varying levels of STRO-1 expression which 
Gronthos and co-workers (2003) characterised as three sub-populations (Dull, 
Intermediate and Bright).  Interestingly, the STRO-1BRIGHT positive fraction bears 
important phenotypic and functional characteristics attributed to stem cells found in 
other renewing tissues (Conget and Minguell, 1999).  Freshly isolated STRO-1BRIGHT 
population lack Ki-67 cell cycle surface antigen indicating quiescence in vivo; increased 
telomerase activity indicating extensive proliferation potential; and exhibit an 
undifferentiated state lacking detectable key differentiation marker expressions 
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(PPARγ2 in adipogenesis, Cbfa-1 in osteogenesis and Collagen Type II in 
chondrogenesis) (Minguell et al., 2001).   
 
The STRO-1 heterogeneity within the hMSC population also reflects the heterogeneity 
in the cells’ proliferative and differentiation potential.  As initially proposed by Owen 
and Friedenstein (1988), CFU-F from the bone marrow represent a mixed population of 
multi-, bi- and uni-potential progenitors at different stages of differentiation (Owen and 
Friedenstein, 1988).  Following this stromal stem cell hierarchy of cellular 
differentiation, it appears that STRO-1 is identifying a population of undifferentiated 
cells with the multipotent cells residing in the STRO-1BRIGHT fraction.  The notion of 
stemness of the mesenchymal progenitors therefore follows that this characteristic is not 
restricted to one cell type but is a spectrum of capabilities within that population.  The 
proliferative hierarchy depicts a structured cell population consisting of stem, 
committed and mature cells with the highest STRO-1 expressive cells possibly 
representing the stem cell subset (Gronthos et al., 2003). 
 
Culture expanded hMSCs have been used in several studies in an attempt to elucidate 
the stem cell characteristics of the population.  This is mainly due to the low incidence 
of hMSCs in the bone marrow (10 % of bone marrow mononuclear cells) resulting in 
insufficient raw material for the various investigative assays.  In addition to the absence 
of a consensus isolation protocol of hMSC, discrepancy in reports also arise from the 
difference in culture conditions used in the studies.  While some studies suggest that 
bFGF addition to the growth culture media during expansion has no effect on the 
multilineage potential of hMSCs (Tsutsumi et al., 2001), others report an enhanced 
adipogenic (Neubauer et al., 2004), osteogenic (Hanada et al., 1997) and chondrogenic 
(Solchaga et al., 2005) potential.  Previous work in this laboratory (Westwood 2006) 
showed that addition of bFGF to the expansion media increases the growth rate and life-
span of hMSCs without diminishing their differentiation potential.  Following these 
observations, hMSC cultures used in this thesis were expanded in media containing 
bFGF.  However, extensive sub-cultivation of hMSCs (beyond passage 25) has been 
reported to cause a change in viability, morphology and subsequently 
immunophenotype (Conget and Minguell, 1999).  Apoptosis is triggered in the cycling 
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hMSC subset at later passages and markers of cell adhesion (ICAM-1 and integrin β1) 
are downregulated corresponding to the apparent morphological changes.  Qualitative 
assessment of differentiation upon extensive culture indicated a loss in adipogenic but 
not in osteogenic potential.  Therefore it was of interest to evaluate the expression of 
STRO-1 after multiple rounds of sub-culturing and its influence on differentiation 
potential quantitatively. 
 
The use of cultured hMSCs in regenerative medicine is unavoidable due to the low 
incidence of the cells in vivo.  While clinical intervention to obtain tissue samples 
containing hMSC is not difficult, the isolation of homogeneous populations of hMSCs 
is proving to be a challenge due to the lack of a standard protocol.  Furthermore, the 
anatomical location of hMSCs is still being debated with analogies to a perivascular 
niche being made.  Nevertheless, regardless of the source of the hMSCs, the demand for 
a cultured multipotential population is still prevalent.  So far, STRO-1 has been shown 
to be a promising candidate in the identification of cells with multilineage potential with 
differential expression during adipogenesis (Simmons and Torok-Storb, 1991).   
 
The STRO-1 status of cultured hMSCs has not been evaluated under an optimised 
protocol to date.  From the discovery of the antibody from a hybridoma supernatant to 
its commercialisation in the lyophilised form, different laboratories have adopted 
different approaches to screen their cell populations for STRO-1 expression.  Although 
hybridoma supernatant is chosen over the lyophilised form due to cost constraints, it is 
important to establish that both sources are directly comparable and equally reliable.  
Based on early indication that STRO-1 antigen may be a differentiation marker, 
elucidating the characteristics and expression profiles of STRO-1 on cultured hMSCs is 
of utmost importance and is the primary focus in this section of the thesis. 
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Aims 
The low frequency of freshly derived bone marrow hMSCs demands for culture 
expanded hMSCs to be used in regenerative medicine.  However, although extensive 
studies have been performed on the isolation and identification of multipotent cells from 
fresh bone marrow mononuclear cells, few studies have focused on culture expanded 
cells.  The STRO-1 marker has been shown to select for cells with multilineage 
potential from fresh bone marrow mononuclear cells.  Therefore, in the primary step of 
this study, the use of differently sourced STRO-1 antibody as a tool for the detection 
and characterisation of hMSCs in culture was investigated.  The expression of STRO-1 
antigen on culture expanded hMSCs and its impact on differentiation potential was also 
studied.  In order to address these, the following objectives were achieved. 
 
• characterisation of hMSC populations using antibody marker profiling 
• optimising the use of the STRO-1 antibody to screen cell populations 
• investigation of STRO-1 expression upon expansion and correlation with 
differentiation potential 
• visualisation of STRO-1 expression in hMSC cultures by dual-colour immuno-
staining 
• investigation of STRO-1 expression at confluency and its impact on 
differentiation potential 
• Assessment of STRO-1 status during adipogenic and osteogenic differentiation 
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3.2 Properties of hMSCs 
 
hMSCs can be derived from a variety of sources and are characterised by a plastic 
adherent culture and a range of marker expression (Table 1.1) and their ability to 
differentiate primarily to adipocytes, osteocytes and chondrocytes.  It is important to 
establish from the onset that the populations intended to be used in this study are in fact 
hMSCs.  Each laboratory has its own established protocol for isolating hMSCs and 
characterising the populations.  In this thesis, hMSCs isolated by plastic adherence were 
characterised by immunophenotyping and differentiation potential. 
 
3.2.1 hMSC marker profile 
 
The panel of markers used to define the hMSC population varies in different 
laboratories but generally refers to the absence of haematopoietic lineage markers and 
presence of mesenchymal, epithelial and endothelial lineage markers (Jones et al., 
2006b).  In this study, the hMSC populations were tested for the expression of the 
documented markers and assayed for their ability to differentiate.  This was done to 
ensure that the hMSC populations studied were comparable to those reported in other 
studies. 
 
hMSCs from the bone marrow of three healthy donors (N24♂, 31♂ and 38♀) were 
previously isolated by plastic adherence and colonies derived were expanded to passage 
2 and stored in 10 % v/v DMSO in liquid nitrogen (Vujovic 2006 and Westwood 2006).  
For subsequent analysis, cells from each donor were thawed and expanded to passage 6 
(Section 2.2). At subconfluency, cells were harvested and stained with antibodies (Table 
2.2) to detect the expression of markers defining hMSCs (Figure 3.1). hMSCs from the 
three donors were positive for STRO-1 antigen, albeit different levels.  The cell 
population 31♂ exhibited a total positive population shift with distinct STRO-1BRIGHT 
and STRO-1DULL subsets.  These two STRO-1 subsets were also apparent in 38♀ 
although the total positive population shift was not as pronounced as 31♂.  The 
population N24♂ showed a long thin positive tail of STRO-1BRIGHT cells, while the 
majority of the STRO-1 positive population was within the STRO-1INT subset.  The 
three hMSC populations were strongly positive for CD13 (mesenchymal marker) and 
                                                                                                               Chapter 3.  Results 
           
 
 85 
SH4, CD105 and CD146 (markers previously used to positively identify cultured 
hMSCs) and were negative for CD133 (marker commonly used to positively identify 
progenitor cells, mainly of haematopoietic origin).  CD271 (positive marker for freshly 
isolated hMSC) was weakly expressed by the passage 6 hMSCs of the three donors.  
Overall, among the panel of markers used to characterise the cultured hMSCs, STRO-1 
was the only marker to display a heterogeneous expression profile within a cell 
population and to exhibit different degrees of positivity across the three cell 
populations.      
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Figure 3.1: Continued overleaf.  Flow cytometry analysis of cell surface markers of 
hMSCs.  Subconfluent, passage 6 hMSCs (from three bone marrow donors (N24♂, 
31♂ and 38♀)) were harvested, washed and stained with the appropriate primary and 
secondary antibody if required (Sections 2.2.2 and 2.5.1).  Expression was normalised 
to 1x104 events per sample (* indicates normalisation to 1x103 cells).  Shaded 
histograms (blue) indicate cells stained with the marker-specific antibodies and red lines 
indicate unstained or secondary antibody controls. 
                                                                                                               Chapter 3.  Results 
           
 
 87 
 
 
Figure 3.1: Flow cytometry analysis of cell surface markers of hMSCs.  
Subconfluent, passage 6 hMSCs (from three bone marrow donors (N24♂, 31♂ and 
38♀)) were harvested, washed and stained with the appropriate primary and secondary 
antibody if required (Sections 2.2.2 and 2.5.1).  Expression was normalised to 1x104 
events per sample (* indicates normalisation to 1x103 cells).  Shaded histograms (blue) 
indicate cells stained with the marker-specific antibodies and red lines indicate 
unstained or secondary antibody controls. 
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3.2.2 Differentiation potential of hMSCs 
The immunophenotyped hMSC populations were induced to differentiate to the 
adipogenic and osteogenic lineages, for 8 and 21 days respectively and stained as 
appropriate (Section 2.3).  Chondrogenesis in the cell populations has been successfully 
achieved previously (Vujovic 2006 and Westwood 2006) and was not repeated in this 
context.   Adipogenic differentiation was apparent as from day 2 of induction, 
characterised by a change from polygonal to rounded morphology, with peri-nuclear 
phase bright lipid droplets which coalesced as differentiation proceeded (data not 
shown).  On day 8, the population was stained with Oil Red O for lipid accumulation   
(Figure 3.2 A1, A2 and A3).  Osteogenesis was apparent as from day 7 of induction, 
with the cells forming a mesh-like structure and becoming alkaline phosphatase positive 
(data not shown).  At day 21, differentiation was terminated and the cells assayed for 
alkaline phosphatase activity (Figure 3.2 B1, B2 and B3) and mineral deposition using 
Alizarin Red salt solution (Figure 3.2 C1, C2 and C3).   
When stained for differentiation, not all the cells within the population showed positive 
differentiation.  The heterogeneous pattern observed was similar in the three cell 
populations.  At the end of adipogenesis, some cells had extensive lipid accumulation 
while in other cells, lipid droplets were very small to totally absent.  Upon osteogenesis, 
alkaline phosphatase activity was stronger in some cells characterised by bright blue 
staining and weaker in others characterised by faint blue staining.  Mineral deposition 
was very patchy with the monolayer indicating nodule formation by a restricted cell 
subset.  
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Figure 3.2:  Differentiation potential of hMSCs from three bone marrow donors 
(N24♂, 31♂ and 38♀).  Cells at passage 6 were induced to differentiate to adipocytes 
and osteocytes using different combinations of induction reagents (Section 2.3.1).  A1, 
A2&A3:  At day 8, adipogenesis was assayed by Oil Red O to visualise lipid 
accumulation (Section 2.3.2.1); B1, B2&B3: At day 21, osteogenic cells were assayed 
for alkaline phosphatase activity (Section 2.3.2.2, blue staining) and C1, C2&C3: 
mineralisation by Alizarin Red staining (Section 2.3.2.3).  Scale bars represent 125 µm. 
 
3.3.3 Heterogeneity of hMSCs cultures 
 
Although the three hMSC cultures were able to terminally differentiate to the 
adipogenic and osteogenic lineages, the pattern of differentiation observed was not 
homogeneous (Figure 3.2); only a sub-population of cells within the induced adherent 
populations had accumulated lipid droplets (adipocytes) or had strong alkaline 
phosphatase activity and mineralised nodules (osteocytes).  While the presence of 
committed progenitors in the hMSC cultures could not be ruled out, it appeared 
plausible to suggest that the heterogeneous differentiation observed within one cell 
population is directly related to the heterogeneous expression of STRO-1 within the 
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cultured population observed (Figure 3.1).  Therefore it was of interest to further 
investigate the heterogeneity of STRO-1 within cultured monolayers.     
 
 In order to visualise the heterogeneous STRO-1 staining, hMSCs from passage 6 N24♂ 
were grown on coverslips and immunostained; FITC-conjugated secondary was used to 
detect STRO-1 and DAPI stained the nuclei blue (Section 2.4). An overview of the 
stained population at x10 magnification (Figure 3.3 A) showed a heterogeneous 
population, with only a few cells positive for STRO-1 (green staining).  Among the 
positive cells, a gradation in the green fluorescence was observed indicating that some 
cells expressed STRO-1 to a higher extent that others within the same population.  At a 
higher magnification of x40 (Figure 3.3 B), STRO-1 appeared to be unevenly 
distributed within the cell membrane and regardless of the cell morphology, STRO-1 
staining was stronger on the cell extremities.  As such, not only STRO-1 was 
heterogeneously expressed within the population, but it was also localised at selective 
positions on the cell membrane.  These observations clearly indicate that plastic-
adherent hMSC populations are heterogeneous in STRO-1 antigen staining. 
    
 
 
Figure 3.3: Expression of STRO-1 on hMSCs demonstrated by dual-colour 
immunofluorescence.  Passage 6 cells of N24♂ were grown on coverslips were stained 
with DAPI (blue nuclei) and STRO-1/FITC (Section 2.4).  STRO-1 expression was 
visualised at x10 magnification (A) and x40 magnification (B). Scale bars represent 125 
µm.  
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3.3 STRO-1 antibody optimisation 
 
STRO-1 has been used by various laboratories to isolate and characterise hMSCs (Table 
1.1).  However, there is no established protocol for the usage of STRO-1, given that 
some groups use hybridoma supernatant produced in house, while others use 
commercially obtained antibody.  Moreover, the use of hybridoma supernatant is not 
consistent as some document using the supernatant neat (Mirmalek-Sani et al., 2006), 
while others document a 1 in 2 dilution (Jones et al., 2002), with no reference to the 
concentration of antibody present.  STRO-1 antibody is of IgM isotype with a low 
binding affinity (Svehag et al., 1967).  The impact on the stability of the antibody with 
freeze-thaw cycles and storage period has not yet been optimised, hence the purpose of 
this experiment.  
 
Hybridoma cells purchased from DSHB (Iowa, USA) were expanded, the supernatant 
harvested (Section 2.2.3), STRO-1 content quantified by ELISA as 4.2 µg/mL (Section 
2.2.4) and stored at 4 ºC.  Sub-confluent hMSCs (N24♂) at p4 were harvested, stained 
for STRO-1 and detected with a RPE-conjugated secondary (Table 2.2).  The 
hybridoma supernatant was used as 100 µL neat or 1:2 diluted per 5x105 cells.  
Commercially obtained STRO-1 was reconstituted, dispensed in aliquots and stored at -
20 ºC.  When required, the aliquot was thawed, diluted to 100 µL of 5 µg/mL and 
incubated with 5x105 cells.  The commercial antibody was also assayed in this way after 
two freeze-thaw cycles and after two months of storage at 4 ºC.   
 
Although all the antibody conditions used positively detected STRO-1 on the hMSCs, 
the number of bright cells detected varied widely (Figure 3.4 and data summarised in 
Table 3.1).  The use of the neat supernatant detected nearly twice as many bright cells as 
using it at 1:2 dilution (Table 3.1).  Repeated freeze-thawing and 4 ºC storage of the 
commercial antibody had a negative effect on the stability of the antibody and therefore 
reduced the number of bright positive cells detected which in turn reduced the 
population geometric mean value by 74 and 103 respectively.  The combined data in 
Table 3.1 shows considerable variation in the geometric mean value when using 
differently sourced and stored STRO-1.  Furthermore, dilution of the antibody 
supernatant and storage conditions of the commercial antibody directly affected the 
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percentage of STRO-1BRIGHT cells detected.  Therefore, using the commercially sourced 
STRO-1 at a single freeze-thaw cycle was the method of choice for the work described 
in this thesis as it gave the strongest straining. 
 
 
Figure 3.4:  Optimisation of STRO-1 usage on passage 4 N24♂ hMSCs.  Cells were 
incubated with STRO-1 as specified and detected with RPE-conjugated secondary 
antibody (Table 2.2).  Flow cytometry analysis was carried out on a sample size of 
5x105 cells per 100 µL of supernatant/antibody solution, analysis normalised to 1x104 
events and gate (R5) set to include 0.02 % of the total control population (Section 2.5).  
Secondary antibody control is indicated by the red line and STRO-1 labelled population 
by the shaded histogram (blue). 
 
 
STRO-1 antibody 
condition 
Gate percentage Geometric mean 
Supernatant neat 13.24 131 
Supernatant 1:2 7.34 66 
Commercial frozen once 29.18 234 
Commercial frozen twice 20.62 160 
Commercial 4 ºC storage 14.20 131 
Control  0.02 3 
 
Table 3.1: Detection of STRO-1BRIGHT population on passage 4 N24♂ hMSCs.  
Stained STRO-1/RPE cells were analysed by flow cytometry (Section 2.5.1) and gated 
to include 0.02 % of positive cells in the secondary only control population.  STRO-1 at 
different conditions was assayed and the percentage within the gated population of 
bright cells and geometric mean of the whole population were recorded. 
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3.4 Effect of passage number on STRO-1 expression and 
differentiation potential 
 
Culture conditions are known to affect the expression of certain markers, especially 
CD271 on bone marrow derived hMSCs (Jones et al., 2002).  These changes in marker 
expression are believed to arise from the lack of stimuli from the in vivo 
microenvironment or as a phenomenon resulting from extensive expansion.  A possible 
correlation between marker expression in hMSC cultures and differentiation potential 
has not been studied before.  Work in this laboratory has previously shown that an 
increase in passage number decreases the adipogenic potential of hMSCs (Westwood 
2006), an effect which has also been reported by other groups (Conget and Minguell, 
1999, Pal et al., 2009).  Therefore, this experiment aimed to investigate the effect of 
passage number on STRO-1 expression and its correlation with adipogenic and 
osteogenic differentiation potentials of the cells. 
 
One-day post confluent hMSCs from the three healthy donors (N24♂, 31♂ and 38♀) 
were harvested at passages 4, 7 and 10 or 11 and stained with STRO-1/RPE or induced 
to differentiate to the adipogenic and osteogenic lineages.  With increasing passage 
number, hMSCs from the three donors showed a decreased proliferation rate and 
distinct morphological changes from predominantly small and compact to large and flat, 
indicative of senescence (Figure 3.5).  However, the rate at which hMSCs from each 
donor reached the stage of senescence varied.  hMSCs from 38♀ reached their 
expansion limit at passage 10, and could not be sub-cultured further.  It was possible to 
expand 31♂ hMSCs until passage 12, but passage 11 cells were used for the purpose of 
this experiment.  Later passage cells (p7 to p11) became very fragile and were 
susceptible to physical damage during the STRO-1/RPE staining procedure resulting in 
a lower event count during flow cytometry analysis.  RPE secondary controls and 
STRO-1/RPE stained cells were normalised pairwise to 10 000 or 6000 events per 
passage, after gating to exclude cell debris.  N24♂ and 38♀ hMSCs showed a decrease 
in STRO-1 expression with increasing passage number (Figure 3.5).  Cells from 31♂ 
had elevated expression of STRO-1 at passage 7 which then decreased at passage 11, 
showing that modulation of STRO-1 expression upon sub-culture was dependent on 
donor (Figure 3.5).   
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When hMSCs from each passage point were induced to differentiate to adipocytes and 
osteocytes (Section 2.3), the extent of differentiation matched the level of STRO-1 
expression (Figure 3.5), whereby an elevated level of STRO-1 antigen resulted in a 
higher adipogenic and osteogenic potential both qualitatively (Figure 3.6) and 
quantitatively (Figure 3.7).  The differentiation pattern observed at each passage number 
for the three donors was heterogeneous.   
 
During adipogenesis, cells with the highest adipogenic potential (N24♂p4, 31♂p7 and 
38♀p4) accumulated lipids rapidly and contained a larger subset of cells stained 
positively for Oil Red O (Figure 3.6, A: N24♂, B: 31♂ and C: 38♀).  Osteogenesis was 
more pronounced in p4 of N24♂ and 38♀ compared to their corresponding later 
passages.  In the case of 31♂, p7 showed higher differentiation potential than p4 and 
p11.  For the osteogenic assay, alkaline phosphatase activity was observed in a few cells 
in the control populations of p4 and p7 of the three donors.  Low level Alizarin Red 
staining was observed in the control populations of the later passages 10 or 11 (Figure 
3.6, A: N24♂, B: 31♂ and C: 38♀).  Quantitative analysis of differentiation was 
performed for both lineages (Figure 3.7, A: N24♂, B: 31♂ and C: 38♀).   
 
Quantification of adipogenesis was primarily carried out by counting the number of 
cells with red stained lipid droplets (irrespective of size) per field of view.  The second 
method used was dye solubilisation with normalisation to DNA content (Section 2.3.3).  
Both methods indicated a significantly higher adipogenic potential in N24♂p4 (p<0.03), 
31♂p7 (p<0.01) and 38♀p4 (p<0.04) compared to their relevant passage numbers.  
However, the difference in adipogenic potential between the different passage numbers 
was not as pronounced as what was obtained by the adipocyte count method (Figure 
3.7, A1&A2: N24♂, B1&B2: 31♂ and C1&C2: 38♀).   
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Quantification of osteogenesis was carried out by measuring the level of alkaline 
phosphatase activity and amount of Alizarin Red recovered, both assays normalised to 
DNA content (Section 2.3.3).  Both assays indicated a significantly higher osteogenic 
potential in N24♂p4 (p<0.01), 31♂p7 (p<0.01) and 38♀p4 (p<0.05) compared to their 
relevant passage numbers.  While both assays reflected the osteogenic potential 
observed by the qualitative staining (Figure 3.7, A3&A4: N24♂, B3&B4: 31♂ and 
C3&C4: 38♀), they did not distinguish between the differentiation heterogeneity within 
each cell population revealed by the microscopy analysis of the staining assay (Figure 
3.6).   
 
Overall, the qualitative staining could be matched to the quantitative assay and 
differentiation potential observed directly correlated with the STRO-1 profile obtained 
at the different passage number.  Additionally, the three donors regulated their STRO-1 
expression differently at different passage number, but all the populations lost STRO-1 
expression at later passage numbers (beyond p7).  Comparatively, beyond p7, 
adipogenic and osteogenic potential was significantly reduced (p<0.04 and p<0.01). 
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Figure 3.5: Changes in cell morphology and STRO-1 expression with passage 
number.  hMSCs from three donors (N24♂, 31♂ and 38♀) were expanded to specified 
passage numbers and assayed for STRO-1 expression by flow cytometry (Section 2.5).  
Prolonged culture progressively initiates cell senescence characterised by large and flat 
cells (inset).  STRO-1 was detected using RPE conjugated secondary and analysed to 
exclude cell debris.  Secondary antibody control is indicated by the red line and STRO-
1 labelled population by the shaded histogram (blue).  Scale bars represent 125 µm. 
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Figure 3.6: Continued overleaf.  Qualitative correlation of passage number with 
adipogenic and osteogenic differentiation potential.  One day post-confluent hMSCs 
from three donors (A.N24♂, B.31♂ and C.38♀) were differentiated to adipocytes and 
osteocytes via the addition of specific induction cocktails (Section 2.3.1).  At day 8, 
adipogenic differentiation was terminated and cultures stained with Oil Red O; at day 
21, osteocytes were assayed for alkaline phosphatase activity (blue) and Alizarin Red 
mineral deposits (brown-red) (Section 2.3.2).  CNT: uninduced control population; 
IND: lineage-specific induced population.  Scale bars represent 125 µm. 
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Figure 3.6: Continued overleaf.  Qualitative correlation of passage number with 
adipogenic and osteogenic differentiation potential.  One day post-confluent hMSCs 
from three donors (A.N24♂, B.31♂ and C.38♀) were differentiated to adipocytes and 
osteocytes via the addition of specific induction cocktails (Section 2.3.1).  At day 8, 
adipogenic differentiation was terminated and cultures stained with Oil Red O; at day 
21, osteocytes were assayed for alkaline phosphatase activity (blue) and Alizarin Red 
mineral deposits (brown-red) (Section 2.3.2).  CNT: uninduced control population; 
IND: lineage-specific induced population.  Scale bars represent 125 µm. 
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Figure 3.6:  Qualitative correlation of passage number with adipogenic and 
osteogenic differentiation potential.  One day post-confluent hMSCs from three 
donors (A.N24♂, B.31♂ and C.38♀) were differentiated to adipocytes and osteocytes 
via the addition of specific induction cocktails (Section 2.3.1).  At day 8, adipogenic 
differentiation was terminated and cultures stained with Oil Red O; at day 21, 
osteocytes were assayed for alkaline phosphatase activity (blue) and Alizarin Red 
mineral deposits (brown-red) (Section 2.3.2).  CNT: uninduced control population; 
IND: lineage-specific induced population.  Scale bars represent 125 µm.   
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Figure 3.7: Continued overleaf. 
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Figure 3.7:  Quantitative correlation of passage number with adipogenic and 
osteogenic differentiation potential.  Bar charts represent data from three hMSC 
donors (A. N24♂, B. 31♂ and C. 38♂).  At day 8, the extent of adipogenesis was 
quantified by adipocyte count per field of view (Section 2.3.3.1) and Oil Red O dye 
extraction (Section 2.3.3.2) with normalisation to DNA content (Section 2.3.3.5).  At 
day 21, osteogenesis was quantified by alkaline phosphatase activity (Section 2.3.3.3) 
and Alizarin Red dye extraction (Section 2.3.3.4), both normalised to DNA content 
(Section 2.3.3.5).  Adipocyte count: A1, B1 and C1; Oil Red O dye recovery: A2, B2 
and C2; Alkaline phosphatase activity: A3, B3 and C3 and Alizarin Red dye recovery: 
A4, B4 and C4.  Student’s t-test p4 versus p7; p4 versus p10/11, **p<0.04, ***p<0.01. 
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3.5 Enrichment of STRO-1 positive sub-population 
 
hMSCs exhibit variable expression of STRO-1, as shown by flow cytometry and dual-
colour immunofluorescence (Figures 3.1 and 3.3).  This heterogeneity was reflected in 
the pattern of differentiation of the cells, whereby the extent of lipid accumulation and 
mineral deposition was not uniform throughout the culture monolayer.  In order to 
investigate whether the STRO-1 positive cells was the population subset possessing the 
potential to extensively differentiate, N24♂ hMSCs at passage 6 were separated on a 
miniMACS® column to enrich for the STRO-1 positive population (Section 2.5.3).  
Enrichment of STRO-1 cells was confirmed via flow cytometry by labelling the cells 
with STRO-1/RPE (Figure 3.8).  Passage 6 hMSCs were used as that population 
displayed a wide population spread (Figure 3.8; green line representing pre-enriched 
population), thus facilitating the enrichment process.  A gate (R9) was drawn to include 
the STRO-1BRIGHT subset of the pre-enriched fraction (31.1 %).  Based on R9, an 
enrichment of 73.5 % was achieved in the STRO-1 enriched fraction while the STRO-1 
depleted fraction contained 4.4 % of STRO-1BRIGHT cells (Table 3.2).   
 
After assaying the three populations obtained (pre-enriched, STRO-1 depleted and 
STRO-1 enriched) for STRO-1 expression, they were induced to differentiate to the 
adipogenic and osteogenic lineages.  On termination of differentiation, adipocytes were 
stained with Oil Red O for lipid accumulation and osteocytes were assayed for alkaline 
phosphatase activity.  Qualitative assays showed that the STRO-1 enriched fraction 
exhibited extensive differentiation characterised by numerous adipocytes and strong 
alkaline phosphatase activity, as compared to the STRO-1 depleted and pre-enriched 
fractions (Figure 3.9).  In the STRO-1 enriched fraction, although the population 
contained numerous adipocytes, there were certain areas which were not as fully loaded 
with lipid droplets as others (Figure 3.9).  Similarly, in the alkaline phosphatase 
staining, although all cells appeared blue (positive), the gradation in the blue staining 
varied.  However, this heterogeneity in staining was not as pronounced as in the pre-
enriched fraction.  The STRO-1 depleted fraction exhibited limited differentiation, 
characterised by sparse adipocytes and faint blue patches (Figure 3.9).  Due to the 
limited number of cells recovered after enrichment, it was not possible to quantify the 
extent of differentiation observed.  
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Figure 3.8: Overlay of flow cytometry analysis of MACS separated passage 6 
N24♂ hMSCs.  Cells were harvested, STRO-1 enriched by passing through magnetic 
column (Section 2.5.3) and the different fractions stained with STRO-1/RPE as 
appropriate (Section 2.5.1 but without final wash).  Gate R9 represent the STRO-
1BRIGHT cell subset based on the pre-enriched fraction.  
 
 
 
 
hMSC fraction Percentage of STRO-1
BRIGHT
 
cells (R9) 
RPE control 0.5 
Pre-enriched 31.1 
STRO-1 depleted 4.4 
STRO-1 enriched 73.5 
 
Table 3.2:  Percentage of STRO-1BRIGHT cells during MACS separation.  Cell 
fractions analysed by flow cytometry using STRO-1/RPE staining were gated (R9) to 
select for the STRO-1BRIGHT subset.   
 
 
 
  
 
                                                                                                               Chapter 3.  Results 
           
 
 104 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9:  Adipogenic and osteogenic differentiation of MACS separated hMSC 
fractions.  Pre-enriched, STRO-1 depleted and STRO-1 enriched fractions of p6 N24♂ 
were induced to differentiate to adipocytes for eight days (stained lipid droplets with Oil 
Red O) and osteocytes for twenty-one days (stained blue for alkaline phosphatase 
activity) (Section 2.3).  Scale bars represent 125 µm. 
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3.6 Modulation of STRO-1 expression at confluency and its impact on 
differentiation  potential 
 
The established and validated protocol for differentiation of hMSCs is the addition of 
lineage-specific induction medium to the cells at one day post-confluency (Pittenger et 
al., 1999).  During expansion, hMSCs are maintained at sub-confluency to maximise 
proliferation and prevent possible contact induced differentiation.  However, upon 
adipogenic and osteogenic differentiation, the cells are induced at post-confluency to 
encourage lineage specific maturation.  Cell to cell contact has been shown to be a 
potent mediator of differentiation in addition to chemical stimuli (Jaiswal et al., 2000).  
It is unknown if STRO-1 expression is modulated at post-confluency and whether it has 
any influence on differentiation potential.  To test this possibility, STRO-1 expression 
was investigated at different time points of post-confluency and then induced to the 
adipogenic and osteogenic lineages.  The two time points investigated were set up in 
parallel using the cell line M24♂. 
 
Passage 4 hMSCs (M24♂) were allowed to expand for one and seven days post-
confluency, at which points the cells were harvested and stained for STRO-1/RPE for 
flow cytometry analysis (Section 2.5.1) or induced to the adipogenic and osteogenic 
lineages (Section 2.3).  The level of STRO-1 expression at seven days post-confluency 
was lower than the expression at one day post-confluency, indicating that upon cell to 
cell contact the surface expression of STRO-1 is reduced (Figure 3.10).  Upon 
differentiation, adipogenesis was reduced when induced at seven days post-confluency 
compared to when induced at one day post-confluency.  This was shown qualitatively 
by sparse adipocyte formation with few lipid droplets (Figure 3.11) and quantitatively 
by the reduced adipocyte count (p<0.05) and Oil Red O recovery (p<0.04) (Figure 3.12 
A&B).  However, osteogenesis was not affected as shown by the similar staining profile 
of ALP activity and AR staining for both time points (Figure 3.11).  This observation 
was subsequently confirmed by the quantitative measurement assays which showed no 
difference in the level of ALP activity and AR dye recovery (Figure 3.12 A&B).    
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Figure 3.10: STRO-1 expression of passage 4 hMSCs (M24♂) at confluency.  Cells 
were grown until one and seven days post-confluency, then harvested and stained for 
STRO-1/RPE (Section 2.5.1).  Red lines indicate RPE control and blue shaded 
histograms represent STRO-1/RPE labelled populations. 
 
 
 
Figure 3.11:  Differentiation of passage 4 hMSCs (M24♂) at confluency.  Cells were 
induced in lineage-specific medium (IND) at one and seven days post-confluency.  
Adipogenesis was assayed after eight days by Oil Red O staining and osteogenesis was 
assayed after twenty-one days by blue alkaline phosphatase activity staining and 
Alizarin Red staining (Section 2.3).  Control populations (CNT) were grown in the 
absence of induction cocktail and assayed for differentiation in a similar manner.  Scale 
bars represent 125µm.  
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Figure 3.12: Quantification of adipogenic and osteogenic differentiation of passage 
4 hMSCs (M24♂) at confluency.  Cells were induced in lineage-specific medium at 
one and seven days post-confluency, after which they were assayed for adipogenic and 
osteogenic differentiation (Section 2.3).  A&B: Adipogenesis was quantified by 
adipocyte count per field of view and Oil Red O dye extraction normalised to DNA 
content.  C&D: Osteogenesis was quantified by alkaline phosphatase activity and 
Alizarin Red dye extraction, both normalised to DNA content.  Student’s t-test 1 Day 
versus 7 Days; *p<0.05, **p<0.04, # p>0.5. 
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3.7 STRO-1 expression during differentiation 
 
The process of differentiation is driven by an initial commitment stage and gradually 
proceeds to a final maturation stage.  During each of these stages, the cell undergoes 
morphological and phenotypical changes based on the induced lineage (Pittenger et al., 
1999).  Here, the expression of STRO-1 as a marker of stemness and its modulation 
during differentiation on passage 5 hMSCs from three donors (N24♂, 31♂ and 38♀) 
was investigated.  Adipogenesis takes place over a period of 8-10 days (Nakamura et 
al., 2003) after which fully matured adipocytes (round cells with peri-nuclear lipid 
droplets) are formed.  Osteogenesis, on the other hand, is a 21-day process, whereby 
hMSCs initially turn into osteoblasts and then slowly mature and deposit calcium 
phosphate (Shur et al., 2001).  However, in order to assay for STRO-1 expression by 
flow cytometry, cells beyond day 8 of differentiation could not be analysed.  Adipocytes 
beyond day 8 became very fragile and did not withstand the staining procedure, giving 
an anomalous scatter profile characteristic of apoptotic cells and cell debris (data not 
shown).  Osteocytes beyond day 8 of differentiation were difficult to dissociate by 
trypsin enzymatic treatment to a single-cell suspension as they had started depositing 
extracellular matrix, thus hindering flow cytometry analysis.  CD13 is a transmembrane 
protein previously used as mesenchymal marker and was therefore used as a positive 
control of marker expression, as it is expected to be consistently expressed.  Non-
induced cells were also analysed for STRO-1 and CD13 expression at days zero (on the 
day of induction), two and seven.   
 
CD13 expression was donor dependent but remained constant throughout 
differentiation, in both the non-induced and induced cells (Figure 3.13).  STRO-1 
expression decreased with time in the non-induced control population (Figure 3.13 A), 
consistent with STRO-1 down-regulation upon confluency (Figure 3.10).  The process 
of adipocyte formation was consistent with a loss in STRO-1 expression as the cells 
matured.  However, 31♂ showed a slight increase in STRO-1 expression at day 8 of 
adipogenesis (* in Figure 3.13 B).  It is to be noted that this population of cells had a 
greater amount of cell debris as compared to the other populations, and therefore the 
profile obtained may be inclusive of cells with a compromised cell membrane stained 
intracellularly with STRO-1. Furthermore, the side population of STRO-1BRIGHT cells 
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was not present, suggesting that those cells have differentiated to adipocytes and 
therefore exhibited a STRO-1DULL profile.  Osteogenesis followed a pattern of initial 
STRO-1 up-regulation at day 2 and gradual down-regulation as differentiation 
proceeded.  However, the rate and extent of this down-regulation was dependent on the 
donor population (Figure 3.13 C).  Given that later time point analyses were not 
possible, the level of STRO-1 expression on mature osteocytes was not obtained.   
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Figure 3.13: Continued overleaf.  Flow cytometry analysis of STRO-1 and CD13 expressions during adipogenic and osteogenic 
differentiation.  Passage 5 hMSCs from three donors (N24♂, 31♂ and 38♀) were induced to differentiate to (B) adipocytes and (C) 
osteocytes, with a (A) control population maintained without induction medium (Section 2.3.1).  At days 0, 2 and 8 of differentiation (D0, 
D2 and D8), cells were harvested, stained for STRO-1/RPE or CD13-PE and analysed by flow cytometry (Section 2.5.1), with 
normalisation to 2x103 cells.  Red lines indicate control population unstained or with RPE only and shaded histograms (blue) marker 
specific labelled population.  The x-axis represents FL2 Log scale and the y-axis represents counts.  * in B indicates population with 
increased cell debris. 
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hMSCs from three donors (N24♂, 31♂ and 38♀) were induced to differentiate to (B) adipocytes and (C) osteocytes, with a (A) control 
population maintained without induction medium (Section 2.3.1).  At days 0, 2 and 8 of differentiation (D0, D2 and D8), cells were 
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represents FL2 Log scale and the y-axis represents counts.  * in B indicates population with increased cell debris. 
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3.8 Discussion 
The aim of the first results chapter of this thesis was to characterise STRO-1 expression 
on cultured hMSCs and correlate the STRO-1 status of the cells to their multilineage 
potential.  In order to achieve this, hMSCs isolated by plastic adherence from the bone 
marrow were immuno-phenotyped to ensure that they were in accordance with the 
profile documented elsewhere (Horwitz et al., 2005).  Thereafter, STRO-1 expression 
was investigated under different culture conditions and its impact on adipogenic and 
osteogenic differentiations was qualitatively and quantitatively assayed. 
 
Due to different isolation and growth protocols, some variability in the phenotype of 
hMSC has been reported (Jones et al., 2002, Tsutsumi et al., 2001, Campioni et al., 
2003).  Under standard growth conditions as proposed by Pittenger and co-workers 
(1999), both the morphology and the marker profile of the hMSC populations observed 
in this study (Figures 3.5 and 3.1 respectively) resembled those documented elsewhere 
(Pittenger et al., 1999, Majumdar et al., 1998).  Uniform expression of mesenchymal 
CD13, endothelial CD105 and hMSC SH4 (epitope of CD73 present on hMSC) markers 
suggested the absence of contaminating cells of different lineage origin (Barry et al., 
2001, Campioni et al., 2003).  The hMSC populations investigated here were also 
positive for the multipotent perivascular cell marker CD146, which has been linked to 
MSCs by virtue of a proposed common niche (Covas et al., 2008).  CD133, a marker 
most commonly found on protrusions of haematopoietic progenitor cells was not 
expressed by cultured hMSCs as previously reported (Wagner et al., 2005, Buhring et 
al., 2009).   
 
However, this study differed from others in that CD271 was weakly detected on the 
cultured hMSCs (formerly known as Low-affinity Nerve Growth Factor Receptor, 
LNGFR).  It is to be noted that the hMSCs used in the profiling were at passage 6 and 
the culture conditions used for expansion included bFGF.  In contrast, Jones and co-
workers showed high levels of CD271 in freshly isolated hMSCs from bone marrow 
samples (Jones et al., 2002).  Here, the difference lies in the state of the cell population 
used (cultured or fresh) and the conditions under which the cells were expanded.  
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Indeed it has been shown that CD271 is quickly down-regulated upon culture (as low as 
passage 3) especially in bFGF supplemented media, therefore explaining the weak 
expression of CD271 observed in the cultured hMSCs in my study (Jones et al., 2002, 
Quirici et al., 2002).   
 
The three cell hMSC populations screened in my study were positive for STRO-1 
although the profile obtained appeared to be donor-dependent as reported by others 
(Stewart et al., 2003).  Among the panel of markers used, STRO-1 was found to be the 
only marker variably expressed in the hMSC populations and the antigen appeared to be 
non-uniformly distributed on the cell surface.  The STRO-1 profile has been classified 
as three subsets indicated by STRO-1DULL, STRO-1INTERMEDIATE and STRO-1BRIGHT, 
possibly with the primitive cells residing in the STRO-1BRIGHT subset (Gronthos et al., 
2003).  In my study, this heterogeneity in antigen expression appeared to be correlated 
with the heterogeneous differentiation observed when induced to the adipogenic and 
osteogenic lineages.  Although the populations terminally differentiated as assayed by 
histochemical stainings, only islands of adipocytes and osteocyte nodules were 
observed, therefore leading to the hypothesis that STRO-1 antigen is a marker of 
multipotency. 
 
Before STRO-1 could be employed in further assays, it was important to optimise its 
use as a number of reports have documented conflicting protocols for STRO-1 
screening.  Furthermore, the most common STRO-1 source which is the antibody 
supernatant has been used at different concentrations, such as neat supernatant 
(Mirmalek-Sani et al., 2006) or a 1:2 dilution (Jones et al., 2002).  Moreover, the 
concentration of antibody produced in hybridoma supernatant is not consistent in every 
culture system and such batch variability should be considered when using antibody 
supernatant (Mohan et al., 1993).  The lack of quality control on STRO-1 hybridoma 
supernatant makes it difficult to determine the molecular integrity and concentration of 
the IgM produced, thus causing variability in the degree of STRO-1 expression detected 
when screening cell populations.  Comparison between hybridoma supernatant and 
reconstituted commercially obtained lyophilised antibody showed that the binding 
ability of STRO-1 antibody was optimal when used at the recommended concentration 
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of 5 µg/mL of the commercial STRO-1 with the least number of freeze-thaw cycle.  
Therefore, this protocol was adopted to detect STRO-1 expression throughout this 
thesis. 
 
Comparative studies of potential hMSC markers indicated that STRO-1 expression is 
lost during in vitro expansion due to the lack of the necessary stimuli normally present 
in the in vivo microenvironment (Jones et al., 2002), but to date, there has been no 
correlation between the modulation of STRO-1 upon culture and its influence on 
multilineage differentiation.  This study demonstrated that STRO-1 expression is not 
consistent throughout culture and the level of expression at different passage number is 
donor-dependent (Figure 3.5).  Indeed, when hMSCs from the three donor populations 
were cultured to passage 4, 7 and 10/11, the cells changed from a compact polygonal 
shape to a large flat appearance indicative of senescence (Wagner et al., 2008).  
However, the rate at which the cells reached the senescence stage varied among the 
populations, showing that the hMSC populations may have an inherent proliferative 
ability, which may be dependent on the donor’s health, lifestyle or age (Murphy et al., 
2002, Coipeau et al., 2009).  Once the cells reached passage10/11, they stopped 
dividing and could not be sub-cultured further.  Other reports document bone marrow 
hMSC cultures for up to passage 25, but it is to be noted that altered conditions 
including lower plating densities and higher serum concentrations accounted for such 
extensive expansion potential (Samuelsson et al., 2009).   
 
Interestingly, changes in the cell morphology appeared to be correlated with the level of 
STRO-1 expression detected, whereby a large flat phenotype exhibited weak STRO-1 
expression.  Furthermore, upon induction to the adipogenic and osteogenic lineages, the 
extent of differentiation as assayed qualitatively and quantitatively (Figures 3.6 and 3.7) 
was directly dependent on the level of STRO-1 expression.  It has been shown that cell 
shape directly influences lineage commitment, but the intracellular mechanism resulting 
from changes in the actin cytoskeleton has not been fully elucidated (McBeath et al., 
2004).  In this study, it can be inferred that the morphological changes observed upon in 
vitro expansion regulates the expression of STRO-1 which in turn acts as a 
differentiation antigen dictating the multilineage status of the cell.  However, the natural 
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process of cell senescence causing a decrease in differentiation cannot be ruled out.   It 
has been proposed that long-term expanded cells can be affected in five different ways: 
1) the heterogeneous hMSC cultures exhibit different proliferative rates which affect the 
rate of culture expansion in vitro; 2) spontaneous genetic mutations of cells in culture 
affecting cell fate; 3) spontaneous differentiation due to culture conditions leading to 
hindering self-renewal capacity of hMSCs; 4) loss of telomeres restricting cell division; 
5) age-related cell senescence depending on hMSC donor (Wagner et al., 2010).  
Therefore, the implication of STRO-1 at any of the different cellular processes 
described remains to be investigated once the identity of STRO-1 antigen is elucidated. 
 
STRO-1 antigen as a multilineage marker was further investigated by primary 
enrichment of STRO-1 positive cells via magnetic cell separation and differentiation 
assays.  Enrichment of passage 6 hMSCs yielded a population of 73.5 % STRO-1 
positive cells (Table 3.2).  Despite the heterogeneous expression of STRO-1 in the pre-
enriched population, it was not feasible to achieve a better enrichment as cells from the 
STRO-1DULL subset were being selected for when enriched at higher stringency.  As 
such, after various optimisation steps, it was possible to achieve a maximum enrichment 
of 73.5 %, a population which in this study was classified as STRO-1BRIGHT, while the 
depleted fraction consisted of 4.4 % of STRO-1BRIGHT cells.  In a similar study 
conducted by Gronthos and colleagues (2003), a population of 75.3 % of STRO-1 
positive cells was achieved from a heterogeneous population of freshly derived bone 
marrow mononuclear cells.  Although the starting population in the two experiments 
differed (uncultured against cultured populations), a directly comparable enrichment 
was achieved therefore suggesting the enrichment obtained in my study was optimal.  
Upon induction, the STRO-1 enriched fraction showed enhanced differentiation 
potential characterised by numerous adipocytes and elevated ALP activity as compared 
to the pre-enriched fraction.  The STRO-1 depleted fraction showed limited 
differentiation, possibly due to the presence of the contaminating 4.4 % STRO-1BRIGHT 
cells which retained differentiation potential.  Due to the limited number of cells, 
mineralisation assays and quantification of differentiation was not possible, but despite 
this, the histological staining pattern observed clearly highlighted STRO-1 as a marker 
of multipotency.  This is the first report of a positive marker which enriches for 
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multipotential hMSCs from adherent cultures.  These data have important implications 
in regenerative medicine as it addresses one major obstacle in hMSC application that is 
limited cell number obtained from bone marrow mononuclear cells.  By expanding 
hMSCs and isolating the multipotential STRO-1 positive subsets of the heterogeneous 
population, enhanced in situ differentiation could potentially be achieved, for instance 
in osteo-chondral injuries where STRO-1 enriched cells could be transplanted to the site 
of repair.     
 
In agreement with Pittenger’s protocol of hMSC culture and differentiation (Pittenger et 
al., 1999), hMSCs are induced at one day post-confluency.  Most evaluations of STRO-
1 expression are carried out at sub-confluency and thus, it is unknown whether 
confluency modulates STRO-1 expression.  In this study, upon extended culture, 
STRO-1 expression was found to be reduced.  While a down-regulation of STRO-1 
negatively influenced adipogenesis, interestingly, osteogenesis was not affected.  The 
extent of ALP activity and AR staining was similar in cells induced at one and seven 
days post-confluency.  This observation indicated that the cells retained their osteogenic 
potential upon extended culture and upon chemical stimulation (addition of osteogenic 
differentiation cocktail), readily differentiated to osteoblasts.  An analogous 
phenomenon has been documented by Seib and co-workers (Seib et al., 2009).  This 
group showed that extended in vitro culture of hMSCs may ‘imprint’ osteogeneic traits 
on hMSCs (especially those derived from the bone marrow) by the activation of 
endogenous BMPs, key factors in bone morphogenesis.  Indeed, a comparative study 
showed that bone marrow derived MSCs are superior in their ability to differentiate 
towards the osteogenic lineage while adipose derived MSCs were more inclined 
towards the adipogenic lineage (Im et al., 2005).  In line with these observations, I 
speculate that adipogenesis of adipose derived MSCs will not be affected while 
osteogenesis may be hampered if they were to be induced at seven days post-
confluency.  Therefore, future studies should take into account the source of MSCs 
being used as the time of induction may be a crucial factor in determining the outcome 
of the differentiation process.  
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When the STRO-1 antibody was first identified, it was highlighted as a marker of 
undifferentiated adherent cells (hMSCs) by its lack of expression on mature adipocytes 
(Simmons and Torok-Storb, 1991).  Upon differentiation, hMSCs lose their stemness 
and commit to a specific lineage.  On doing so, they change from multipotential to 
unipotential and mature towards a specific cell type.  If STRO-1 were to be a marker of 
multipotency, then it is fair to hypothesise that its expression will be gradually lost as 
the cell commits and matures.  To investigate this hypothesis, the STRO-1 profile of 
hMSCs was assayed at different time points of adipogenesis and osteogenesis.  Relative 
to osteogenesis, adipogenesis is a rapid process.  Adipogenesis is characterised by lipid 
accumulation and mature lipid-laden adipocytes become visible within eight days of 
induction (Ntambi and Young-Cheul, 2000).  The expression of STRO-1 was constantly 
down-regulated as adipogenesis progressed, indicating lineage commitment and 
maturation as initially proposed by Simmons and Torok-Storb (1991).  On the other 
hand osteogenesis is a temporal event characterised by primary osteoblast formation and 
subsequent mineral deposition taking place over an average period of twenty-one days.  
However, beyond day eight of osteogenesis, due to extracellular matrix deposition, 
trypsin enzymatic treatment was not effective, resulting in samples unsuitable for flow 
cytometry analysis.  Therefore, the latest time point for flow cytometry analysis was day 
eight.  Osteogenesis, as opposed to adipogenesis, showed an initial upregulation of 
STRO-1 followed by a gradual down-regulation.  This phenomenon may be explained 
by the fact that the experimental design to capture STRO-1 expression during 
osteogenesis is reliant on the early processes of cell commitment to the lineage, and 
therefore may be a natural property of STRO-1 to display an initial upregulation before 
being downregulated upon maturation.  This phenomenon was not observed in 
adipogenesis as the process is rapid and I speculate that if samples were taken at earlier 
stages of adipogenesis (for instance four hours post induction), the initial upregulation 
might have been observed.  Transcriptional changes have been shown to occur within 
few hours of hormonal stimulation to the adipogenic lineage (Tang and Lane, 1999) and 
based on this, it can be suggested that STRO-1 expression is altered during the early 
stages of differentiation.  Since CD13 remained constant throughout the differentiation 
processes, it can be concluded that the modulation observed by STRO-1 was not an 
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artefact, but a real phenomenon characterised by the nature of the antigen.  This report 
is the first to document STRO-1 expression during the processes of differentiation.   
 
Although hMSCs express a range of other antigens of mesenchymal, epithelial and 
endothelial characteristics which aid in the identification of the population, STRO-1, as 
yet unidentified, is the only antigen which shows heterogeneity in the hMSC population 
and which may potentially discriminate between the primitive and committed 
progenitors by identifying the multipotent subset in hMSC cultures.  Given that the 
identity of the STRO-1 antigen is unknown, it is a challenge to explain the behavioural 
changes observed during the different culture conditions the hMSC populations have 
been subjected to in this study.  However, the evidence provided by this series of 
experiments highlights STRO-1 as a marker of multipotency but also infers caution to 
other researchers when it comes to using the STRO-1 antibody as a tool for hMSC 
identification.  The source and condition of the STRO-1 antibody is paramount to 
successfully characterise STRO-1 positive populations.  STRO-1 antigen is therefore a 
marker worthy of further investigation.  Elucidating the identity of this antigen will help 
in understanding the factors which determine stemness and cell fate.  Furthermore, 
identifying the antigen will help in generating antibodies of different isotypes which are 
not as sensitive to storage conditions as IgM, therefore promoting STRO-1 as the 
marker of choice for hMSC isolation in clinical settings. 
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4.1 Introduction 
The isolation of multipotent hMSCs is most commonly carried out by plastic adherence 
and upon culture, these cells are defined by the differentiation potential of the whole 
population of cells.  The inconsistency in MSC preparations from different anatomic 
locations has led to inconsistent reports thereby urging for a consensus protocol to be 
adopted (Wagner and Ho, 2007).   Although a combination of selective markers has 
been unanimously employed in the identification of freshly derived hMSCs (Table 1.1), 
to date, the markers approved by the ISCT do not distinguish the multipotent hMSCs 
from contaminating fibroblastic cells (Haniffa et al., 2009).  Early studies in this 
laboratory indicated that cultured hMSC can be discriminated from fibroblasts (MRC5 
cell line) by selective STRO-1 expression (unpublished data).  There is mounting 
evidence in the literature (Section 1.2.2) suggesting that STRO-1 expression may be an 
indicator of differentiation potential and in Chapter 3, the significance of STRO-1 
modulated expression as a marker of multipotency in cultured hMSCs has been 
established.  However, the antigen to which STRO-1 antibody binds remains 
unresolved. 
 
Systemic cues as well as cell to cell contact are believed to influence MSC fate in vivo 
(Ball et al., 2004).  In vitro studies have demonstrated that fate determination is 
accompanied by modulation of antigenic markers and that stem cell state may be 
identifiable by its immunophenotype (Salipante and Horwitz, 2007).   Initial studies by 
Simmons and Torok-Storb (1991) indicated that STRO-1 may be a differentiation 
antigen when it was observed that mature adipocytes did not express the antigen.  These 
observations and the modulation in STRO-1 expression reported in Chapter 3 taken 
together led to the hypothesis that STRO-1 antigen may be a ligand which is involved in 
either cell-to-cell signalling or may act as a receptor to inductive stimuli.  By identifying 
the nature of STRO-1 antigen, the downstream signalling cascades involved in the 
initial commitment stages of hMSC differentiation can be elucidated therefore 
contributing to the understanding of the mechanisms regulating hMSC fate.   This may 
lead to tailored stem cell therapies whereby homogeneous multipotent hMSC can be 
manipulated and directed to the specific lineage required for tissue regeneration.  Until 
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now, STRO-1 antigen has been acknowledged as a protein which is resistant to trypsin 
and collagen treatment (Simmons and Torok-Storb, 1991, Jones et al., 2002).  However, 
it cannot be ruled out that the epitope recognised by the STRO-1 IgM antibody is a 
carbohydrate moiety although glycosidase treatment studies performed showed that 
STRO-1 binding was not affected (unpublished data).  Identifying the STRO-1 antigen 
will also help generate higher affinity antibodies given that the currently available 
STRO- 1 antibody is of IgM isotype with a characteristic low binding affinity. 
 
Multiple approaches have been implemented to identify surface antigens including 
immunoprecipitation, over-expression libraries, phage display technology and peptide 
microarrays amongst others.  This work focused on peptide phage display as an initial 
approach to attempt to map the epitope recognised by STRO-1 antibody.  An alternative 
approach was also employed using comparison analysis of gene expression microarray 
of STRO-1 expressing cells as a means to identify potential candidate gene family the 
antigen belongs to. 
 
4.1.1 Peptide phage display approach 
 
Phage display technology was first introduced in 1985 whereby short peptide fragments 
were successfully expressed as a fusion to filamentous phage coat protein (Smith, 
1985).  Although a variety of biological vectors have been used as peptide display 
vehicles, the filamentous bacteriophage M13 remains the best characterised system and 
the platform of choice for the generation of peptide libraries (Rodi and Makowski, 
1999). 
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Structure of the M13 phage particle 
The phage particle has a filamentous shape of variable length (average of 930 nm) 
which is dependent on the size of the genome but has a fixed diameter of 6.5 nm.  It 
contains a circular genome of single stranded DNA (ssDNA) of about 6.4 kb packaged 
within five coat proteins named pIII, pVI, pVII, pVIII and pIX (Figure 4.1).  The 
structural proteins can be divided into the major coat protein pVIII and the minor coat 
proteins pIII, pVI, pVII and pIX.  The major coat protein pVIII wraps the phage ssDNA 
and is made up of around three thousand copies while the minor coat protein pIII 
present as five copies is located at the distal end of the virion (Day et al., 1988).   
 
 
 
 
Figure 4.1: Structure of M13 phage particle.  The particle is cylindrical with a 6.4 kb 
ssDNA encapsulated by five coat proteins which can potentially be used to display 
peptides.  The coat proteins are coloured according to their corresponding gene in the 
genome.  The intergenic regions are marked by IG and the non-structural proteins are 
unshaded (Adapted from (Carmen and Jermutus, 2002). 
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Although all the five coat proteins are potential peptide display units, pIII and pVIII 
have been exploited the most.  The minor coat protein pIII is the longest coat protein 
with a sequence consisting of 406 amino acids.  The protein consists of two glycine rich 
flexible segments inter-spaced between two domains downstream from the N-terminus 
(N1 and N2) (Figure 4.2).  The flexible spacers (G1 and G2) facilitate the interaction of 
N1 and N2 to Tol A protein and F-pilus respectively on the E.coli membrane during the 
process of infection (Riechmann and Holliger, 1997).   
 
 
 
 
Figure 4.2: The structure of minor coat protein pIII.  The N1 domain interacts with 
the Tol A membrane protein of E.coli.  The N2 domain binds the F-pilus and the CT 
domain is necessary for termination of phage assembly.  G1 and G2 are the glycine-rich 
linkers facilitating infection.  Fusion of foreign peptides can occur either at the N or CT 
terminus (Adapted from (Carmen and Jermutus, 2002).  
 
 
The major coat protein pVIII is a small protein of 50 amino acids.  This protein has a 
helical structure which enables it to compile one on top of the other and over the phage 
ssDNA to form a ‘fish scale’ conformation (Cabilly, 1999).  The number of displayed 
peptides on the phage virion is relative to the number of fused coat proteins; five on pIII 
and about 3000 on pVIII.  The insertions vary in length depending on the coat protein 
fusions as excessively long extensions (longer than 20 amino acids) may be 
unfavourable to the phage propagation mechanism (Smith and Scott, 1993). 
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Panning 
The fundamental aspect of peptide phage display is the link between genotype and 
phenotype and as such, the foreign peptide expressed as a fusion protein (phenotype) is 
dependent on the position at which the peptide DNA (genotype) has been incorporated 
inside the phage genome.  The bacteriophage library therefore consist of viral particles 
each expressing random fused peptides of defined length on its exterior surface and the 
DNA encoding this fusion resides inside the phage.  The library is screened for a 
specific target peptide against an immobilised antibody.  The selection is carried out in 
vitro and is termed ‘panning’.  Throughout the subsequent rounds of panning, 
enrichment of the complementary peptide occurs and thus the peptide target of the 
immobilised antibody can be recovered.  In this study, two panning systems were 
optimised in order to identify the target epitope of STRO-1 IgM antibody; solid-phase 
panning (Figure 2.1) and liquid-phase panning (Figure 2.2) and two peptide libraries 
were screened; Ph.D-12™ (pentavalent display of 12-mer peptides fused to pIII minor 
coat protein) and Dean’s library (multivalent display of 16-mer peptides fused to pVIII 
major coat protein).   
 
4.1.2 Microarray approach 
 
Comparison of gene expression microarrays 
Osteosarcoma is a malignant tumour of the bone often exhibiting clinical and molecular 
heterogeneity due to a varying degree of mesenchymal differentiation (Olstad et al., 
2003).  Recent studies have revealed heterogeneity among different osteosarcoma cell 
lines in terms of their extracellular matrix composition and their antigenic profiles 
(Pautke et al., 2004, Gibbs et al., 2005).  Stewart and colleagues (Stewart et al., 1999) 
previously reported the high expression of STRO-1 by the human osteosarcoma cell line 
MG-63 compared to Saos-2 and STRO-1 coupled with ALP was inversely associated 
with the early progenitors of the osteoblast lineage .  This comparative study indicates 
that STRO-1, among other markers, may be a marker that is differentially expressed at 
varying levels in osteosarcoma cell lines.  Therefore, by comparing the gene expression 
microarray profiles of different osteosarcoma cell lines and MSC to their respective 
antigenic phenotype, a list of genes with similar expression pattern to STRO-1 can be 
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obtained.  In this way, a list of potential candidate genes encoding the STRO-1 antigen, 
hence the epitope, can be obtained.  
 
Flow cytometry characterisation of seven osteosarcoma cell lines was carried out using 
different antibodies, including STRO-1 (Section 2.5).  The pattern of expression 
observed was scored and calculated as the difference in the mean fluorescence between 
the control population and the marker-specific labelled population.  The pattern 
obtained by flow cytometry was then compared to the gene expression microarray 
profile (Microarray analysis was performed by Stephen Henderson, Cancer Institute, 
University College London, UK).  This resulted in a list of candidate genes, of which 
the first twenty were selected and studied using reviewed protein database softwares 
(such as Uniprot). 
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Aims 
The main aim of this part of the study was to identify the target protein recognised by 
STRO-1 antibody.  To achieve this, two approaches have been implemented.  In the first 
instance, two phage libraries (Ph.D-12™ and Dean’s libraries) were screened by two 
panning methods in order to map the specific epitope recognised by the STRO-1 
antibody.  In order to identify potential gene candidates encoding the STRO-1 antigen, 
seven osteosarcoma cell lines were immuno-phenotyped on the basis of their expression 
of specific antigens: STRO-1, CD271, CD13, CD133 and HLA-ABC.  The profiles 
obtained were matched to gene expression microarray data, and similar patterns of 
expression were identified using a bioinformatics approach.  To achieve this, the 
following objectives were employed: 
 
• Confirmation of successful adsorption of STRO-1 to plastic microtitre wells for 
solid phase panning studies 
• Solid and liquid phase panning of Ph.D-12™ and Dean’s libraries 
• Positive identification of STRO-1 peptide displayed on phage particle using 
plaque lifts 
• Detection level of STRO-1 antibody on a solid membrane 
• Optimisation of osteosarcoma cell line screening using a live/dead 
discrimination 
• Marker profiling of seven osteosarcoma cell lines 
• Identification of potential gene candidates encoding STRO-1 antigen by 
comparing gene expression microarray data 
 
 
 
 
 
 
 
 
                                                                                                               Chapter 4.  Results    
 128 
4.2 Solid phase panning 
The Ph.D-12™ peptide library was primarily screened by solid-phase panning.  Ph.D-
12™ is a M13 phage library expressing 12-mer peptides in a pentavalent format.  The 
fusion peptides are linked to the pIII coat protein and are exposed at the distal end of the 
phage particle.   The solid phase panning process involved coating of the plastic 
microtitre plate wells with STRO-1 antibody (100 µg/mL) and selecting for 
complementary peptides from the library via a series of incubation and washing steps 
(Figure 2.1).  The input phage titre was kept constant at 1x1011 pfu/mL for each round 
of panning.  Eluted phage was quantified after each round using the plaque assay 
(Section 2.6.4) and propagated (Section 2.6.3) for the subsequent rounds of panning.  In 
order to confirm the successful binding of the IgM STRO-1 antibody to the plastic wells 
of the microtitre plate, a colourimetric assay was used.  An antibody of a different 
isotype (IgG TUJ1) was also used as a negative control and the readings were blanked 
against a BSA control.  The immobilised antibodies were bound to a goat anti-mouse 
IgM which was then detected by an anti-goat conjugated HRP.  The colour was 
developed using ABTS and the absorbance readings measured at 405 nm (Section 
2.6.7).  A significantly high absorbance reading (p<0.01) in the STRO-1 coated well 
indicated positive adsorbtion of the antibody to the plastic surface.  Once the successful 
immobilisation of STRO-1 antibody was confirmed (Figure 4.3), the panning procedure 
was undertaken with BSA as a negative control.  Each panning round was designated as 
‘R’ and five rounds were carried out altogether (R1 to R5).  Due to the increase in the 
number of washes at R2, the STRO-1 output phage titre declined.  A minor enrichment 
which was more significant from R4 to R5 (20 % increase, p<0.04) was observed.  The 
BSA control fluctuated from R1 to R4 but increased significantly (p<0.04) at R5, thus 
suggesting the enrichment observed in the STRO-1 phage output was non-specific.   
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Figure 4.3:  Detection of STRO-1 IgM bound to microtitre plate.  Overnight STRO-
1 IgM/TUJ1 IgG coated wells were incubated with goat anti-mouse IgM and detected 
with anti-goat HRP.  Colour development using ABTS substrate was read at an 
absorbance of 405 nm (Section 2.6.7).  Student’s t-test STRO-1 versus TUJ1, 
***p<0.01. 
 
 
 
 
 
 
Figure 4.4: Outcome of solid phase panning of Ph.D-12™ peptide library.  The 
Ph.D-12™ library was selected against wells coated with STRO-1 IgM or BSA 
(control) (Section 2.6.1).  Eluted phage was quantified in triplicate after each round of 
panning as pfu/mL (Section 2.6.4).   represents STRO-1 and  represents BSA 
control.  Student’s t-test R4 STRO-1 versus R5 STRO-1, **p<0.04. 
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4.3 Liquid phase panning 
Following the poor enrichment observed during solid phase panning (Figure 4.4), the 
liquid phase panning was attempted in the first instance with the Ph.D-12™ library, 
then with the Dean’s library.  Dean’s library is a multivalent library of 16-mer peptides, 
expressing the peptide sequences on the pVIII coat protein, compared to the pentavalent 
expression of the 12-mer peptides of Ph.D-12™ library which are confined to the pIII 
coat protein.  The liquid phase panning is more favourable to antibodies such as low 
affinity IgM as it provides the right physiological conditions promoting antibody 
binding.  It has been shown that the secondary structure of antibody molecules may be 
affected when adsorbed to plastic surfaces but by maintaining them in solution at the 
right pH, the 3D conformation is minimally affected and thus preserved (Brahms and 
Brahms, 1980).  Therefore, in order to allow the 3D structure of the IgM molecules to 
interact freely with the peptides, the liquid phase panning was implemented.  The 
rounds of panning were carried out on the Ph.D-12™ and the Dean’s libraries as 
described in section 2.6.2 using BSA as a control.  For each round, a phage titre of 
1.5x1011 pfu/mL was incubated with 10nM STRO-1 antibody, and the eluted phage was 
quantified by plaque assay (Section 2.6.4) and propagated (Section 2.6.3). 
 
 There was a weak enrichment of output phage in the liquid phase panning of the Ph.D-
12™ library.  The number of washes before elution was increased from 8 (R1) to 10 
(R2 to R5) explaining the decrease in the phage titre at R2.  The following round (R3) 
showed an increase in the STRO-1 eluate titre (p<0.05) whilst the BSA remained 
constant.  However, with the subsequent rounds, both the BSA control and the STRO-1 
titres coincided with a minimal increase from R3.  From R4 to R5, STRO-1 enrichment 
was weak (p<0.04) and concomitant with BSA control increase (Figure 4.5). 
 
 The Dean’s library was screened by the same liquid phase panning approach.  The 
output phage eluates of the BSA control and STRO-1 remained constant throughout the 
different rounds of panning indicating no enrichment of a specific peptide (Figure 4.6).  
The increase in the number of washes from R1 to the subsequent rounds decreased the 
overall output titres.  Although a slight increase in output titres from R2 to R5 was 
observed, it was not significant (p>0.5).   
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Figure 4.5: Outcome of liquid phase panning of Ph.D-12™ peptide library.  The 
Ph.D-12™ library was selected against STRO-1 IgM or BSA (control).  The 
phage/antibody complex was immuno-precipitated with protein A agarose beads coated 
with anti-mouse IgM and the bound phage eluted (Section 2.6.2).  The eluted phage was 
quantified in triplicate after each round of panning as pfu/mL (Section 2.6.4).   
represents STRO-1 and  represents BSA control.  Student’s t-test R4 STRO-1 versus 
R5 STRO-1, **p<0.04. 
 
 
Figure 4.6: Outcome of liquid phase panning of Dean’s peptide library.  The Dean’s 
library was selected against STRO-1 IgM or BSA (control).  The phage/antibody 
complex was immuno-precipitated with protein A agarose beads coated with anti-mouse 
IgM and the bound phage eluted (Section 2.6.2).  The eluted phage was quantified in 
triplicate after each round of panning as pfu/mL (Section 2.6.4).   represents STRO-1 
and  represents BSA control.   
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4.4 Plaque lifts 
Plaque lifts were carried out at the end of each panning experiment to confirm if the 
STRO-1 antibody had enriched phage with the target peptide.  The phage plaques were 
immobilised on nitrocellulose membrane and incubated with 1 µg/mL STRO-1 solution 
(Section 2.6.6).  Bound STRO-1 was then detected using DAB colour development 
assay by probing with polyclonal rabbit anti-mouse HRP conjugated secondary 
antibody (1:1000) (Section 2.6.5). When using the standard techniques of plaque lifts, 
no plaques could be detected indicating no enrichment in STRO-1 target peptide 
(example blot shown in Figure 4.7 A).  The level of detection of the HRP conjugated 
secondary antibody was examined by spotting the antibody at different dilutions on 
nitrocellulose membrane.  Peroxidase activity was then confirmed using DAB as a 
substrate for colour development.  The outcome of this control experiment showed that 
the HRP conjugated secondary antibody was efficient down to a 1:3000 dilution (very 
faint brown spot), beyond which no positive colour development was detectable (Figure 
4.7 B). 
     
 
 
Figure 4.7: Detection of STRO-1 binding on plaque lift.  (A) A specimen of negative 
plaque lift obtained after a panning round.  The plaques formed on agar plates were 
transferred to nitrocellulose membranes and incubated in 1 µg/mL STRO-1 solution and 
probed with polyclonal rabbit anti-mouse HRP.   Binding was detected using 2 mg/mL 
DAB substrate (Section 2.6.5). (B) Positive detection of polyclonal rabbit anti-mouse 
HRP spotted at different dilutions (Section 2.6.6).  The limit of detection of the HRP 
conjugate was 1:3000, beyond which no positive colour development was detectable 
(indicated by arrowheads).  
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4.5 Sensitivity of STRO-1 detection on nitrocellulose membrane 
In order to establish the concentration at which STRO-1 can be successfully detected 
when bound to a membrane, a dot blot using decreasing concentrations of the STRO-1 
antibody was carried out as described in section 2.6.6.  The detection level was 
compared to TUJ1, an antibody of IgG isotype.  Two blocking reagents, namely 1 % 
BSA and 1 % semi-skimmed milk, were also compared.  The intensity of the brown 
colour developed as a result of positive detection decreased with decreasing 
concentration of the antibodies.  STRO-1 IgM could not be detected at or below 10 
µg/mL while TUJ1 IgG could still be detected at 1 µg/mL. 
 
 
 
 
Figure 4.8:  Sensitivity of STRO-1 IgM detection compared to TUJ1 IgG detection 
on nitrocellulose membrane.  STRO-1 IgM and TUJ1 IgG were spotted at decreasing 
concentrations on nitrocellulose membrane and detected using anti-mouse HRP.  Two 
blocking reagents were applied; (A) 1 % semi-skimmed milk and (B) 1 % BSA.  DAB 
substrate was used as colour development and in both cases STRO-1 IgM could not be 
detected below 100 µg/mL concentration as indicated by arrowheads (Section 2.6.6). 
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4.6 BSA control enrichment during liquid phase panning 
The liquid phase panning was designed as a sandwich reaction between anti-mouse IgM 
coated protein A agarose beads and phage-STRO-1 complex (Figure 2.2).  The concept 
behind this technique was to combine the coated agarose beads with the phage-STRO-1 
complex, and allow the STRO-1 selected phage particles to pull down the target 
peptide.  Enrichment of the BSA controls during the liquid phase panning may have 
been due to the anti-mouse IgM immobilised on the agarose beads binding to random 
peptides expressed by the phage particles.  To investigate this possibility, plaque lifts at 
rounds 5 of the liquid phase panning of Ph.D-12™ and Dean’s library were incubated 
with goat anti-mouse IgM and detected with anti-goat HRP.  After colour development 
using DAB, the lifts displayed no positive signal (as shown in figure 4.7A) indicating 
that the BSA control enrichment observed was not due to the anti-mouse IgM enriching 
for its complementary peptide. 
 
 
4.7 Significance of live/dead screening of osteosarcoma cell lines with 
STRO-1 
 
Some markers, for instance CD133, have been shown to be expressed in cytoplasmic 
vacuoles inside the cells (Fonseca et al., 2008).  Therefore upon flow cytometry 
analysis, cells with compromised membranes are likely to take up the fluorescent 
labelled antibodies of the specified marker and show up as positively stained cells on 
the scatter plots.  Upon data analysis, since intracellular staining is not discriminated 
against surface staining, data interpretation may be misleading as false positives are 
included in the total cell subset identified as expressing the antigenic marker.  I have 
shown that the STRO-1 antigen is expressed intracellularly (illustrated in Figure 4.14) 
and thus to identify this rare cell population in osteosarcoma cell lines, it was important 
to distinguish intracellular staining from cell surface staining.  In an attempt to achieve 
this, a live/dead screening dye compatible with simultaneous RPE staining was 
employed.     
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Binding of STRO-1 antibody was detected with anti-mouse IgM RPE conjugated 
secondary antibody and the population was stained for live/dead discrimination by the 
APC-Cy7 compatible dye (Section 2.5.3).  The live/dead discrimination assay is based 
on the reaction of the fluorescent dye with cellular amines.  This dye is able to permeate 
cells with compromised membranes and react with the interior and cell surface amines 
to yield intense staining.  In contrast, live cells exhibit dim staining as the dye only 
reacts with surface amines.  The stained cells were analysed by flow cytometry and 
population counts were normalised to 1x104 cells for each sample.  Scatter plots were 
gated to distinguish between live and dead cells (representative scatter plot shown in 
Figure 4.9).  Upper quadrants R6 and R10 represent live STRO-1 positive cells while 
lower quadrants R8 and R12 represent STRO-1 negative live cells.  When stained with 
the RPE secondary only, the background staining observed in quadrant R6 (-Live/Dead 
panel) representing 1.1 % of the total population was also represented by quadrant R11 
(1.11 %) in the +Live/Dead panel.  Notably, when cells were stained for STRO-1 
without live/dead discrimination (R6 in –Live/Dead panel), the STRO-1 positive subset 
was represented by 6.01 % of the total population.  However, when cells were co-
stained with STRO-1 with dead cell exclusion dye, the STRO-1 positive subset was 
represented by only 3.68 % of the whole population (R10 in +Live/Dead panel).  This 
phenomenon was also observed for all the other markers used in this study (scatter plot 
data not shown).  These findings suggest that it is necessary to exclude dead cells in the 
analysis of cell surface marker expression and was therefore implemented in the marker 
profiling of the osteosarcoma cell lines.    
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Figure 4.9: Optimisation of STRO-1 screening using Live/Dead discrimination.  G-
292 cells were harvested and labelled as indicated; (UNST: unstained, RPE: anti-mouse 
IgM and STRO-1+RPE: STRO-1 IgM detected with anti-mouse IgM), with and without 
the Live/Dead discrimination stain (Sections 2.5.1 and 2.5.3).  The scatter profiles were 
gated to distinguish between STRO-1 positive live cells (R6&R10), STRO-1 positive 
dead cells (R7&R11), STRO-1 negative live cells (R8&R12) and STRO-1 negative 
dead cells (R9&R13).  RPE was detected on the PE Log scale and the dye for live/dead 
discrimination was detected on APC-Cy7 Log scale.  The analysis was normalised to 
1x104 cells for each sample. 
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4.8 Marker profile of osteosarcoma cell lines 
 
After optimisation of the live/dead discrimination, the seven osteosarcoma cell lines 
143B, CAL72, G-292, HOS, MG-63, Saos-2 and U-2-OS were screened for their 
expression of the stem cell markers STRO-1, CD271, CD133, CD13 and their HLA-
ABC expression.  The cells were harvested and incubated with their specific 
fluorescently labelled primary and secondary antibodies if required (Section 2.5.1) and 
then stained with the live/dead discriminatory dye (Section 2.5.4).  The cells were 
analysed by flow cytometer and the number of cells for each sample was normalised to 
2x104 cells.  Each labelled sample was compared to their respective control (either 
unstained or secondary only stained).  An overlay histogram plot was produced (Figure 
4.10) and the mean fluorescence between control and labelled cells was recorded (Table 
4.1).   
 
All of the cell lines were positive for STRO-1, although MG-63 had the highest STRO-
1 expression level (Table 4.1) displaying a heterogeneous population profile.  The 
STRO-1 profile of MG-63 was analogous to the profile observed for hMSCs, whereby 
three subsets of cells could be distinguished; STRO-1DULL, STRO-1INT and STRO-
1BRIGHT.  G-292 also appeared to have a side population of STRO-1BRIGHT cells thus 
giving a difference in mean fluorescence of 9.87.  The other cell lines exhibited a minor 
total population shift to the right hand side of the log scale indicating positive 
expression although approximately 8-10 fold lower than G292, with 143B having the 
smallest shift.   
 
All the cell lines were positive for CD271, although Saos-2 was the only population 
with an extended positive tail giving a mean fluorescence difference of 11.08.  HOS had 
the lowest level of CD271 expression with a difference in mean fluorescence of only 
0.25 while the other cell lines exhibited a difference in mean fluorescence ranging from 
0.82 to 3.45.  CD133 was heterogeneously expressed among the cell lines, with 143B, 
HOS and Saos-2 expressing it to the highest level while G-292 and MG-63 exhibiting a 
close to zero shift and CAL72 and U-2-OS not expressing it at all.  CD13 was also 
expressed in a heterogeneous fashion across the different cell lines, with some cell lines 
expressing it to a high level and others to a lower level.  G-292 and MG-63 exhibited a 
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total population shift to the right hand side of the log scale indicating high binding when 
stained with CD13, while 143B and HOS exhibited an overlapping shift with their 
respective controls.  CAL72 displayed a near zero population shift while Saos-2 and U-
2-OS were negative for CD13.  All the cell lines expressed varying levels of HLA-
ABC, with HOS being the highest and G-292 the lowest.  
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Figure 4.10: Continued overleaf. 
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Figure 4.10: Continued overleaf. 
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Figure 4.10:  Flow cytometry overlay analysis of maker profiles of seven 
osteosarcoma cell lines.  Cells were harvested and labelled with primary and secondary 
antibodies as appropriate (Section 2.5.1) and stained with live/dead discriminatory dye 
(Section 2.5.4).  The stained populations were gated to exclude dead cells and the 
analysis was normalised to 2x104 cells.  The unstained or secondary only control is 
represented by red lines and the marker-specific labelled cells are represented by the 
shaded histrograms (blue). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                               Chapter 4.  Results    
 142 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1: Marker expression profiles of seven osteosarcoma cell lines and hMSC 
(M24♂p4).  The values indicate the difference in mean fluorescence between control 
population (unstained or secondary only) and marker-specific labelled population after 
dead cell exclusion.  The degree of positivity of each cell surface marker is based on 
populations normalised to 2x104 cells.  The values indicated in red represent the cell 
line exhibiting markedly elevated expression of the corresponding marker. 
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4.9 Identification of candidate genes encoding STRO-1 antigen 
The flow cytometry profile obtained was compared to gene expression microarray 
profiles and a list of the top twenty candidate genes was selected (Appendix Table I) 
which were subsequently narrowed down to the known antigens which are expressed on 
the plasma membrane.  The gene expression microarray analysis was performed by 
Stephen Henderson (The Cancer Institute, University College London). 
 
Based on the correlation rankings obtained (Figure 4.11), the top twenty probesets were 
selected and a heatmap generated using gplots package (Figure 4.12).  The gene 
expression of the twenty candidate genes selected by the software closely matched the 
cellular expression obtained by flow cytometry analysis (Figure 4.13).  Using the Gene 
Ontology (GO) database, the sub-cellular locations of the candidate genes were 
extracted and eight potential candidate genes encoding STRO-1 were selected based on 
plasma membrane expression (Table 4.2).  Using the Uniprot database, information on 
function and size of the proteins were obtained and analysed.  
 
Of the eight potential candidate genes, ARHGEF4 (also known as Asef) bears sub-
cellular locations analogous to the expression pattern observed by the STRO-1 antigen 
when visualised by imunofluorescence staining (Section 4.91).  TNFSF11 (clustered as 
CD254) is an interesting candidate as it is involved in osteoclast differentiation (Lacey 
et al., 1998).  Another interesting candidate is P2RY6 which is a subtype of the family 
of purinoreceptors which has been shown to be expressed in bone tissues (Maier et al., 
1997). 
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Figure 4.11: Correlation curve to determine candidate genes for STRO-1 antigen.  
The flow cytometry expression of STRO-1 antigen was compared to gene expression 
microarray profiles.  Using Pearson’s R2 value, the top twenty probesets representing 
candidate genes for STRO-1 antigen were selected. 
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Figure 4.12: Heatmap of potential candidate genes encoding STRO-1 antigen.  The 
heatmap was generated by gene expression comparison of seven osteosarcoma cell lines 
and three MSC populations. 
 
 
 
Figure 4.13: Relative expression of STRO-1 antigen in seven osteosarcoma cell 
lines and one hMSC population.  Cells were cultured, harvested, labelled with STRO-
1 antibody and analysed by flow cytometry (Section 2.5).  The difference between the 
mean fluorescence units was calculated between the secondary only and STRO-1 
labelled populations to obtain the level of STRO-1 expression by each cell line. 
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HGNC 
Symbol 
 
Sub-cellular locations 
 
Biological function Size of protein (AA) 
 
DDX3Y 
 
-Nucleus 
-Cytoplasm 
-Plasma membrane 
 
ATP-dependent RNA 
helicase involved in 
spermatogenesis 
 
660 
OPRL1 -Plasma membrane 
 
G-coupled receptor  336 
P2RY6 -Plasma membrane  
(apical and basolateral) 
 
G-coupled receptor 
involved in calcium 
second messenger 
system 
 
328 
ARHGEF4 -Plasma membrane 
-Cell projection 
-Intracellular 
 (cytosol, cytoplasm) 
 
Cell migration and E-
cadherin mediated 
cell-cell adhesion 
690 
TNFSF11 -Plasma membrane 
-Cytoplasm 
-Extracellular space 
 
Activation of 
osteoclast 
differentiation and 
involved in immune 
response 
 
317 
LMF1 -Membrane 
-Endoplasmic reticulum  
 
Maturation and 
transport of active 
lipoprotein lipase 
(LPL) 
 
567 
CD14 -Plasma membrane 
(membrane raft, 
lipolysaccharide receptor 
complex) 
-Extracellular region 
 
Upregulates adhesion 
molecules and 
mediates immune 
response 
375 
CPD -Membrane fraction 
-Nucleus  
-Microsome (trans-Golgi 
network) 
Proteolysis 1380 
 
Table 4.2:  Details of potential candidate antigens representing STRO-1.  A 
summary of their sub-cellular locations and functions is also described.  In red is the 
most promising antigen whose sub-cellular location closely matches that observed for 
STRO-1.  
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4.9.1 Sub-cellular characterisation of STRO-1 
 
The sub-cellular localisation of STRO-1 on hMSCs was further characterised by 
immunofluorescence (Section 2.4).  Cells were labelled with STRO-1/FITC (green), 
nuclei and cytoskeleton were stained with DAPI (blue) and Phalloidin (Texas Red) 
respectively wherever required.  The mounted slides were visualised by fluorescence or 
confocoal microscopy. 
 
STRO-1 antigen is expressed by a minor subset of cells in hMSC adherent monolayers 
as illustrated in Chapter 3 (Figure 3.3).  To determine the pattern of surface expression 
of STRO-1 on hMSCs, stained cells were further analysed by confocal microscopy.  
This procedure revealed ‘islands’ of STRO-1 antigen over the cell surface, with stronger 
staining at the cell extremities (Figure 4.14 A).  Some cells were also permeabilised 
using Triton X-100 and stained for STRO-1/FITC to determine whether STRO-1 is 
expressed in the cytosol.  The slides were visualised by confocal microscopy and 
indicated positive intra-cellular staining of STRO-1 around the nucleus (Figure 4.14 B). 
 
 
 
 
 
Figure 4.14: Surface and intracellular localisation of STRO-1 antigen.  Cells grown 
on coverslips were stained with STRO-1/FITC as described in section 2.4 and visualised 
by confocal microscopy.  (A) STRO-1 antigen is present on the cell surface as ‘islands’ 
and spreads on the cell projections.  (B) STRO-1 antigen is expressed intra-cellularly 
around the nucleus and into the cell extremities.  Scale bar represents 100 µm. 
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Since STRO-1 appeared to be concentrated on the cell extremities, it was interesting to 
examine whether STRO-1 was co-expressed with the actin filaments of the 
cytoskeleton.  Therefore, the cytoskeleton was stained with Phalloidin (Texas Red), the 
cells location identified by nuclear staining (DAPI, blue) and STRO-1 labelled by FITC 
conjugated secondary antibody (green).  Interestingly, STRO-1 appeared to localise on 
one side of the cell as shown by the green staining on part of the cell which was 
completely stained red for cytoskeleton (Figure 4.15 C).  Comparatively to the 
Phalloidin staining alone (Figure 4.15 B), there was stronger expression of STRO-1 at 
the cell extremities (Figure 4.15 C, indicated by the white arrowhead).  Interestingly, the 
cell projections were directed towards a neighbouring cell.   
 
 
 
 
 
Figure 4.15: Localisation of STRO-1 on cell membrane projections.  Cells were 
cultured on slides and stained as described in section 2.4.  (A) Cell nucleus stained blue 
with DAPI and with STRO-1/FITC, (B) Cytoplasm staining by Phalloidin (Red) and (C) 
Merged staining showing brighter staining on cell extremities (indicated by white 
arrowhead).  Scale bars represent 200 µm. 
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Closer analysis of STRO-1 expression in relation to their neighbouring cells was 
analysed by higher magnification using fluorescence microscopy.  Interestingly the cells 
displayed higher STRO-1 expression on the ruffled part of the membrane (Figure 4.16 
A, indicated by white arrowhead).  Moreover, at the cell junctions (that is where two 
cells meet), STRO-1 expression was elevated (Figure 4.16 B, indicated by white 
arrowheads). 
 
 
 
 
 
 
Figure 4.16: Localisation of STRO-1 on ruffle membrane and cell junctions.  Cells 
were permeabilised and stained using DAPI (blue nucleus), Phalloidin (red cytoplasm) 
and STRO-1/FITC (green) (Section 2.4).  (A) STRO-1 antigen is strongly expressed on 
ruffle membrane as indicated by white arrowhead.  (B) STRO-1 localised at point of 
contact between two cells as indicated by white arrowheads.  Scale bars represent 50 
µm. 
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4.10 Discussion 
 
The primary aim of this part of the study was to identify the epitope that STRO-1 
antibody binds to, and secondly to identify the potential candidate genes encoding the 
antigen.  In chapter 3, the importance of STRO-1 as a differentiation marker in hMSCs 
was illustrated.  The modulation of STRO-1 expression during differentiation suggests 
that the protein antigen may be involved in the fate determination process of hMSCs. 
Moreover, establishing STRO-1 as the marker of multipotency by further defining its 
characteristics and functions may contribute towards a consensus protocol among 
researchers to adopt STRO-1 as a key marker in the isolation of hMSCs both in vivo and 
in vitro.  Given the low binding affinity nature of the current STRO-1 antibody, 
identification of the STRO-1 antigen will allow for higher affinity antibodies to be 
engineered. 
 
Among the myriad of techniques available for epitope mapping, phage display 
technology was chosen as it was a relatively rapid, convenient and proven method for 
affinity selection of peptides (Rodi and Makowski, 1999).  Peptide phage display is 
primarily employed as a method of raising antibodies against antigens and has recently 
been adopted to identify novel antibodies against rare cell populations, such as the 
generation of C15 antibody against MSCs (Letchford et al., 2006).  With the success of 
antibody generation, the display of peptide fragments of different lengths on the surface 
of the phage particle was improved and the technology has been adapted for epitope 
mapping against immobilised antibodies, whole cells and even in vivo screening 
(McGuire et al., 2009).  The choice of library for epitope mapping depends on many 
factors and in the absence of structural information regarding STRO-1 to target 
interaction, it is not possible to predict which specific library will yield the most 
productive results.   
 
In this study, given that STRO-1 is an IgM with a low binding affinity, two formats of 
multivalent display were chosen over monovalent displays.  Monovalent displays imply 
the expression of peptides fused to only one copy of the phage coat protein, most 
commonly pIII, and this format is best suited for high affinity binders (Mullaney and 
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Pallavicini, 2001).  For the IgM STRO-1, the pentavalent pIII fused 12-mer peptide 
Ph.D-12™ and the multivalent pVIII fused 16-mer peptide libraries were screened.  In 
the first instance, Ph.D-12™ library was screened by solid-phase panning.  The direct 
adsorption of STRO-1 IgM to a plastic surface is mediated by electrostatic and Van-der-
Waals interactions.  In some cases, where the molecule to be immobilised is very small, 
conjugation to a carrier protein is recommended.  This was not necessary for STRO-1 
IgM as being a large pentameric molecule (30 nm in diameter) (Svehag et al., 1967), it 
could easily expose its epitope binding regions for easy accessibility by the peptide 
phage particles.  Successful binding of STRO-1 to the solid surface was confirmed by 
ELISA.  The level of detection obtained was not as high as what would be expected for 
an antibody of a different isotype detected with the appropriate secondary.  The critical 
step in this panning procedure was the first round as it had to ensure that all potentially 
complementary peptides were selected for subsequent amplification and screening.  
Therefore a low stringency was implemented at the first panning rounds by having a 
reduced number of washing steps to exclude unbound phage particles. 
 
Although a promising enrichment was observed at round 5 of the panning procedure, 
the concomitant increase in the BSA control indicated that the enrichment was not 
specific to STRO-1 antibody.  The lack of enrichment of specific peptides could be due 
to a possible denaturation of the antibody caused by the process of passive adsorption 
(Brahms and Brahms, 1980).  The change in conformation of the STRO-1 IgM might 
have resulted in non-specific binding of phage particles since the denatured form is 
bound to expose hydrophobic residues presenting a ‘sticky’ surface to phage particles 
(Friguet et al., 1984).  Furthermore, plaque lifts taken at rounds 4 and 5 yielded no 
positive binding suggesting that the solid-phase panning procedure was not successful.   
 
Given the low affinity of STRO-1 IgM and its weak adsorption and possible 
denaturation upon attachment to the plastic surface, the liquid-phase panning was 
implemented.  This alternative approach presented an antibody-target binding within the 
normal physiological condition, which is favoured by the freely available epitope 
binding sites of the IgM to the target peptides in a 3D interactive format.  By selecting 
for positive peptide phage particles to STRO-1 IgM in solution, the possible drawbacks 
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posed by solid-phase panning were limited.  Both the 12-mer Ph.D-12™ and 16-mer 
Dean’s libraries were screened by the liquid phase panning.  Despite using a solution 
system to promote peptide-antibody interaction, the resulting peptide phage enrichment 
observed in both selections was not significant.  In fact, this system involved the 
capturing of the phage-antibody complex by protein A agarose beads coated with anti-
mouse IgM.  Therefore, the number of high molecular weight components involved in 
the design of this reaction may have reduced its efficiency by increasing the probability 
of dissociation during the pull-down procedure.  The dissociation of the components 
may have been exacerbated by the low affinity of the STRO-1 IgM, thus resulting in the 
same level of eluate titre as in the BSA controls, with no positive enrichment specific to 
STRO-1 as shown by the plaque lifts.   
 
In relation to the BSA control, there was a possibility that the anti-IgM captured on the 
agarose beads were pulling down their own complementary peptide from the library of 
unbound phage instead of selecting for STRO-1-phage complexes.  In other words, the 
anti-IgM was enriching for phage particles binding to itself.  To explore this probable 
phenomenon, plaque lifts at the end of each liquid panning experiment was incubated 
with anti-IgM to detect any positive binding.  While it was possible to detect positive 
anti-IgM binding on nitrocellulose membrane down to a concentration of 1 µg/mL, no 
plaques were detected on the plaque lifts.  This led to the conclusion that anti-IgM was 
not selecting for its complementary peptide from the phage libraries.  The negative 
plaque lifts for putative STRO-1 epitopes further suggested that either the epitope was 
not present within the randomly generated libraries or it was simply not possible to 
detect STRO-1 IgM when it was bound to nitrocellulose membrane.  Overall, the level 
of detection of STRO-1 IgM as compared to a different isotype such as TUJ1 IgG, was 
very low on nitrocellulose membrane, further emphasising the difficulty of working 
with an antibody of the IgM isotype.  In this case, although the corresponding epitope to 
STRO-1 antibody might have been present in the phage libraries, the low level of 
detection on nitrocellulose membranes would have hindered its positive identification. 
 
Optimising the screening strategies (such as method of panning, blocking reagents used 
and sensitivity of antibody detection) was of utmost importance in this part of the study.  
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Nevertheless, the main obstacle remains the nature of the STRO-1 IgM antibody.  Early 
studies have revealed the pentameric structure of IgM with a molecular weight of 900 
KDa (Svehag et al., 1967).  Although the IgM molecule has 10 possible antigen binding 
sites, the affinity for the antigen is very low and therefore dissociation of the antigen-
antibody complex is unavoidable.  The interaction between antigen and antibody is 
either ionic, Van-der-Waals or hydrophobic and these forces help to maintain stability 
of the antigen-antibody complex.  In the case of STRO-1 IgM interaction with its 
antigen, these forces appear to be overcome by the high molecular weight of the IgM 
causing the complex to be readily dissociated.  Moreover, the probable linear or folded 
characteristic of the STRO-1 peptide may be limiting the binding affinity of the 
antibody.  Elucidating the nature of the antigen may help to generate antibodies of a 
different isotype, therefore promoting the use of STRO-1 in hMSC isolation. 
 
Despite the fact the STRO-1 antigen is still unknown, the STRO-1 antibody has been 
used by many researchers in an attempt to isolate homogeneous populations of hMSCs 
(Table 1) and also to identify putative cancer stem cells of mesenchymal origin in 
osteosarcoma (Gibbs et al., 2005).  However, from the time that the antibody was 
discovered in hybridoma supernatant (Simmons and Torok-Storb, 1991) to the 
commercialisation in its lyophilised form (R&D system), numerous laboratories have 
employed differently sourced STRO-1 and therefore reported conflicting results, such as 
enhanced tri-lineage differentiation potential of bone-marrow derived hMSCs in cells 
lacking STRO-1 expression (Colter et al., 2001).  Having established the most reliable 
source of STRO-1 antibody (Section 3.3), it was important to distinguish between 
surface expression and intracellular expression of the antigen on osteosarcoma cell lines 
in order to accurately ascribe an immuno-phenotypic profile to each cell population for 
subsequent comparison of gene expression microarray data.  To date, the use of STRO-
1 for the screening of osteosarcoma cell lines has not been optimised and in order to 
undertake a full comparison of surface expression of markers on these cells, a method to 
distinguish between live and dead cells was optimised.  Many markers, for instance 
CD133, have been shown to be expressed intracellularly at high levels (Fonseca et al., 
2008), and therefore a compromised membrane exhibited by dead cells may lead to 
false positives in the analysis, especially when attempting to identify rare cell 
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populations and low expressive cells.  Of particular interest in this investigation, 
approximately half of the cell population which might have been considered as STRO-1 
positive were actually a result of intracellular staining.  Therefore, the marker 
expression observed in this study may not be directly comparable to the expression 
reported by others.  For instance, Tirino and colleagues (Tirino et al., 2008) reported a 
CD133 positive sub-population in three osteosarcoma cell lines, namely MG-63, Saos-2 
and U-2-OS.  While my study shows CD133 expression in Saos-2 and not in MG-63 
and U-2-OS, it is to be noted that the stringency of analysis employed for both studies 
are dissimilar.  Without the live/dead discrimination factor in my study, all the three cell 
lines were positive for CD133 (data not shown).  However, surface expression of 
CD133 was exhibited by Saos-2 only and not by MG-63 and U-2-OS as reported by 
Tirino and co-workers (2008).  Similarly, the level of STRO-1 expression in MG-63 
reported by others (Pautke et al., 2004, Gibbs et al., 2005, Tare et al., 2009) do not 
necessarily represent surface expression but may also includes intra-cellular staining.  
This study presents the first report of the characterisation of osteosarcoma cell lines 
exclusively based on the surface expression of stem cell markers (STRO-1, CD271, 
CD133), mesenchymal marker (CD13) and marker of nucleated cells (HLA-ABC). 
 
In order to identify the gene encoding STRO-1 antigen, a comparative gene expression 
microarray analysis was undertaken.  This resulted in a list of top twenty matched 
expression profiles, out of which eight are expressed on the plasma membrane.  The 
sub-cellular localisation of STRO-1 closely matched the reported localisation of 
ARHGEF4 (Rho guanine nucleotide exchange factor 4 or also referred to as APC-
stimulated guanine nucleotide exchange factor, Asef).  ARHGEF4 exists as three 
isoforms and is expressed at low levels in the brain, kidney, lung and muscle (Thiesen et 
al., 2000).  It is involved in colorectal tumour cell migration and mediates cell-to 
adhesion (Kawasaki et al., 2000, Kawasaki et al., 2003).  Apart from the sub-cellular 
localisation of this protein which resembles that observed for the STRO-1 antigen, the 
functions described in the literature does not directly relate to the hypothesised function 
of STRO-1 antigen as being a transmembrane protein involved in differentiation.  
However, although this protein may not be the STRO-1 antigen, it is plausible to 
suggest that STRO-1 may be co-expressed with ARHGEF4 as the phenotypic data 
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observed from the immunofluorescence staining of STRO-1 closely matches the sub-
cellular location of ARHGEF4.  On the other hand, TNFSF11 (Tumour necrosis ligand 
of superfamily member 11, clustered as CD254), which is also known as the 
osteoprotegerin ligand, is a cytokine that binds to RANK (Receptor activator of nuclear 
factor kappa-B) to activate and induce osteoclast differentiation (Lacey et al., 1998).  
The expression of an osteoclast activator on hMSCs is an intriguing observation as 
osteoclasts and osteoblasts follow distinctly different lineages.   P2-Purinoreceptors 
have been shown to be expressed on osteoblast and the Saos-2 cell line (Schofl et al., 
1992).  They are present as different subtypes and are involved in calcium ion influx 
when bound to extracellular ATP (Maier et al., 1997).  It has been proposed that ATP 
released by neighbouring damaged cells in vivo or by controlled secretion may mediate 
bone remodelling by acting via the calcium signalling pathway (Schofl et al., 1992).    
Therefore P2RY6 (purinoreceptor of subtype 6) may be structurally related to the 
STRO-1 antigen.  Interestingly, in chapter 3 (Section 3.7) the level of STRO-1 
expression was shown to be elevated two-days after osteogenic induction, a mechanism 
which may be indirectly related to the expression of the P2RY6 receptor on hMSCs.  
Overall, the three most likely potential candidate genes of STRO-1 antigen (ARHGEF4, 
TNFSS11 and P2RY6) may not represent the identity of the antigen itself as this 
remains to be confirmed by further co-localisation and expression studies, but may 
represent components of the signalling cascade of hMSC fate determination. 
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5.1 Introduction 
 
Osteosarcoma is the most common bone sarcoma in children and adolescents and can be 
broadly categorised as central or surface,  as approved by the World Health 
Organisation (Schajowicz et al., 1995) (Section 1.5).  In the report of Klein and Siegal 
(2006) which sub-classified the different types of osteosarcoma based on anatomic and 
histologic variations, the two most common forms of the disease are central 
conventional osteosarcoma and surface parosteal osteosarcoma.  Conventional 
osteosarcoma occurs as an intraosseous tumour growth involving the marrow cavity 
while surface parosteal osteosarcoma appears as a lesion on the surface of the bone.  
Both types occur as low-grade and high-grade tumours, although central conventional 
osteosarcoma appears to be more aggressive (Unni, 1998, Klein and Siegal, 2006).  The 
last twenty-five years have witnessed remarkable progress in the management of 
osteosarcoma.  Despite its detrimental side effects, chemotherapy is still the front line 
treatment and involves the use of immune suppressants including methotrexate and 
DNA intercalating agents which restrict cell division, such as cisplatin and doxorubicin 
(Ferrari et al., 2003).  In localised disease, a combination of chemotherapy and limb-
sparing surgery resulted in an average of five year survival rate in approximately 70 % 
of patients and more than 90 % of cases of limb preservation (Ferrari et al., 2005).  
However, despite this improvement in survival rate around 50 % of patients with 
initially localised disease subsequently develop recurrence.  Of newly diagnosed cases, 
20 to 30 % present with metastatic disease where neither chemotherapy nor surgical 
intervention is successful (Ferrari et al., 2003).  This data undeniably urges for new 
therapies to be developed but above all, there is an urgent need for the identification of 
prognostic factors in osteosarcoma patients in order to predict the outcome of therapy, 
relapse and survival.   
 
Progress in the understanding of malignant cancers has led to the growing belief that 
CSCs are implicated in the disease and that this rare cell subset is the cause of 
recurrence (Section  1.5.2).  While current treatments involve tumour shrinkage, there is 
emerging evidence suggesting that the CSCs remain unaffected by chemotherapy and 
are responsible for disease relapse (McDonald et al., 2009). The CSC population is now 
                                                                                                               Chapter 5.  Results    
 158 
the prime target of therapy as these cells have been shown to have developed a drug 
efflux mechanism which renders them resistant to chemotherapy.  The CSCs have been 
identified within distinct SPs by flow cytometry in a number of cancers, a profile 
indicating their enhanced ability to expel cytotoxic agents such as mitoxantrone, thus 
conferring cell survival (Hirschmann-Jax et al., 2004).  A SP showing drug-resistance 
features and with cancer-initiating ability in vitro and in vivo has also been 
demonstrated in a panel of osteosarcoma cell lines (Murase et al., 2009).  The ability of 
the CSCs to suppress immune response in order to survive has also been proposed but 
research in this area is still at the early stages (Baguley, 2010).  All cancer therapies so 
far have been based on the classical and now challenged view that tumour cells have 
equal proliferative potential (Sarraf, 2005).  However, with emerging evidence of the 
existence of CSCs, it has become clear that not all tumour cells divide at the same rate 
and if the CSCs were to follow the hierarchical patterns of stem cell division (Figure 
1.6), then asymmetric cell division may be a model which explains the maintenance of 
the CSC sub-population within the tumour and recurrence of the tumour after drug-
induced atrophy.  The presence of CSCs replenishing the tumour mass is analogous to 
the homeostatic mechanism in normal adult tissues which contain a small sub-
population of cells that have the ability to self-renew and give rise to differentiated 
progeny (Reya et al., 2001).  The anomaly resides in the aberrant self-renewal and 
poorly regulated differentiation of the cells which leads to tumour formation.  Based on 
these characteristics, the cells responsible for this phenomenon, apart from being 
commonly referred to as CSCs, have also been termed tumour-initiating cells and 
tumorigenic cells (Clarke et al., 2006).  CSCs have been identified in numerous solid 
tumours based on phenotype by morphological and marker characterisations and the 
ability of these cells to initiate tumours in vitro and in serial transplantation studies 
(McDonald et al., 2009).   
 
The prime focus of CSC identification has been largely focused on solid tumours of 
epithelial origin, for instance in breast, colon and prostate (Al-Hajj and Clarke, 2004).  
In an attempt to identify the CSCs subset in human osteosarcomas, Tirino and co-
workers (2008) employed CD133 as a positive marker.  By FACS separation, CD133 
positive populations of three osteosarcoma cell lines (MG-63, Saos-2, U-2-OS) were 
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highly proliferative, included in the SP cell subset and able to form sarcospheres in 
semi-solid serum-free medium, a widely used and accepted in vitro tumourigenic assay.  
Interestingly, the sub-population of cells which did not express CD133 on the cell 
surface produced detectable amounts of CD133 mRNA transcripts and indeed expressed 
the CD133 antigen in cytoplasmic vesicles (Tirino et al., 2008).  In a canine 
osteosarcoma model, CSCs were identified by the expression of embryonic stem cell 
markers (Nanog and Oct4) in sarcospheres.  Interestingly, this study also showed that 
STRO-1 expression was restricted to sarcospheres and the monolayer cultures of the 
same cell lines lacked STRO-1 expression (Wilson et al., 2008).  Many other antigenic 
markers (including the CD44high/CD24low profile) have been used to identify CSCs in 
solid tumours, more so in carcinomas, but to date, the presence of CSCs in 
osteosarcoma are still elusive and require further characterisation.  
 
Following the classic multi-step model of carcinogenesis, there is mounting evidence to 
suggest that CSCs originate from adult stem cells which are long-lived highly 
proliferative cells and therefore are potential targets in which multiple genetic hits can 
occur.  It has also been proposed that the multiple genetic hits may occur in the stem 
cell niche where stem cells have unlimited self-renewal ability, in a progenitor or a 
differentiated cell with limited or no proliferative potential, thereby acquiring an 
aberrant ability to extensively undergo cell division (Figure 5.1) (Huntly and Gilliland 
2005).  Irrespective of the cell of origin, normal adult stem cell or progenitor cell, the 
CSC is defined by its stem cell-like properties.  
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Figure 5.1:  Multiple possibilities for the generation of cancer stem cells.  Mutations 
can occur at any stage of the cell lineage which gives rise to causing the cell to acquire 
self-renewal capacity and become a cancer stem cell.  These genetic transformations 
cause imbalance in the normal regulatory mechanisms of the cell leading to tumour 
progression (Adapted from (Huntly and Gilliland, 2005). 
 
MSCs, by definition, are able to give rise to mesenchymal tissues and based on the 
multi-step model of carcinogenesis, it can be hypothesised that mutated MSCs are the 
origin of sarcomas.  As such, Ewing’s sarcoma has recently been shown to be a stem 
cell tumour (Meltzer, 2007).  Ewing’s sarcoma, a tumour of undefined origin, is 
characterised by a specific (11:22)(q22:q12) translocation which results in the 
expression of a chimeric oncoprotein, EWS-FLI1 (Delattre et al., 1992).  Mutated 
MSCs have been implicated as the cell of origin and the work of Torchia and co-
workers provided the initial evidence for this.  Ectopic expression of EWS-FLI1 in 
MSCs caused dramatic changes in their cellular morphology and impaired their 
differentiation potential (Torchia et al., 2003).  The involvement of MSC was further 
supported via silencing studies by Tirode and colleagues (2007).  Following long-tem 
inhibition of the oncoprotein EWS-FLI1 in Ewing’s cells, they were successful in 
showing that the cells acquired an MSC phenotype whereby when induced to the 
adipogenic and osteogenic lineages, the cells successfully differentiated (Tirode et al., 
2007).  These studies provide compelling evidence of the involvement of MSC as the 
precursor cells in Ewing’s tumours.  However, unlike Ewing’s sarcoma, there is no 
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single mutation characterising osteosarcoma, thus hindering investigations of possible 
MSC involvement as the precursor cell in osteosarcoma.  
 
Osteosarcoma has a poor prognosis, especially due to the chemoresistant nature of the 
secondary tumours (Yen, 2009).  The lung is the primary site of metastasis and a recent 
study of ninety-one osteosarcoma patients showed that the rate of metastasis is 
increased by large tumour volume and elevated levels of serum lactodehydrogenase 
(Wu et al., 2009).  The ability of the cells to form secondary tumours relies on their 
self-renewal ability in an adaptable environment.  Biopsies of secondary pulmonary 
tumours have revealed differentiated cells within the tumour mass (Halldorsson et al., 
2009).  In order for the cells to successfully engraft in a distant site and form secondary 
tumours, they have to be able to break down cell-cell and cell-extracellular matrix 
connections, enter and survive in the circulation (Kondo et al., 2003).  This 
phenomenon is brought about by a physiological phenotypic shift known as epithelial-
mesenchymal transition (EMT) and has been studied in a number of carcinomas (Mani 
et al., 2008).  By adopting the mesenchymal phenotype, the cells are able to migrate 
away from the primary tumour and invade distant tissues where they undergo 
mesenchymal-epithelial transition (MET) (Figure 1.4).  Studies in breast cancer lines 
have shown that induction of stem-cell like properties is possible by ectopic expression 
of Snail and Twist resulting in EMT (Mani et al., 2008). The majority of cells 
undergoing EMT are derived from progenitors with limited self-renewal capacity 
making up the tumour bulk.  Upon EMT, the epithelial cells gain the stem cell antigenic 
profile and unlimited self-renewal capacity and are therefore able to colonise a distant 
site (Radisky and LaBarge, 2008, Hollier et al., 2009).   
 
EMT is a stepwise process whereby studies in carcinoma cell lines revealed three clonal 
morphologies (holoclones, meroclones and paraclones) that can be adopted by the cell 
population in vitro (Locke et al., 2005).  Mackenzie’s group established a cellular 
hierarchy, whereby cells of epithelial morphology forming tightly compacted colonies 
are termed holoclones and are believed to harbour cells with stem cell characteristics by 
virtue of their extensive proliferative potential and ability to give rise to differentiating 
progenitors.  Cells exiting the holoclonal stage become flattened and less-compacted 
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and lose their proliferative potential forming meroclones and ultimately become 
migratory paraclones (Locke et al., 2005, Harper et al., 2007).  While a cellular 
hierarchy has been established based on phenotype, the functional role of each cell type 
in the tumour remains to be clarified.  
 
Data accumulated from the studies of solid epithelial tumours and sarcomas strongly 
implicate CSCs in carcinogenesis.  CSCs are nowadays the main target for cancer 
therapy as there is mounting evidence to suggest that these rare cells are the cause of 
disease recurrence and relapse (Baguley, 2010).  CSCs have been proposed to originate 
from mutated stem, progenitor or differentiated cells which render them highly 
proliferative (Figure 5.1).  Evidence from Ewing’s sarcoma studies show that mutated 
MSCs are the cause of the tumour (Meltzer, 2007).  Therefore, it is of value to identify 
the CSC population in osteosarcoma and present them as potential targets for therapy.  
In order to achieve this, the biology of osteosarcoma has to be characterised and its 
cellular hierarchy established, so that the right cell population can be exploited for 
successful therapy development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                               Chapter 5.  Results    
 163 
Aims 
As illustrated in Chapter 4, STRO-1 is expressed heterogeneously across the seven 
osteosarcoma cell lines therefore suggesting that cells may retain MSC-like properties.  
Having established STRO-1 as a marker of multipotency (Chapter 3), the ability of the 
seven osteosarcoma cell lines to differentiate to the adipogenic and osteogenic lineages 
was investigated.  Furthermore, due to the limited evidence of CSCs in osteosarcoma, 
this study investigated the cellular heterogeneity in osteosarcoma cell lines with a view 
to establishing the identity of the CSC population.  The specific objectives of the study 
are as follows: 
 
• Comparison of the proliferation profiles of osteosarcoma cell lines to determine 
if this varies between different cell lines 
• Investigation of MSC-like characteristics of osteosarcoma cell lines by 
differentiation to the adipogenic and osteogenic lineages, further illustrating 
heterogeneity between the different cell lines 
• Establishment of cellular heterogeneity within osteosarcoma cell lines when 
grown in monolayer culture and colony formation in soft agar 
• Identification of putative CSCs by anchorage-independent growth potential of 
different osteosarcoma cell lines 
• Isolation of pure holoclones and paraclones from osteosarcoma cell lines 
pointing towards the persistence of a cellular hierarchy in vitro 
• Characterisation of the relationship between cells of holoclonal and paraclonal 
morphologies with identification of an EMT-like process 
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5.2 Osteosarcoma proliferation and differentiation 
 
Osteosarcomas are tumours made up of a heterogeneous group of cells and the disease 
outcome varies from patient to patient.  By using cell lines in this study, it was 
interesting to investigate from the onset whether the different osteosarcoma cell lines 
showed similar proliferative potential in vitro.  Furthermore, since STRO-1 was 
expressed heterogeneously among the different cell lines (Chapter 3), their MSC-like 
differentiation potential was also investigated by induction to the adipogenic and 
osteogenic lineages.  The differentiation potential of the cell lines was assayed both 
qualitatively and quantitatively.  The molecular expression of some key osteogenic 
markers was also investigated in an attempt to establish a gene expression profile for 
osteo-inducible cell lines.   
 
5.2.1 Proliferative potential of osteosarcoma cell lines 
 
Seven osteosarcoma cell lines (143B, CAL72, G-292, HOS, MG-63, Saos-2 and U-2-
OS) were pulse labelled with green CFSE dye and cultured at 1080 cells/cm2 density in 
triplicates in a 6-well plate (Section 2.5.4).    At day 1, 2 and 3 post-seeding, the cells 
were harvested and analysed by flow cytometry.  The last harvest was at day 3 as 
beyond that time point, some cell lines, namely 143B, became confluent and the cells’ 
growth would have been contact inhibited.  This procedure was repeated two more 
times and a representative profile is shown in figure 5.2.   
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CFSE dye permeates the cells and is cleaved by intracellular esterases to yield a 
fluorescent compound that is retained by the cell.  At each cell division, the dye is 
diluted and loses fluorescence intensity.  The amount of fluorescence loss over a period 
of time indicates the proliferation rate of the cells.  The difference in mean fluorescence 
intensity between day 1 and day 3 for three independent experiments were recorded and 
analysed (Figure 5.3).  The mean fluorescence intensity decreased steadily over every 
24 h period for each of the cell line as shown in figure 5.2.  However, day 3 of CAL72 
and Saos-2 gave a wide profile spread indicating that the rate at which the dye was lost 
was not constant among all the cells in the population.  Among the seven cell lines, 
CAL72 and Saos-2 lost the least fluorescence (decrease of approximately 30 % less) 
indicating their low proliferation rate.  Cell lines G-292, MG-63, HOS and U-2-OS 
divided at similar rates while 143B was the fastest growing cell line in the group (Figure 
5.3). 
 
    
Figure 5.2: Proliferation profile of seven osteosarcoma cell lines analysed by flow 
cytometry overlay of CFSE stained cells over a period of 3 days.  CFSE stained cells 
were seeded at a density of 105 in 6-well plates and harvested at day 1, 2 and 3.  Each 
harvest was analysed on the FITC channel.  Red line indicates day 1, green line 
indicates day 2 and blue line indicates day 3 of the harvest. 
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Figure 5.3: Proliferation rate of osteosarcoma cell lines.  The chart represents 
percentage decrease in CFSE fluorescence in seven osteosarcoma cell lines over 48 
hours.  The difference in mean fluorescence intensity between day 1 and day 3 harvests 
of three independent experiments were analysed.  Student’s t-test of 143B versus 
CAL72 and Saos-2 versus U-2-OS, ***p<0.01. 
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5.2.2 Adipogenic differentiation 
 
The seven osteosarcoma cell lines were grown to confluency (Section 2.2) and induced 
to the adipogenic lineage at one day post-confluency via the addition of specific 
induction cocktail (Section 2.3.1.1).  The cells were induced for eight days and fourteen 
days after which they were fixed and stained with ORO dye (Section 2.3.2.1).  None of 
the cell lines showed evidence of lipid accumulation characteristic of adipocyte 
formation even after extended induction period (14 days).  Over-growth of the cells 
resulted in a high number of apoptotic cells (Figure 5.4) which in turn gave a high ORO 
background staining (observed as red patches without peri-nuclear lipid vacuoles in 
Figure 5.5 A and B).  The experiment was carried out in triplicate and a representative 
picture of day 8 analysis is shown (Figure 5.5).   
 
 
 
 
 
 
 
Figure 5.4: Cell death in over-confluent HOS cell line.  Non- adherent floating dead 
cells have a characteristic phase bright appearance, indicated by arrowheads.  Scale bar 
represents 150 µm.   
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Figure 5.5: Adipogenic potential of osteosarcoma cell lines.  Seven osteosarcoma cell 
lines and hMSC M24♂p5 (positive control) were grown to confluency and induced to 
the adipogenic lineage at one day post-confluency (Section 2.3.1.1).  After 8 days, the 
cells were stained with Oil Red O (Section 2.3.2.1) and visualised under x10 
magnification.  (A) represents enlarged section of 143B control and (B) represents 
enlarged section of 143B induced.  Scale bars represent 125 µm. 
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5.2.3 Osteogenic differentiation 
 
The seven osteosarcoma cell lines were grown to confluency and induced to the 
osteogenic lineage at one day post-confluency (Day 0 of induction) via the addition of 
specific induction cocktail (Section 2.3.1.2).  The basal level of ALP activity and 
mineralisation was determined at day 0 before induction and the cells induced for seven 
and fourteen days.  The extent of differentiation was visualised by histochemical 
staining (Figure 5.6) and also quantified.  The inducibility of the cells to the osteogenic 
fate was determined as the difference in the mean level of ALP concentration or AR dye 
recovered between the control population and the induced population at days 7 and 14 
(ALP: Figure 5.7; AR: Figure 5.8).  The assay could not be extended beyond fourteen 
days as a high number of dead cells were observed in the non-induced population whilst 
the induced cells became loosely attached and were lost during media changes.  The 
expression of some key osteogenic markers was also investigated by RT-PCR (Section 
2.7).   
 
 
143B 
The basal level of ALP activity in 143B was minimal, with only a few specs of blue 
stained cells (Day 0 control) (Figure 5.6 A).  More cells became faintly ALP positive at 
day 14 both in the control and induced populations indicating a low level of ALP 
activity in some cells.  There was no evidence of mineralisation by day 14 as shown by 
AR staining. 
 
CAL72 
CAL72 showed no ALP activity before induction (Day 0 control) (Figure 5.6 B).  At 
day 7 of induction, a few blue stained cells were observed but at day 14, the few blue 
stained cells were apparent in both the control and induced population.  Both control 
and induced population had an elevated level of cell death at day 14.  The cells retained 
some AR dye at day 14 of differentiation, but this appeared to be due to the high level 
of cell death rather than mineralisation. 
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G-292 
The G-292 population showed a few scattered bright blue cells before induction (Day 0 
control), indicative of ALP activity (Figure 5.6 C).  The number of bright blue cells 
increased from day 7 to day 14 in the control population, but remained as scattered 
spots.  However, from day 7 of induction, clear patches of blue stained cells were 
observed and these patches were enlarged at day 14.  G-292 was able to mineralise by 
day 14, appearing only as sparse emerging nodules.  However, the non-induced 
population retained some AR dye at the edge of the monolayer. 
  
HOS 
Before induction, the HOS cell line showed clear patches of cells differentially 
expressing ALP positive cells (Day 0 control) (Figure 5.6 D).  With time, both the 
control and induced population had clear ALP positive patches which grew larger by 
day 14.  Not all the cells in the population were ALP positive, and the degree of 
positivity in those cells that stained blue was highly variable.  The HOS cell line could 
not be induced to mineralise as shown by AR staining. 
 
MG-63 
MG-63 was not able to differentiate although there was some background staining of 
ALP activity and AR dye accumulation (Figure 5.6 E).  The cells were highly 
proliferative and underwent cell death with time.  Cell death was apparent as early as 
day 7 into induction and loosely attached cells were lost at subsequent feeding rounds. 
 
Saos-2 
Saos-2 was the only cell line with a high level of ALP activity before induction (Day 0 
control) (Figure 5.6 F).  Both the control and the induced population increased their 
ALP activity with time.  It was also the only cell line able to mineralise extensively by 
day 14.  Clear brightly stained nodules were visible by day 7 and by day 14 when 
staining with AR, with some nodules appearing darker and more concentrated in areas. 
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U-2-OS 
U-2-OS behaved in a similar way to the HOS cell lines (Figure 5.6 G).  Before 
induction, only a few cells stained blue and by days 7 and 14, the ALP positive areas 
became larger and darker in the induced population.  The cells could not be induced to 
mineralise although some background AR staining was observed. 
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Figure 5.6: Continued overleaf.  Osteogenic potential of osteosarcoma cell lines.  
Seven osteosarcoma cell lines (A. 143B, B. CAL 72, C. G-292, D. HOS, E. MG-63, F. 
Saos-2 and G. U-2-OS) were gown to confluency and induced to the osteogenic lineage 
at one-day post confluency via the addition of specific induction cocktail.  The 
populations were assayed for alkaline phosphatase activity (AR, blue staining) and 
mineralisation was detected by Alizarin Red dye staining (AR, brown-red).  Day 0 
indicates the population before induction, and day 7 and day 14 indicate 7 and 14 days 
after induction respectively (Section 2.3).  CNT indicates non-induced population and 
OST indicates osteogenic induced population.  Scale bars represent 200 µm.   
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Figure 5.6: Osteogenic potential of osteosarcoma cell lines.  Seven osteosarcoma cell 
lines (A. 143B, B. CAL 72, C. G-292, D. HOS, E. MG-63, F. Saos-2 and G. U-2-OS) 
were gown to confluency and induced to the osteogenic lineage at one-day post 
confluency via the addition of specific induction cocktail.  The populations were 
assayed for alkaline phosphatase activity (AR, blue staining) and mineralisation was 
detected by Alizarin Red dye staining (AR, brown-red).  Day 0 indicates the population 
before induction, and day 7 and day 14 indicate 7 and 14 days after induction 
respectively (Section 2.3).  CNT indicates non-induced population and OST indicates 
osteogenic induced population.  Scale bars represent 200 µm.   
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Quantification of ALP activity between cell lines 
 
A quantitative assay for ALP activity was performed to allow comparison to be made 
between cell lines (Figure 5.7).  After normalisation to cell number, Saos-2 stood out as 
the cell line with the highest level of ALP activity at Day 0 (Figure 5.7 A).  This 
enzymatic activity was inherent within the cells as osteogenic induction did not increase 
its level of activity (both the control and the induced populations showed similar level 
of ALP activity at day 7 (Figure 5.7 B) and day 14 (Figure 5.7 C).  An extended period 
of confluency appeared to increase ALP activity in the control populations of HOS and 
U-2-OS, although the levels of ALP activity in the induced populations were higher 
than the controls.   
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Figure 5.7: Quantification of alkaline phosphatase activity in seven osteosarcoma 
cell lines.  Cells were grown to one-day post-confluency and induced to the osteogenic 
lineage for seven and fourteen days.  After the specific time points, the cells were 
quantified for alkaline phosphatase activity (ALP) which was then normalised to DNA 
content (Section 2.3.3).  A. Day 0: Basal level of ALP activity before induction; B. Day 
7: 7 days after induction and C. Day 14: 14 days after induction.   represents control 
population (uninduced) and  represents osteogenic induced population.  Student’s t-
test control against induced; *p<0.05, ** p<0.04, ***p<0.01. 
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Quantification of AR dye recovered 
 
A quantitative assay for AR staining was performed to allow comparison of 
mineralisation to be made between cell lines (Figure 5.8).  In most of the cell lines, 
because of the excessive cell growth and limited differentiation, a high level of AR 
background staining was observed in the uninduced populations.  This was evident in 
the quantification of AR recovery at day 0 (Figure 5.8 A).  Although Saos-2 was the 
only cell line which exhibited extensive mineralisation, CAL72 and MG-63 appeared to 
show an increase in AR dye recovery at day 7 (Figure 5.8 B) and day 14 (Figure 5.8 C).  
However, this was not evident in the histochemical staining of the cell lines (Figure 
5.6).  The increase in G-292 AR dye recovery at day 14 (Figure 5.8 C) was consistent 
with the very few mineralised nodules observed during the staining procedure in the 
induced population, but not consistent with lack of staining in the control population 
(Figure 5.8 C). 
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Figure 5.8: Quantification of mineralisation in seven osteosarcoma cell lines.  Cells 
were grown to 1-day post-confluency and induced to the osteogenic lineage for seven 
and fourteen days.  After the specific time points, the cells were quantified for AR 
staining which was then normalised to DNA content (Section 2.3).  A. Day 0: 
Background level of AR dye before induction; B. Day 7: 7 days after induction and C. 
Day 14: 14 days after induction.   represents uninduced population (control) and  
represents osteogenic induced population.  Student’s t-test control against induced;** 
p<0.04, ***p<0.01. 
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Osteogenic inducibility of cell lines 
 
In order to evaluate the inducibility of the cell lines to the osteogenic lineage, the 
difference in ALP activity and AR dye recovered between the control and induced 
populations was calculated (Figure 5.9).  This was performed for both time points, that 
is days 7 and 14.  G-292 (day 7 and 14: p<0.04), HOS (day 7: p<0.04, day 14: p<0.01) 
and U-2-OS (day 7 and 14: p<0.05) were able to increase their ALP activity upon 
addition of the inducers indicative of osteogenic differentiation.  However, they were 
unable to undergo terminal differentiation and mineralise.  Saos-2 was the only cell line 
that was AR inducible (day 7: p<0.04, day 14: p<0.01), indicative of terminal 
differentiation (Figure 5.8 F). 
 
 
 
 
 
 
Table 5.1: Osteogenic inducibility of seven osteosarcoma cell lines.  After osteogenic 
induction and quantification of alkaline phosphatase activity and mineralisation, the 
mean difference between the control and induced population was analysed at days 7 and 
14 of differentiation.  The red font indicates osteogenic inducible cells lines calculated 
as the difference between control and induced population for each line at the specified 
time point.  Student’s t-test; *p<0.05, **p<0.04, ***p<0.01. 
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Gene expression analysis of osteogenic differentiation 
 
Cells were harvested and RNA isolated (Section 2.7.1) at day 0 (before induction), day 
7 and day 14.  RT-PCR was carried out as per section 2.7.2 and primers flanking 
specific regions of the genes of interest are listed in Table 2.3.  Gene expression 
analysis was normalised to β-actin level and the absence of contaminating DNA was 
confirmed by the negative control (-RT) (Figure 5.9).  In all of the cell lines except 
CAL72, the presence of MSX2 product was concomitant with the expression of the key 
transcription factor of osteogenesis, Cbfa-1.  However Cbfa-1 was expressed by all of 
the cell lines at day 14 of induction (Figure 5.9), despite the lack of positive 
histochemical staining in some populations (Figure 5.6).  Similarly expression of 
BMP8, Col1A1, OCN and OP does not reflect the differentiation status of the cell line.  
However, the increase in ALP expression from day 0 to day 14 reflected the pattern 
observed by the histochemical staining of the ALP positive cell lines. 
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Figure 5.9: Gene expression profile of seven osteosarcoma cell lines during 
osteogenic differentiation.  Total RNA was isolated before induction (D0) and at days 
7 (D7) and 14 (D14) of differentiation in control (CNT) and induced (OST) populations.  
RT-PCR was carried out using gene specific primers.  The PCR products were run on 
agarose gels, stained with Ethidium Bromide and visualised under UV light (Section 
2.7). 
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5.3 Cellular heterogeneity of osteosarcoma cell lines 
 
 
When osteosarcoma cultures were examined by phase contrast microscopy, some cell 
lines appeared to have a mixed morphology.  Furthermore, when cultured for extended 
time period, the HOS line exhibited a non-uniform pattern of ALP activity suggestive of 
a heterogeneous population of cells (Figure 5.6 B).  In order to investigate this cellular 
heterogeneity in the seven osteosarcoma cell lines, cells were seeded at low density and 
the colonies formed were observed in an adherent monolayer culture and matrix 
suspension format.  The clones identified were further characterised and a cellular 
hierarchy was investigated. 
 
5.3.1 Cellular heterogeneity within osteosarcoma cell lines 
 
Cells from the seven osteosarcoma cell lines were seeded at 100 cells per 10 cm dish 
and colonies were allowed to form under standard culture conditions (Section 2.2.1).  
Colony formation was monitored every 2-3 days and after 7-14 days, distinct epithelial 
and fibroblastic phenotypes could be observed (Figures 5.10 and 5.11), although one 
specific phenotype appeared to be predominant in each cell line.  CAL72 and Saos-2 
took longer to form colonies which appeared smaller compared to the other cell lines.  
As the colonies grew larger, morphologies typical of holoclones and paraclones were 
observed (Figure 5.11). 
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Figure 5.10: Cellular heterogeneity of osteosarcoma cells within monolayer 
cultures.  Cells from the seven osteosarcoma cell lines were seeded at 100 cells per 10 
cm dish and allowed to form colonies for 7-10 days under standard culture conditions 
(Section 2.2.1).  Black arrows indicate holoclonal colonies and white arrows indicate 
paraclonal colonies. Both types of colonies co-exist within the culture monolayer.  Scale 
bars represent 250 µm. 
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Figure 5.11: Formation of holoclonal and paraclonal colonies.  The figure represents 
enlarged images of examples of holoclones and paraclones observed in low density 
cultures of the osteosarcoma cell lines.  Holoclonal colonies appear circular and cells 
are in close proximity (epithelial-like) while paraclonal colonies are distant from one 
another and cells have a polygonal shape (fibroblastic-like).  Photo-micrographs 
adjusted for representation purposes and are not to scale. 
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5.3.2 Anchorage dependent cell growth  
 
Cells from the seven osteosarcoma cell lines were seeded in soft agar and incubated 
under standard culture conditions (Section 2.2.5).  Spherical colony formation was 
monitored over twelve days.  Beyond this time period, a monolayer of cells started to 
form on the surface of the agar.  Acidification of agar matrix (colour change to yellow) 
caused apoptosis of cells within the cell clusters.  At day 12 post-seeding, the colonies 
were visualised at x10 magnification (Figure 5.12) and the diameters of the colonies 
were measured.  The rapidly proliferating cells 143B, G-292 and MG-63 formed 
anchorage independent colonies at a faster rate than the other cell lines.  The HOS cell 
line, which was derived from the same parent as 143B was not able to form colonies in 
soft agar.  U-2-OS despite being a rapidly proliferating cell line in monolayer cultures 
(Section 5.2.1), did not withstand anchorage independent growth as well as the other 
cell lines of the same proliferative potential.  U-2-OS formed cell clusters of an average 
diameter of 20 µm while 143B for instance formed colonies of an average diameter of 
300 µm.  The size and shape of the spherical colonies varied within each cell line 
illustrating heterogeneity in the ability of individual cells to form colonies within the 
cell population.  The spheres formed had either a smooth or rough edge, reminiscent of 
the morphology observed during holoclonal and paraclonal colony formation. 
 
 
 
Figure 5.12:  Anchorage independent growth potential of osteosarcoma cell lines.    
Cells at a density of 1080 cells/cm2 were seeded in soft agar and colonies allowed to 
form for 9-12 days under standard culture conditions.  Spherical colonies were 
visualised at x10 magnification.  Scale bars represent 250 µm. 
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5.4 Establishment of cellular hierarchy within the HOS osteosarcoma 
cell line 
 
The identification of holoclonal and paraclonal colonies in the monolayer and soft agar 
cultures prompted the investigation of a possible cellular hierarchy similar to that 
observed by Mackenzie’s group (Locke et al., 2005, Harper et al., 2007) within the 
osteosarcoma cell lines.  The HOS cell line was chosen as it exhibited a more 
pronounced difference in cellular morphology, both at low and high density monolayer 
cultures.  The presence of a heterogeneous population within a tumour mass which is 
subsequently maintained upon cell line derivation implies that different sub-populations 
of cells possess distinct functional properties.  Therefore, clonal populations of 
epithelial and fibroblastic morphologies were isolated and expanded from the HOS cell 
line to establish if a cellular hierarchy exists.  
 
5.4.1 Identification and characterisation of clones  
  
HOS cells were clonally selected by low density seeding (Section 2.2.1) and single 
clones were expanded and labelled as holoclones or paraclones depending of the 
morphology of colonies they formed (Figure 5.14).  Although colonies of meroclonal 
formation were observed, these were not isolated as they were intermediate colonies and 
were not expected to stay as meroclones for the duration of the culture period.  
Holoclonal cells grew well as single clones and were highly proliferative under standard 
culture conditions.  When paraclonal cells were selected as single cell clones under 
standard culture conditions, they divided very slowly and after only a few divisions they 
underwent cell death (Figure 5.13).  However, when cultured in HOS conditioned 
media, the paraclonal cells grew readily and healthy colonies were formed (Figure 
5.15).  The apparent dependency of the paraclones on the holoclones was further 
investigated by culturing HOS cells at low density (1.3 cell/cm2) in either fresh medium 
or HOS conditioned medium and by allowing colonies to grow for one week.  The ratio 
of holoclones to paraclones formed per dish was directly related to the culture medium 
used (Figure 5.16), whereby out of 50 colonies counted, the ratio was 1:2 and 2:1 in 
fresh and conditioned media respectively.  In monolayer culture, when HOS was seeded 
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at low density and colonies allowed to form for more than one week, the paraclonal 
cells appeared to migrate towards the holoclonal population (Figure 5.16 A&B), and 
when left into culture for an extended time period, the paraclonal cells subsequently 
formed a tight boundary around the holoclonal colony (Figure 5.16 C).  With time, cells 
at the centre of the holoclonal colony appeared compressed and ultimately became 
phase bright and underwent cell death. 
 
 
 
 
 
 
Figure 5.13: Aborted paraclonal colony.  Paraclones were clonally selected from a 
low density culture and expanded under standard culture conditions (Seciton 2.2.1).  
Paraclones underwent a limited number cell division after which they became large, flat 
and granular and released their cell contents (indicated by black arrowhead).  Ultimately 
the cells round up and become phase bright (indicated by white arrowhead) indicative of 
cell death.  Scale bar represents 150 µm. 
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Figure 5.14: Identification of holo- and paraclones in HOS cell line.  HOS was 
seeded at a density of 1.3 cell/cm2 and colonies allowed to form.  By limited dilution, 
single cell clones were expanded under specified culture conditions and identified as 
pure holoclones and pure paraclones.  Scale bar represents 300 µm. 
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Figure 5.15: Dependency of paraclones on conditioned media.  HOS cells were 
seeded at 50 cells per 10 cm dish and colonies allowed to form, in conditioned and non-
conditioned media.  After one week, the number of colonies were counted and recorded 
as either holoclones ( ) or paraclones ( ), based on cellular morphology.  Student’s t-
test holoclone versus paraclone, **p<0.04.  
 
 
 
 
 
Figure 5.16: Migration of paraclone towards holoclone.  HOS cells were seeded at 
low density and colonies allowed to form.  Once a holoclonal and a nearby paraclonal 
colony were identified, the dish was marked and the migration of the paraclonal cells 
monitored over 1 week.  (A) Initial migration of paraclonal cells was led by cell 
division in the direction the holoclonal colony, (B) paraclonal cells merging with the 
holoclonal colony and (C) finally paraclonal cells forming a layer around the holoclonal 
cells which then became compacted and underwent cell death in the centre.  Scale bars 
represent 125 µm. 
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5.4.2 Epithelial-mesenchymal transition (EMT) in osteosarcoma 
 
The cellular heterogeneity observed in the HOS cell line appeared to be regulated by a 
defined cellular hierarchy.  When single cells from a holoclonal colony was seeded and 
allowed to form second generation holoclonal colonies, some cells appeared to exit the 
tight compact holoclonal morphology and become loose, possibly migrating away from 
the holoclonal parent colony to form a paraclonal colony.  Transition from paraclonal to 
holoclonal formation was not observed in the pure paraclonal colonies. 
 
 
 
 
 
Figure 5.17: Epithelial-mesenchymal transition in HOS cell line.  Cells from the 
parent holoclonal colony detached from the compact organisation and adopted a 
fibroblastic morphology characteristic of paraclonal cells.  Scale bar represents 250 µm. 
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5.5 Discussion 
 
Osteosarcoma has a poor outcome despite advances in chemotherapy.  The obstacle to 
successful treatment of this disease remains the lack of definite prognostic markers due 
to the high degree of heterogeneity of the tumour among patients.   This heterogeneity 
arises from the many different possible mutations that are thought to occur in the 
precursor cells of the tumour, thus determining the prognosis of the disease.  
Furthermore, the prevalence of putative CSC in the tumour has been identified as the 
cause of recurrence in patients. 
 
This study investigated the characteristics of seven osteosarcoma cell lines and 
identified a cellular hierarchy within each cell line which may further our knowledge 
about the development of sarcomas. Human cell lines have been successfully employed 
in the study of carcinogenesis from the 1970s onwards and the HOS cell line was 
among the first successful cell lines to be established (Rhim, 2000).  Since then a 
number of cell lines for the study of osteosarcoma has been generated with the most 
recent one being UTOS-1.  After two years of maintenance in culture, this cell line 
retained the molecular and phenotypic characteristics of the original tumour cells 
(Yasuda et al., 2009).  These observations support the validity of osteosarcoma cell 
lines as a reliable in vitro system to study the mechanisms of carcinogenesis.  Moreover, 
the maintenance of a culture system allows for an equalised population to develop, 
which are free from contaminating loosely associated cells which do not actively 
contribute to the tumour.  In cancer drug development, toxic agents have a narrow 
therapeutic index and cell lines as in vitro models are the tool of choice as they 
represent controlled conditions which can be uniformly monitored (Zhang and Dolan, 
2009).  Nowadays, drug development companies are advocating for the use of cell lines 
for targeted cancer therapies before entering the phases of clinical trial, therefore 
highlighting the importance of understanding and fully characterising oncogenesis in 
cell lines as a primary step (Tuma, 2006).  Characterisation of specific properties in 
osteosarcoma cell lines has previously involved an average of three cell lines (Tirino et 
al., 2008).  In this study, seven osteosarcoma cell lines were used to account for the 
high degree of tumour heterogeneity observed among patients. 
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The immunophenotypic characteristics of the seven osteosarcoma cell lines has been 
presented and discussed in chapter 4.  In this part of the thesis, their proliferative 
potential and their ability to undergo multilineage differentiation were investigated 
based on their expression of certain stem cell markers, such as STRO-1 and CD133 
(Figure 4.10).  The proliferative potential observed in the seven cell lines used could be 
categorised cell lines as either slow or rapid dividing cells, whereby CAL72 and Saos-2 
represented the slow dividing populations and 143B, G-292, HOS, MG-63 and U-2-OS 
represented the rapid dividing ones.  Using a cell density measurement assay, Shapira 
and Halabi (2009) showed that Saos-2 proliferated at a slower rate than MG-63, which 
is in line with the observation of this study which employed a fluorimetric dye dilution 
method to show that indeed, MG-63 had a higher proliferative potential than Saos-2.  
This difference in in vitro proliferative potential was the first indication that not all 
osteosarcoma behave in a similar manner.  Most comparative studies of proliferation 
rates of osteosarcoma cell lines to date have focussed on population subsets, such as 
CD133 positive sub-populations, instead of the population as a whole (Tirino et al., 
2008).  This study is the first evidence of osteosarcoma cell line classification based on 
their proliferative rates.  Taken together, the heterogeneity in in vitro proliferative rates 
of the tumour cells may reflect the heterogeneity of tumour burden observed in patients 
and hence represent determinant factors in disease outcome. 
 
As illustrated in Chapter 4 (Section 4.8), some osteosarcoma cell lines expressed the 
MSC marker STRO-1 suggesting that cells within those lines might have retained MSC 
characteristics.  However, unlike MSCs, both the STRO-1 positive and the STRO-1 
negative populations failed to undergo adipogenic differentiation.  Upon osteogenic 
differentiation, some cell lines appeared to be more inducible than others, again re-
iterating the heterogeneity among osteosarcoma cell lines.  Contrary to the other cell 
lines and in addition to its unique mineralisation potential, the basal level of ALP 
activity in the Saos-2 cell line was unexpectedly elevated and maintained for fourteen 
days in the uninduced populations.  This observation has been previously reported in a 
study looking at the osteoblastic properties of Saos-2, where they found that the highest 
level of ALP activity in the cell culture was at confluency  (Rodan et al., 1987).  Recent 
reports have shown that the osteoblastic potential of MG-63 could be enhanced by 
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different culture conditions, such as alendronate-supplemented media (anti-resorptive 
agent)  (Xiong et al., 2009), 5-azacytidine treatment (DNA methylation inhibitor) 
(Locklin et al., 1998) or cell growth on titanium coated surfaces (Shapira and Halabi, 
2009).  Using the standard osteogenic induction medium, in my hands, MG-63 cells 
were negative for ALP activity and failed to mineralise.  This may be due to the 
different culture conditions used by other groups to assess osteogenic potential of MG-
63, whereby the cells are grown on different matrix or expanded in medium 
supplemented with osteogenic inducers (Shapira and Halabi, 2009, Sun et al., 2009).  
Apart from the apparent uniform positivity and negativity of ALP activity observed in 
Saos-2 and MG-63 respectively, the other cell lines displayed heterogeneity in their 
staining patterns.  More precisely, not all the cells within the population were able to 
commit to the osteoblastic lineage and it appeared that each individual cell within the 
population possessed inherent differentiation potential.  This could be explained by the 
multi-step model of carcinogenesis which stipulates that various different genetic 
mutations accumulate in the cells at the different stages throughout the progression of 
the tumour.  Depending on the number of hits and the stage the cell is at when the 
mutation occurred, the cell’s properties are altered by acquiring proliferative potential.  
Therefore, if the cell had already passed the commitment stage, it would express basal 
levels of ALP activity but due to the nature of the mutation may not be able to progress 
to mature osteoblasts.  Similarly, certain mutations may impair the cell’s commitment 
mechanism which results in complete inhibition of differentiation.  Identifying a 
positive marker to distinguish between the multipotent cells from the committed ones 
may help to reveal the mechanisms of carcinogenesis in osteosarcoma. 
 
Differentiation heterogeneity among the seven osteosarcoma lines was further 
highlighted by molecular characterisation.  Expression of key genes traditionally 
indicative of osteogenic differentiation was detected at the different time points in an 
induced and non-induced population.  Expression of the ALP gene correlated with the 
enzymatic activity recorded in the assays, for instance the continuous ALP activity 
detected in Saos-2 at the induced and non-induced level was reflected in the strong band 
products during RT-PCR.  However expression of Cbfa-1 the master regulator of 
osteogenesis, did not correlate with osteogenic potential of the cell lines.  Although 
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ALP and AR positive Saos-2 expressed Cbfa-1, CAL72 which was comparatively 
negative for ALP and AR expressed Cbfa-1 to the same level.  The expression of OCN 
in Saos-2 is similar to that reported by Benayahu and co-workers (Benayahu et al., 
2001) and the molecular heterogeneity among the different cell lines characterised in 
this study is analogous to the molecular heterogeneity observed in a different set of 
osteosarcoma cell lines by Olstad and colleagues (Olstad et al., 2003).  Although the 
majority of the cells in a cell line could not differentiate, the small subset of cells which 
were able to differentiate accounted for the expression of osteogenic specific markers 
during RT-PCR.  As such, molecular characterisation of osteosarcoma cell lines by RT-
PCR is not reflective of the differentiation potential of that particular cell line under the 
standard culture conditions employed in this study.  The differentiation and molecular 
heterogeneity observed across the lines further emphasises on the multi-step model of 
carcinogenesis.  
 
The uneven pattern of differentiation within the cell lines pointed towards the possible 
presence of a cellular hierarchy within the population. The phenotype of the seven 
osteosarcoma cell lines has been described in the literature as either epithelial or 
fibroblastic or both (Table 5.1). This description of the cell lines is based on the 
apparent predominant morphology when the cells are seeded at normal/high density and 
observed at confluency.   
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Cell line Phenotype 
143B Mixed 
CAL72 Epithelial 
G-292 Fibroblastic 
HOS Mixed 
MG-63 Fibroblastic 
Saos-2 Epithelial 
U-2-OS Epithelial 
 
Table 5.2: Prominent cellular morphology of osteosarcoma cell lines.  The 
phenotypes are as described by the ATCC® bank database.  The accession number for 
each cell line is illustrated in table 2.1. 
 
When the cells were cultured at low density in monolayer and anchorage independent 
formats, two distinct morphologies became apparent.  As a monolayer, the cells adopted 
an epithelial or a fibroblastic morphology when grown as monolayer, forming 
holoclonal and paraclonal colonies respectively.  A similar observation has been 
reported by Mackenzie’s group working on carcinoma cell lines (Locke et al., 2005, 
Harper et al., 2007).  This cellular heterogeneity was further investigated in soft agar 
matrix to assay their anchorage independent growth.  This is a widely used in vitro 
method to identify cells with tumourigenic potential and has been validated as a method 
to determine the tumorigenic potential of MSC derived cell lines (Funes et al., 2007).  
Cells which are able to form spherical colonies in soft agar are anchorage-independent 
and therefore more tumourigenic than their anchorage-dependent counterparts which are 
unable to form colonies in the matrix.  Here, the osteosarcoma cell lines showed a 
heterogeneous ability to undergo anchorage-independent growth.  In the twelve day 
period allocated for colony formation, CAL72 and Saos-2 the slow dividing cell lines, 
formed occasional clusters in soft agar.  The cells lines 143B, G-292 and MG-63 readily 
formed colonies of mixed sizes indicating that within the population not all the cells are 
able to undergo anchorage-independent growth.  Although U-2-OS represented a 
rapidly dividing population, only occasional colonies were observed.   
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In sarcosphere formation assays which involved growth of cells in a semi-solid serum-
free media, it has been proposed that the rare CD133 positive cells represent the CSC of 
osteosarcoma (Tirino et al., 2008), although my data contradict the level of CD133 
positive cells observed in MG-63 and U-2-OS cell lines reported by  that group.  Tirino 
and co-workers (2008) isolated the CD133 positive subset in Saos-2 as CSCs and 
showed that those specific cells were more tumourigenic than their negative 
counterparts.  This observation leads to the supposition that in my study, the occasional 
clusters observed in the Saos-2 cell line represent the CD133 positive subset of cells, 
and by extrapolation, the prominent spheres observed in the other the cell lines also 
represent the putative CSCs.  This hypothesis is further supported by the identification 
of CD133 positive cells at the centre of the holoclonal colonies in head and neck 
squamous cell carcinoma cell lines, thus highlighting the holoclonal populations as the 
CSC population (Harper et al., 2007).  However, although CD133 has been shown to 
identify for the CSC in a number of tumours, recently work on six prostate cancer cell 
lines showed that CD133 does not identify for the tumour initiating cells.  Although 
colonies of holoclonal, meroclonal and paraclonal morphologies were identified, unlike 
paraclonal cells which lacked self-renewal ability in standard culture conditions, 
holoclonal cells were successfully serially passaged.  Nevertheless the CD133 positive 
cells were no more clonogenic and did not form more holoclonal colonies than the 
CD133 negative subset (Pfeiffer and Schalken, 2009).   
 
Another marker which has been attributed to the holoclonal cells is CD44.  CD44 was 
found to be expressed at higher levels on the holoclonal cells than on the larger 
paraclonal cells in a breast tumour cell line (MCF7) and squamous cell carcinoma cell 
line (VB6 subclone of H357 line) (Locke et al., 2005). In carcinoma studies, by serial 
transplantation in immunocompromised mice, the CD44highCD24low profile has been 
attributed to the CSC population in breast cancers (Al-Hajj et al., 2003).  The question 
which now remains is whether a similar antigenic profile can be attributed to the subset 
of cells capable of anchorage-independent growth given that initial surface 
characterisation of Saos-2 and U-2-OS by Benayahu and colleagues showed positive 
CD44 expression (Benayahu et al., 2001).   
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As reported by others, paraclonal colonies in my study showed limited self-renewal 
ability under standard culture conditions (Locke et al., 2005, Pfeiffer and Schalken, 
2009).  However, conditioned media of the parent population appeared to support 
growth of the paraclonal cells.  When the HOS cell line was grown as single cell clones 
by limited dilution, it was possible to derive and expand pure holoclonal (in standard 
culture media) and paraclonal (in conditioned culture media) populations.  This is the 
first report of colonies of holoclonal and paraclonal morphologies identified in a 
sarcoma model and successful paraclonal cell expansion in parental cell conditioned 
media.  This dependency of the paraclonal cells on the holoclonal cells was further 
demonstrated when the HOS cell line was cultured at low density.  The migration of 
paraclonal cells towards holoclonal cells was observed and with time, the paraclonal 
cells formed a tight boundary around the holoclonal colony.  Cancer cell migration has 
been attributed to response to chemoattractants such as cytokines (Kriebel et al., 2008).  
The evidence in this study suggests that the holoclonal cells secrete specific cytokines 
which the paraclonal cells are responsive to and require for proliferation. 
 
The cellular hierarchy established by Mackenzie’s group while working on carcinoma 
cell lines indicate that the holoclonal cells form the CSC population in the tumour as 
they undergo a series of morphological changes to give rise to intermediate meroclones 
and terminal paraclones.  Based on the pattern of stem cell division and differentiation 
(Figure 1.6), they concluded that the meroclones are the early amplifying cells while the 
paraclones are the late amplifying cells (Mackenzie, 2006).  The findings in this chapter 
point towards a transition stage which occurs within the holoclonal colonies, whereby at 
a specific stage in culture, cells at the periphery of the colony detach, adopt a 
fibroblastic morphology and appear to migrate away from the main colony.  Paraclones 
have been shown to down-regulate E-cadherin expression (Locke et al., 2005), a profile 
consistent with aggressive migratory cells of a mesenchymal morphology (Zajchowski 
et al., 2001).  However, the inconsistency lies in the expression of CD44.  While the 
tumour-initiating cells have been associated with a CD44high population consistent with 
the expression level found in holoclones (Locke et al., 2005), it has been shown that the 
migratory cells of mesenchymal morphology acquire a CD44high profile upon EMT 
(Mani et al., 2008).  This leads to the hypothesis that the paraclones may actually 
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represent the migratory cells which lose CD44 expression at the transition stage but are 
able to re-acquire its expression and other stem cell antigenic profile upon migration to 
different anatomical locations in vivo.  Moreover, the CD44 antigen on paraclonal cells 
is not completely absent but is comparatively lower than on holoclonal cells (Locke et 
al., 2005), which may lead to the conclusion that CD44 is a modulated antigen on the 
cell surface and is regulated by systemic cues in vivo.  While the morphological changes 
observed point towards a similar identity, further antigenic profiling work is required to 
conclusively assess the relationship between paraclonal cells and the migratory cells 
responsible for metastasis. 
 
This study has shown for the first time that osteosarcoma cell lines are comparatively 
heterogenous.  They exhibit varying levels of osteo-inducibility across the different cell 
lines as well as within an individual cell line.  This observation is likely to be due to the 
variety of genetic mutations accumulated in different osteosarcoma cells therefore 
giving rise to the cellular heterogeneity within the cell line.  Furthermore, the gene 
expression profile does not correlate with the pattern of mineralisation observed upon 
osteogenic induction, further highlighting the impact of genetic mutations in 
osteosarcoma cells.  The maintenance of two cellular morphologies within the cell lines 
in vitro suggests that a cellular hierarchy is crucial for the maintenance of the cell 
population.  This study has shown that there is indeed an inter-dependency between the 
holoclones and the paraclones, although the mediators involved have not yet been 
identified.  Moreover, the EMT-like process observed in the holoclonal-paraclonal 
transition remains to be confirmed on the basis of antigenic profiles and migration-
invasion assays.   
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6.1 General discussion 
 
This thesis set out to characterise STRO-1 antigen as a marker of multipotency in 
culture expanded hMSCs.  The STRO-1 antigen has previously been established as a 
marker of multilineage potential in uncultured bone marrow derived hMSCs (Simmons 
and Torok-Storb, 1991, Pittenger et al., 2000).  However, due to the low incidence of 
hMSC in the bone marrow (0.001 to 0.01 %), there is a need to culture expand those 
cells before they can be employed as a favoured tool in clinical settings (Gronthos and 
Simmons, 1996, Habisch et al., 2007).  There is a panel of other markers which have 
been successfully used to identify hMSCs, notably CD271, but to date, they all have 
been optimised and characterised on freshly isolated bone marrow mononuclear cells 
(Jones et al., 2002).  The aspect that sets STRO-1 apart from the other markers 
employed until now is the fact that it is expressed heterogeneously on hMSC 
populations.  This has been shown by Gronthos and co-workers (2003) on uncultured 
bone marrow derived hMSCs and has been re-iterated in my work in section 3.2.1, on 
culture expanded hMSCs.  Furthermore, in my study, this heterogeneous expression of 
the STRO-1 antigen appeared to be reflected in the uneven differentiation pattern 
observed in in vitro adherent cultures of hMSC upon adipogenic and osteogenic 
induction (Section 3.2.2).  These prime observations formed the basis of the 
experiments which followed. 
  
In Chapter 3 of this thesis, it was shown that upon expansion of hMSCs in culture, 
STRO-1 expression was maintained only on a sub-population of cells which retained 
adipogenic and osteogenic differentiation potential (Figure 3.6).  Moreover, the level of 
STRO-1 expression was found to be modulated at different passage number, a 
phenomenon which appeared to be donor-dependent and concomitant with a change in 
cellular morphology (Figure 3.5).  As the cells became flatter and larger (a phenotype 
indicative of senescence), the level of STRO-1 expression decreased.  This down-
regulation of STRO-1 expression was also concommittant with a reduced adipogenic 
and osteogenic potential of the total hMSC population, suggesting that STRO-1 antigen 
can be used as a marker of multipotency (Section 3.4).   
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Furthermore, a cell population magnetically enriched in STRO-1BRIGHT cells exhibited 
an enhanced adipogenic and osteogenic potential upon induction compared to the 
STRO-1 depleted and pre-enriched fractions (Section 3.5).  This leads to the assumption 
that a cellular hierarchy is maintained in bone marrow derived hMSCs whereby cells 
with a gradient of lineage potential co-exist.  This assumption is analogous to the 
studies carried out in mice bone marrow MSCs, whereby a cellular hierarchy with 
SSEA-1 (Stage Specific Embryonic Antigen-1) positive cells representing the most 
primitive cells was established (Anjos-Afonso and Bonnet, 2007).  Based on these 
observations, I speculate that the heterogeneity in differentiation observed in the hMSC 
populations may be due to a mixed population of cells, some of which are still in the 
primitive state (multipotential) while others are at different stages of lineage 
commitment (bipotential or unipotential).  Thus, a cellular hierarchy in hMSC 
population can be proposed based on STRO-1 expression where the highly expressive 
cells are the multipotent population and the weakly/non-expressive cells are nullipotent 
(Figure 6.1).  This may have important implications in clinical settings, for instance, in 
orthopaedic applications, whereby a large number of cells with high osteogenic 
potential are required for transplantation at the site of repair. 
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Figure 6.1: Proposed cellular hierarchy of hMSC based on STRO-1 expression.  
The figure illustrates an overlay analysis of STRO-1/RPE labelled cells (blue shaded 
histogram) against the secondary control population (red line).  Green circles ( ) 
represent STRO-1 antigen molecule on the cell surface.  The plastic-adherent hMSCs 
contain a heterogeneous cell population with a spectrum of potential reflected by the 
heterogenous STRO-1 expression; the highest STRO-1 expressing cells represent the 
multi/pluripotent cells while the weakest STRO-1 expressing cells represent the 
terminally lineage-committed or differentiating cells.   
 
However, if culture expanded hMSCs are to be implemented in the clinic, it is important 
to consider donor variability in basal STRO-1 level and the extent to which the cells can 
be expanded so as they retain their hMSC properties.  Understanding the ageing effect 
and fitness of the individual on hMSC is crucial for cell based therapies, especially in 
autologous transplantation as the elderly people are the primary candidates for hMSC 
based therapies.  It has been recently shown that hMSCs undergo a decline in cell 
number, expansion and differentiation ability during ageing (Roobrouck et al., 2008, 
Stolzing et al., 2008).  Furthermore, the hMSC pool in disease afflicted individuals may 
be depleted, for instance in the elderly, inadequate bone marrow hMSC pools is thought 
to be linked to osteoporosis or metastatic bone diseases (Motaln et al., 2010).  The 
investigation in this thesis showed a relationship between the decrease in expansion 
potential of hMSCs and loss of STRO-1 expression (Section 3.4).  The explanations 
supporting this observation may be due to out-growth of fast proliferative contaminating 
fibroblasts. In relation to STRO-1 expression, this observation suggests that the STRO-1 
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antigen may act as a determinant of self-renewal capacity.  While these data are not 
sufficient to infer STRO-1 as a marker of expansion potential, it will be of interest to 
thoroughly investigate this hypothesis in future experimental designs.  Clonal isolation 
of STRO-1BRIGHT cells from a wider range of donors of varying age groups could be 
monitored for their expansion potential and tri-lineage differentiation potential.  The 
outcome of this may further support STRO-1 as a biomarker of multipotent hMSCs. 
 
In Chapter 3, the expression of STRO-1 during the processes of differentiation was 
investigated and it was found that the level of STRO-1 expression was not constant at 
induction and during lineage commitment (Section 3.7).  Although it can be argued that 
the overall down-regulation of STRO-1 observed in this setting was due to the extended 
time in culture (time taken for differentiation to occur), the degree of down-regulation 
during differentiation was more pronounced than that observed in the control uninduced 
populations which were in parallel culture for the same period.  The down-regulation in 
the control populations was indeed analogous to that observed in the adherent hMSC 
populations at seven and fourteen days post-confluency (Section 3.6), suggesting that 
there may be an auto-inhibitory mechanism of STRO-1 antigen mediated by cell-to-cell 
contact.  Furthermore, the pattern of down-regulation observed during adipogenesis was 
different to that observed during osteogenesis, further implying STRO-1 as a marker of 
differentiation (Section 3.7).   
 
The proposed model is based on the hypothesis that the level of STRO-1 antigen 
expression confers differentiation potential.  Therefore depending on the degree of 
STRO-1 positivity (low or high), the cells have the ability to differentiate to either the 
adipogenic or osteogenic lineage or both.  However, the route the cell takes during 
commitment is dependent on the lineage to which it is induced as specific transcription 
factors are involved in each lineage.  From the results in Chapter 3, commitment to the 
adipogenic lineage follows a different STRO-1 expression pattern to that observed upon 
commitment to the osteogenic lineage.  The main difference pertaining to these two in 
vitro assays is the length of time the cells take to undergo differentiation to their specific 
lineages.  Osteogenesis is a process which takes place over twenty-one days while 
adipogenesis takes place over eight days.   Osteogenesis followed a transient up-
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regulation of STRO-1 at the early stages of commitment, which is gradually lost as the 
induced cells progress towards maturation.  Given the experimental design of my 
experiments, relative to osteogenesis, the immediate stages of commitment to 
adipogenesis were not captured.  Therefore, any possible transient up-regulation of 
STRO-1 expression during the early stages of adipogenic commitment analogous to 
osteogenic commitment may not have been recorded.  To elucidate this possibility, 
future experiments should focus on the immediate effects of adipogenic induction on 
STRO-1 expression, for instance analysis of populations on a two-hourly basis post-
induction. Based on the behaviour of STRO-1 antigen observed during differentiation, it 
can be speculated that STRO-1 is a transmembrane protein (for example, a receptor) 
which translates external stimuli to the cytosol, thus activating the downstream 
signalling cascades, such as the Notch or Wnt signalling pathways, known to be 
involved in fate determination of hMSC (Vujovic et al., 2007, Etheridge et al., 2004).  
On initial stimulation, the cells up-regulate STRO-1 expression to indicate induction 
which occurs prior to lineage commitment.  As commitment progresses, the cells down-
regulate STRO-1 expression which is ultimately lost once the cells become fully 
differentiated. 
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Figure 6.2: Modulation of STRO-1 expression at lineage commitment. Green circles 
( ) represent STRO-1 antigen molecule on the cell surface.  A basal level of STRO-1 
expression is required for differentiation to occur.   During osteogenesis (blue and green 
arrows), cells expressing STRO-1 weakly (blue arrow) or strongly (green arrow) are 
responsive to osteo-inductive stimuli and during the initial commitment stage the cells 
up-regulate their STRO-1 expression.  Upon terminal osteogenic differentiation, STRO-
1 expression is lost while the osteo-progenitors mature to fully functional osteoblasts.  
During adipogenesis (pink arrows), cells expressing STRO-1 are responsive to adipo-
inductive stimuli and commit to the adipogenic lineage.  The adipogenic commitment 
pathway is rapid as compared to the osteogenic pathway, and the intermediate up-
regulation of STRO-1 as observed during osteogenesis has not been elucidated (pink 
dashed arrow).  Upon adipocyte maturation, STRO-1 expression is quickly lost as the 
cells accumulate lipid vacuoles. 
 
 
As illustrated and explained in Chapter 3 and sections above, the STRO-1 antigen 
appears to have a defined role in hMSC differentiation potential.  Identifying the nature 
of this antigen may reveal its mechanism of action and its potential links with the 
intracellular pathways of differentiation and the way it affects some key regulators of 
differentiation such as PPARγ in adipogenesis and Cbfa-1 in osteogenesis 
(Muruganandan et al., 2009).  The first approach to identify the STRO-1 epitope in this 
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thesis was phage display technology which yielded no promising results, mainly due to 
the nature of the STRO-1 antibody.  This further emphasises the need to elucidate the 
identity of the antigen, so that novel antibodies of higher affinity can be generated 
against the putative marker of multipotency, STRO-1.  In an attempt to determine the 
nature of STRO-1 antigen, a gene expression microarray analysis was implemented to 
compare the STRO-1 expression profiles of seven different osteosarcoma cell lines and 
hMSC populations.  However, before this analysis could be undertaken, it is to be noted 
that a stringent and thoroughly optimised screening procedure had to be implemented. 
 
First and foremost, the source of STRO-1 antibody and the maintenance of its molecular 
integrity upon storage had to be validated as, to date, there is no consistent protocol in 
the literature documenting the use of the antibody as a selective marker, may it be on 
hMSCs or osteosarcoma cells.  In this study, the use of STRO-1 was optimised and the 
variability in binding efficiency at different storage conditions of resuspended 
lyophilised and hybridoma culture supernatant of the antibody was demonstrated.  In 
addition to its low binding affinity, the molecular integrity of the STRO-1 IgM antibody 
was further affected by storage conditions (Section 3.3).  The yield of antibody in 
hybridoma supernatant is batch dependent and thus a lack of quality control at this level 
may result in weak detection of STRO-1 expression on cell populations.  Furthermore, 
confocal microscopy analysis showed that STRO-1 is also expressed intra-cellularly 
(Figure 4.11), implying that cells with a compromised membrane may incorporate the 
antibody inside their cytoplasm and show up as false positives upon flow cytometry 
analysis.  Indeed that was the case when osteosarcoma cell lines, which potentially 
harboured rare surface expressing STRO-1 positive cells, were profiled without a dead 
cell exclusion assay (Section 4.7).  Therefore, when screening for rare STRO-1 positive 
cells by flow cytometry, it is important to discriminate between live and dead cells and 
without a robust dead cell exclusion method, the proportion of positive to negative cells 
is inaccurate.  This is particularly important when identifying rare CSCs in cancer cell 
lines.  When profiling hMSCs, dead cell exclusion is important but need not be carried 
out simultaneously with STRO-1 staining (dual staining) as the STRO-1 expression 
levels are high and heterogeneous in hMSCs.  Therefore, in my work (Chapter 3), an 
hMSC population stained solely with PI was included in every experiment and gates 
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were drawn to exclude PI positive cells (dead cells) to define the flow cytometry 
protocol.  As such, the marker profile of osteosarcoma cell lines illustrated in my study 
whereby a robust dead cell exclusion procedure was implemented, did not necessarily 
reflect the profile reported by others; one such example is the expression of CD133 on 
MG-63, Saos-2 and U-2-OS cell lines which differs from that reported by Tirino and 
colleagues (2008). Therefore, when screening for surface antigens, especially in 
comparative studies to identify rare cell populations, it is crucial to undertake a dead 
cell exclusion assay in order to obtain reliable and reproducible data.  
 
The flow cytometry scores obtained for STRO-1 expression on the different 
osteosarcoma cell lines was matched to their respective gene expression microarray 
profiles to identify potential candidate genes encoding STRO-1 antigen.  The list 
obtained was narrowed down to eight potential candidates whose products are expressed 
on the plasma membrane.  Out of those eight candidates, one particular candidate, 
ARHGEF4, displayed an expression pattern similar to that observed by STRO-1 
antigen.  More precisely, is it expressed on plasma membrane, cell projections as well 
as in the cytoplasm.  There is no reports of its link to fate determination of stem cells, 
but has been implicated in cytoskeleton rearrangement and cellular morphology.  Co-
localisation studies of this antigen with STRO-1 antigen will help to reveal whether the 
two antigens are one and the same.  Further confirmation may be obtained from knock-
in and knock-out experiments of candidate genes to determine the identity and function 
of STRO-1 antigen.  The two other promising candidates are P2RY6 (bone formation) 
and TNFSF11 (bone resorption) which are involved in bone remodelling although the 
lineage in which they exert their functions is totally different.   
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The high expression of STRO-1 by the MG-63 cell line in my study led to the 
investigation of potential stem cell characteristics which may have been maintained by 
the tumour cells (Section 4.8).  This follows from the report by Gibbs and colleagues 
(2005) which showed that a subset of cells in freshly derived osteosarcoma cell lines 
exhibited STRO-1 expression and was associated with sarcosphere formation and 
differentiation potential suggesting the maintenance of MSC-like cells in osteosarcoma.  
As such, this study is the first to present a full comparative analysis of seven 
osteosarcoma cell lines (143B, CAL72, G-292, HOS, MG-63, Saos-2 and U-2-OS) in 
terms of their marker phenotype, molecular profile, cellular morphology and 
differentiation potential. 
 
STRO-1 expression was retained to different levels in some of the osteosarcoma cell 
lines, however, unlike hMSCs this did not reflect MSC multilineage potential.  
Similarly, upon osteogenic induction, the expression of the key osteogenic genes did not 
reflect the osteogenic differentiation potential of the cell lines.  This discrepancy may be 
due to the variety of mutations accumulated over time in different tumours, resulting in 
maturation arrest.  A mutation in any of the osteogenic transcription factors (illustrated 
in Figure 1.3) may also lead to maturation arrest, depicting heterogeneity in different 
tumours.   More recently, over-expression of mitotic arrest defective protein 2 (MAD2) 
was associated with osteosarcoma of lower differentiation and higher clinical stage (Yu 
et al., 2010).  Similarly, depending on the stage of maturation at which the cell was at 
before it acquired tumorigenic mutations, certain stem cell characteristics were retained, 
such as STRO-1 expression and osteo-inducibility.  This observation suggests that 
osteosarcoma may be a disease of dis-regulated differentiation caused by MSC 
transformation, although this theory remains to be proven. 
 
The heterogeneity in osteogenic differentiation potential of osteosarcoma cell lines led 
to a proposed model characterising the different cell lines with an association to their 
STRO-1 status.  Depending on the nature and extent of the mutations, some cell lines 
(MG-63, CAL72 and 143B) remained non-inducible as they could not be stimulated to 
further differentiate.  On the other hand, some cell lines (G-292, U-2-OS, HOS and 
Saos-2) retained the ability to mature, although the extent of differentiation was variable 
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depending on the stage at which maturation arrest occurred.  Interestingly, the stage at 
which each category of cell lines (inducible and non-inducible) was arrested represents 
the level of STRO-1 expression observed (Section 5.2.3).  The further down the 
osteoblastic lineage, the lower the level of STRO-1 expression.  This proposed model 
reflects the heterogeneity of the tumours observed among osteosarcoma patients and 
highlights the difficulty in developing reliable prognostic markers of the disease. 
  
 
 
 
Figure 6.3: Proposed model characterising the osteosarcoma cell lines.  The 
heterogeneity among osteosarcoma cell lines is due to different stages of maturation 
arrest.  The osteoblast lineage follows initial commitment of MSC to osteo-progenitors 
which are weakly ALP positive.  As the progenitor cell differentiates to functional 
osteoblast, the level of ALP activity increases and further maturation results in 
mineralising AR positive cell osteocyte.  Osteosarcoma arises when the cells 
accumulate mutations during the differentiation process and are able to exit the lineage 
at any stage, thus resulting in varying levels of differentiated tumours.  In blue are cell 
lines which are osteo-inducible and in red are cell lines which are not inducible.   
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The poor prognosis in osteosarcoma patients has been attributed to a lack of reliable 
early prognostic factors and high metastatic potential of the tumours.  In Chapter 4, the 
level of CD13 expression was higher in the cell lines bearing a dominant fibroblastic 
morphology (Table 6.1).  These cell lines, specifically G-292 and MG-63, exhibited 
prominent anchorage independent growth potential as illustrated in Section 5.3.2.  On 
the basis of these observations, CD13 appeared to be an interesting molecule which 
could be further exploited as a prognostic marker for aggressive sarcomas.  This 
speculation is based on a number of studies reporting the pathological significance of 
CD13 in carcinomas including pancreatic (Ikeda et al., 2003) and gastric (Kawamura et 
al., 2007).  It has also been shown that CD13 positive tumour cells have migratory 
properties and are able to degrade extracellular matrix, both of which are invasive 
characteristics of metastatic cells (Saiki et al., 1993).  Moreover, CD13 has been shown 
to be associated with the process of epithelial to mesenchymal transition (EMT) in 
normal human dermal fibroblasts (Sorrell et al., 2003), a process which has also been 
associated with the invasive properties of CSCs in breast cancer cell lines (Section 
1.5.4).   
 
While immunophenotyping the seven osteosarcoma cell lines, it was interesting to note 
that the pre-dominating fibroblastic morphology of the cell line was concomitant with 
an elevated expression of CD13 (G-292 and MG-63).  Mixed populations (143B and 
HOS) exhibited intermediate levels of CD13 and those with a pre-dominating epithelial 
morphology (CAL72, Saos-2 and U-2-OS) were CD13 negative (Table 6.1).  Whether 
the CD13 expression in those cell lines represents an EMT phenomenon remains to be 
confirmed, possibly by investigating EMT related genes such as Twist or Snail (Figure 
1.5) in future experiments. Regarding mesenchymal tumours, the metastatic potential of 
CD13 positive cells has not yet been investigated and should therefore be the focus of 
future studies when trying to identify prognostic markers of osteosarcoma.  Recent 
advances in anti-cancer therapies are focussing on CD13 inhibitors in the hope of 
preventing metastasis in carcinomas (Zhang and Xu, 2008) and defining CD13 as a 
prognostic marker of metastatic osteosarcoma may benefit from those inhibitors of 
EMT. 
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Cell line Dominating  phenotype 
CD13 
expression 
143B Mixed 9.52 
CAL72 Epithelial 0 
G-292 Fibroblastic 30.48 
HOS Mixed 12.91 
MG-63 Fibroblastic 43.86 
Saos-2 Epithelial 0.2 
U-2-OS Epithelial 0 
 
Table 6.1: CD13 as a potential prognostic marker in osteosarcoma.  The values 
represent the mean difference in fluorescence, determined by flow cytometry (Section 
2.5), between CD13 labelled samples and control unstained samples.  CD13 expression 
reflects a dominating fibroblastic morphology (in red) which may be indicative of 
cancers of a more aggressive nature. 
 
 
The cellular heterogeneity within osteosarcoma cell lines was first identified by the 
uneven osteo-inducibility of the G-292, U-2-OS and HOS cell lines but was found to be 
a common feature of all osteosarcoma cell lines studied by observing distinct 
morphologically different sub-populations of cells when cultured at low density 
(Section 5.4).  The formation of cells of holoclonal and paraclonal morphology 
indicates the existence of a cellular hierarchy within osteosarcoma cell lines which is 
probably present in tumours and subsequently maintained in culture.  The generation of 
paraclonal cells in a sarcoma cell line by EMT has not been proven yet.  However, this 
study is the first to demonstrate the presence of a cellular hierarchy in osteosarcoma cell 
lines and the transition of paraclonal cells from holoclonal colonies, hypothesising the 
holoclonal cells as the putative CSCs in osteosarcoma.  In order to present the 
holoclonal cells as the target for chemotherapy, they have to be further characterised 
and their CSC properties proven both in vitro and in vivo.   
 
To achieve this, the next step in this study would be to characterise the antigenic profile, 
especially in terms of CD44 expression of the holoclones and the paraclones in order to 
establish their CSC identity.   CD44 has been shown to be a key molecule that is 
regulated between the holoclonal and paraclonal cells in carcinoma cell lines, and a 
CD44high profile has been attributed to the holoclonal cells.  In accordance with other 
studies, it is of interest to investigate the CD44 status of the holoclonal and paraclonal 
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cells in the seven established osteosarcoma cell lines and possibly in freshly derived 
osteosarcoma cell lines as well.  It is also important to investigate other markers 
associated with CSCs, such as ALDH and the ability of cells to pump out cytotoxic 
drugs (Side Population characterised by expression of ABC membrane transporters) 
(Section 1.5.3).  In vitro tumour formation assays such as sarcosphere formation in 
serum starved suspension cultures will need to be implemented once putative CSCs are 
identified in the osteosarcoma cell lines.  In vivo assays of tumour formation may also 
be studied by serial transplantation of the holoclonal cells in animal models, although 
robust in vivo models of osteosarcoma are yet to be achieved (Tirino et al., 2008).   
 
The dependency of the paraclonal cells on the holoclonal cells in the HOS cell line has 
been demonstrated in vitro by the conditioned media culture systems (Section 5.4.1).  
This phenomenon remains to be confirmed in the other osteosarcoma cell lines and 
perhaps in other cancer cell lines as well.  The most intriguing and interesting aspect of 
this study would be to identify the cytokines responsible for this dependency.  
Paraclonal cells exhibit tropism towards the holoclonal colony and this has been 
illustrated by phase contrast micrographs in this thesis.  An interesting approach would 
be to test the migration of paraclonal cells using a live imaging system.  The holoclonal 
or paraclonal cells can be transfected to express GFP for instance, and the two cell 
morphologies can be monitored in real time.  In addition, the release of known 
cytokines involved in cancer metastasis (for example, CCL5) can be investigated.  
Presumably a similar cytokine, if not the same, may be responsible for this paraclonal 
migration phenomenon.  Identifying the nature of this cytokine will help to understand 
the cause of metastasis and may help tailor therapies to prevent cancer dissemination.   
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On the basis of these preliminary observations, and combined studies reported in the 
literature on carcinoma cell lines, I propose a cellular hierarchy in osteosarcoma cell 
lines whereby the holoclonal cells represent the putative CSCs.  This hierarchy is 
brought about by EMT which mediates metastasis and MET at the site of secondary 
tumour formation in vivo (Figure 6.4).  MET has not been observed in vitro in this 
thesis, neither has it been reported in the literature.  This may be due to the lack of 
stimuli inducing MET or perhaps in a culture environment, EMT inducing stimuli are 
maintained.  Furthermore, EMT is part of a process whereby migratory cells home to 
secondary anatomical sites which are conducive to their growth (by providing the right 
micro-environment in terms of structural or/and hormonal support).  The cells are then 
able to seed new tumours by undergoing MET and aberrant proliferation, most likely to 
be driven by the putative holoclonal CSCs.  The lack of such a nourishing secondary 
site in a culture system may potentially explain why MET is not observed in vitro. 
Developing chemotherapeutic agents to target the holoclonal cells may provide a means 
to better manage osteosarcoma and extend life expectancy of patients. 
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Figure 6.4: Proposed cellular hierarchy in osteosarcoma.  The primary tumour is a 
heterogeneous cell mass in which rare CSCs reside (cell shaded pink).  This cellular 
heterogeneity is maintained in culture and three cell types forming a cellular hierarchy 
are present; adherent epithelial-like holoclones, intermediate meroclones and migratory 
paraclones.  The holoclones represent the putative CSCs which can give rise to 
intermediate meroclones and migratory paraclones by EMT, a process accompanied by 
a loss in stem cell properties, such as down-regulation of CD44 expression.  In vivo the 
paraclonal cells are potentially able to enter the blood stream or lymphatic system, 
survive and home to distant sites (metastasis), where they undergo MET, a process 
accompanied by a gain in stem cell properties, for instance up-regulation of CD44 
expression.  MET generates cells with stem cell properties (holoclonal CSCs) which 
have the potential to spawn secondary tumours.  In vitro, paraclonal cells are dependent 
on holoclonal secretory factors to survive and expand.   
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The proposed metastatic abilities of paraclonal cells have not been established yet.  A 
very interesting experiment that needs to be undertaken is the evaluation of the 
migratory and invasive properties of the paraclonal cells as compared to the holoclonal 
cells.  In vitro assays subsequently remain to be confirmed by in vivo studies.  In order 
to confirm that holoclonal cells are the CSCs, pure holoclonal cells have to be 
xenotransplanted into nude mice, tumour formation evaluated and the cells should be 
able to be serially transplanted in vivo and seed new tumours.  Unless this gold standard 
of CSC assay is achieved, the holoclonal cells can only be hypothesised as being the 
CSC population in osteosarcoma.  
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6.2 Conclusions 
 
Hence, to conclude, the study described in this thesis resulted in the following main 
novel observations: 
 
• STRO-1 antigen is a biomarker of the multipotent subset of adherent cultured 
hMSCs and is modulated upon different culture conditions. 
• STRO-1 antigen is down-regulated in a temporal manner during adipogenic and 
osteogenic differentiation. 
• STRO-1 antigen is localised intra-cellularly and on the cell surface with the 
identification of surface expressing rare cell populations requiring stringent 
screening procedure such as optimal antibody staining conditions to retain 
antibody integrity and dead cell discrimination to exclude false positives. 
• The identity of STRO-1 antigen has been narrowed down to eight potential 
candidate genes, of which ARHGEF4 appears to exhibit similar sub-cellular 
localisation to the STRO-1 antigen. 
• Osteosarcoma cell lines exhibit cellular heterogeneity as demonstrated by varied 
antigenic profiles, different levels of osteo-inducibility and expression of 
osteogenic markers. 
• Cellular hierarchy is maintained in osteosarcoma cell lines in vitro; retention of 
intrinsic stem cell patterns illustrated by holoclonal colonies may represent the 
putative CSCs in osteosarcoma. 
• Paraclonal cells are migratory and their in vitro expansion is dependent on 
holoclone-derived factors. 
 
To summarise, the study represented in this thesis has firstly contributed towards the 
potential applications of hMSC in the regenerative field and secondly opened up 
avenues for anti-cancer therapies by exploring the presence of putative CSCs in 
osteosarcoma cell lines.   
 
 
 
                                         Chapter 6.  General Discussion, Conclusions and Future Work    
 221 
6.3 Future Work 
 
In summary, future directions of this thesis should focus on the following main aspects: 
 
• Co-localisation studies of the expression of potential candidate genes of STRO-1 
• On identification of the potential STRO-1 gene, the identity of STRO-1 can be 
confirmed by ectopic expression of the antigen in fibroblasts (STRO-1 negative 
cell line) 
• Expression of accepted CSC markers such as CD133 and CD44 on holoclones 
and paraclones to establish the putative CSC population in osteosarcoma 
• Migration and invasion assays to confirm proposed migratory properties of 
paraclones 
• Time-lapsed photography to establish the dependency of paraclones on 
holoclones and identify factors responsible for this dependency 
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Appendix 
 
I.  Calibration curve to determine ALP concentration 
 
To quantify osteogenic potential, the concentration of ALP was determined for 
individual sample population (Section 2.3.3.3).  For each experiment carried out, a 
calibration curve of ALP concentration was constructed using two sets of phosphate 
standards (0 to 4 mM), and absorbance readings at 405 nm were taken in triplicates.  An 
example of the calibration curve obtained for each experiment is shown below (Figure 
I) and the accepted R2 value lies between 0.95 and 1. 
 
 
Figure I: Calibration curve of ALP concentration.  Phosphate standards were 
prepared in duplicate (Section 2.3.3.3).  Absorbance readings were taken at 405 nm 
wavelength in triplicates and the average values used to construct the line of best fit.    
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II.  Isotype control for STRO-1 IgM antibody 
 
STRO-1 primary IgM was detected using a FITC or RPE labelled mouse anti-IgM (µ-
chain specific) antibody.  To determine specific binding of the secondary antibody to 
the primary STRO-1 IgM, the isotype control used was unlabelled mouse IgM isotype 
control (Southern Biotech, Birmingham, USA).  The binding of the isotype control was 
compared to the binding of the secondary antibody only (Appendix figure II A).  For the 
IgG binding of the other fluorescent conjugated antibodies used in this thesis, the 
isotype control used was mouse IgG1 Isotype Control PE/FITC conjugated (Assay 
Designs, Michigan, USA).  PE detection is illustrated as an example in figure I B. 
 
 
Figure II: Analysis of isotype controls for IgM and IgG antibodies used in flow 
cytometry.  hMSCs were cultured, harvested and labelled using specific isotype 
controls (Section 2.5).  Cells were analysed by flow cytometry and normalised to 1x104 
cells.  (A) Red line represents secondary RPE labelled population and blue shaded 
histograms represent IgM isotype labelled population; (B) Red line represents unstained 
population and blue shaded histogram represents IgG isotype PE labelled population. 
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  III.  Gene expression microarray analysis  
(Performed by Stephen Henderson, The Cancer Institute, UCL) 
 
The procedure leading to the identification of eight potential candidate genes is outlined 
below. 
 
 
 
Figure III: Outline of procedure to identify potential candidate genes encoding the 
STRO-1 antigen (Section 2.7). 
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From the correlation values obtained (Section 4.9), the twenty probesets with the 
highest correlation were selected and their sub-cellular locations retrieved from the 
Gene Ontology (GO) database. 
 
 
 
Ensembl Gene 
ID GO Term Name (cc) HGNC symbol 
Affy HG 
U133A 
ENSG00000067646 nucleus ZFY 207246_at 
ENSG00000067646 intracellular ZFY 207246_at 
ENSG00000114374 cytoplasm USP9Y 206624_at 
ENSG00000067048 nucleus DDX3Y 205000_at 
ENSG00000067048 cytoplasm DDX3Y 205000_at 
ENSG00000067048 plasma membrane DDX3Y 205000_at 
ENSG00000067048   DDX3Y 205000_at 
ENSG00000012817 intracellular KDM5D 206700_s_at 
ENSG00000012817 nucleus KDM5D 206700_s_at 
ENSG00000012817 cellular_component KDM5D 206700_s_at 
ENSG00000198692 cytoplasm EIF1AY 204409_s_at 
ENSG00000198692  EIF1AY 204409_s_at 
ENSG00000103227 endoplasmic reticulum LMF1 219136_s_at 
ENSG00000103227 membrane LMF1 219136_s_at 
ENSG00000103227 integral to membrane LMF1 219136_s_at 
ENSG00000103227   LMF1 219136_s_at 
ENSG00000120659 extracellular space TNFSF11 210643_at 
ENSG00000120659 plasma membrane TNFSF11 210643_at 
ENSG00000120659 extracellular region TNFSF11 210643_at 
ENSG00000120659 
integral to plasma 
membrane TNFSF11 210643_at 
ENSG00000120659 cytoplasm TNFSF11 210643_at 
ENSG00000120659 membrane TNFSF11 210643_at 
ENSG00000124491 extracellular region F13A1 203305_at 
ENSG00000124491 
platelet alpha granule 
lumen F13A1 203305_at 
ENSG00000124491 cytoplasm F13A1 203305_at 
ENSG00000124491  F13A1 203305_at 
ENSG00000130813  C19orf66 218429_s_at 
 
Table I: Continued Overleaf. 
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ENSG00000108582 nucleus CPD 201941_at 
ENSG00000108582 membrane fraction CPD 201941_at 
ENSG00000108582 membrane CPD 201941_at 
ENSG00000108582 integral to membrane CPD 201941_at 
ENSG00000108582 trans-Golgi network CPD 201941_at 
ENSG00000108582 microsome CPD 201941_at 
ENSG00000170458 membrane raft CD14 201743_at 
ENSG00000170458 
lipopolysaccharide receptor 
complex CD14 201743_at 
ENSG00000170458 extracellular region CD14 201743_at 
ENSG00000170458 plasma membrane CD14 201743_at 
ENSG00000170458 anchored to membrane CD14 201743_at 
ENSG00000170458 extracellular space CD14 201743_at 
ENSG00000161570 extracellular space CCL5 1405_i_at 
ENSG00000161570 extracellular region CCL5 1405_i_at 
ENSG00000161570 soluble fraction CCL5 1405_i_at 
ENSG00000161570 cytoplasm CCL5 1405_i_at 
ENSG00000087116 extracellular region ADAMTS2 214535_s_at 
ENSG00000087116 
proteinaceous extracellular 
matrix ADAMTS2 214535_s_at 
ENSG00000087116 extracellular matrix ADAMTS2 214535_s_at 
ENSG00000087116  ADAMTS2 214535_s_at 
ENSG00000125510 integral to plasma membrane OPRL1 206564_at 
ENSG00000125510 plasma membrane OPRL1 206564_at 
ENSG00000125510 integral to membrane OPRL1 206564_at 
ENSG00000148671 cellular_component C10orf116 203571_s_at 
ENSG00000148671  C10orf116 203571_s_at 
ENSG00000171631 integral to plasma membrane P2RY6 208373_s_at 
ENSG00000171631 plasma membrane P2RY6 208373_s_at 
ENSG00000171631 
basolateral plasma 
membrane P2RY6 208373_s_at 
ENSG00000171631 apical plasma membrane P2RY6 208373_s_at 
ENSG00000171631 integral to membrane P2RY6 208373_s_at 
ENSG00000136002 intracellular ARHGEF4 211891_s_at 
ENSG00000136002 cytosol ARHGEF4 211891_s_at 
ENSG00000136002 plasma membrane ARHGEF4 211891_s_at 
ENSG00000136002 cell projection ARHGEF4 211891_s_at 
ENSG00000136002 cytoplasm ARHGEF4 211891_s_at 
ENSG00000136002 cellular_component ARHGEF4 211891_s_at 
ENSG00000003402  CFLAR 208485_x_at 
ENSG00000129824  RPS4Y1 201909_at 
ENSG00000129824 cytosol RPS4Y1 201909_at 
ENSG00000129824 ribosome RPS4Y1 201909_at 
ENSG00000129824 polysome RPS4Y1 201909_at 
ENSG00000129824 
cytosolic small ribosomal 
subunit RPS4Y1 201909_at 
ENSG00000129824 intracellular RPS4Y1 201909_at 
 
Table I: Sub-cellular locations of top twenty probesets which match STRO-1 
antigen expression.  The highlighted cells represented potential candidate genes 
representing STRO-1 antigen based on their location on the plasma membrane. 
